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SUMMARY
Weakness and fatigue are the commonest symptoms in patients with advanced cancer. 
They are symptoms which have largely eluded precise definition, but have been reported 
to seriously affect quality of life and ability to perform basic daily activities. Reduced 
muscle bulk due to cancer cachexia and alteration in intrinsic muscle function have been 
suggested as causes of both reduced muscle strength and subjective weakness and 
fatigue. It has been reported that anxiety/depression, anaemia, deranged biochemistry 
and the inflammatory response may contribute to weakness and fatigue. However, the 
relationship between subjective weakness and fatigue and objective strength in cancer 
patients is not clear. To date, such relationships have not been studied in cancer 
patients.
The aims of the present work were twofold. First, to investigate the importance of 
weight loss, altered body composition, the inflammatory response, haematological and 
biochemical parameters in the experience of weakness and fatigue in patients with 
advanced cancer. The second aim of this work was to examine the relationships between 
objective tests of strength and function and measures of weakness and fatigue and 
patient-related quality of life in patients with advanced cancer.
In chapter 5, a typical hospice population was studied retrospectively, to provide a 
background and baseline to the prospective studies. A heterogeneous group of 229 
cancer patients, who had died in the preceding 6 months, was described. Of these 
patients, more than half had the presence of weight loss documented in the casenotes. 
Weakness, fatigue and tiredness were documented as important symptoms in some 
patients, but not as frequently as in previous prospective studies. Many patients had
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increased difficulty in performing the activities of daily living. The difficulties of 
establishing symptom prevalence retrospectively from casenotes is discussed. Many of 
the patients were taking drugs implicated in the aetiology of weakness and fatigue, such 
as opioids, benzodiazepines, antidepressants and corticosteroids.
In chapter 6, a group of patients with advanced cancer was compared with an age, sex 
and healthy body mass index matched healthy control group. The cancer group were 
clearly more unwell, having lost weight including both fat and muscle. The cancer 
patients also had a lower performance status and had significantly more weakness and 
fatigue. The correlations obtained between the weakness scale and the two fatigue scales 
suggested that weakness and fatigue tend to co-exist and that patients tend to use the 
terms weakness and fatigue synonymously.
The cancer patients were more anaemic and had evidence of an inflammatory response. 
Correlations with the weakness and fatigue scales suggest that anaemia and the 
inflammatory response may be aetiological factors in the pathogenesis of weakness and 
fatigue. It was of interest that patients taking benzodiazepine drugs had higher fatigue 
scores than those not receiving such drugs.
Those cancer patients who had lost greater than 5% of their body weight were compared 
with those who were weight-stable. The weight-losers had lost muscle mass, had more 
weakness and fatigue and reported greater difficulty in carrying out activity than the 
weight-stable patients. The weight-losers had a more marked inflammatory response, 
suggesting that the inflammatory response is involved in ongoing weight loss in patients 
with advanced cancer.
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In chapter 7, it was observed that in addition to having more weakness and fatigue, the 
cancer patients had lost physical strength, compared with the healthy controls, as well as 
performing less well in the chair, stair and walking functional tests. The cancer group 
also had poorer levels of self-rated functioning, an increased symptom burden and 
poorer quality of life. Although there was no apparent relationship between the 
weakness score and the strength measures, multivariate analysis suggested that muscle 
bulk may be an important factor in determining muscle strength.
The fatigue and weakness scale scores in the cancer group were related to objective 
function, and handgrip strength was related to chair stand time. The relationship 
between strength and function was not as striking as in previous work in the healthy 
elderly. However, it was clear that cancer patients were a more rapidly changing group 
than the healthy elderly. Moreover, small decrements in strength could lead to a large 
deterioration in function as the patient crosses the threshold of ability to inability.
Patient-rated global quality of life was correlated with fatigue, weakness, the chair stand 
and depression. Therefore, it is likely that poor quality of life, in part, is the result of 
weakness and fatigue and poorer functioning. Depression was strongly correlated with 
fatigue scores and was the strongest single predictor for fatigue on multivariate analysis.
When the weight-losing patients were compared with the weight-stable patients, the 
weight-losers had lower handgrip strength, poorer self-assessed function and poorer 
performance in the chair and stair tests. The weight-losing patients had more anxiety 
and depression as well an increased symptom burden. Many of the symptom scores of 
the EORTC questionnaire were correlated with the weakness and fatigue scores. This
20
may be because more unwell patients often have multiple symptoms at the same time, 
but it is also possible that other symptoms may contribute to the pathogenesis of 
weakness/fatigue.
In chapter 8, the characteristics of those patients who were followed up to 6 weeks were 
compared with those who were not followed up due to death or disease progression. 
Patients without follow-up had lost more of their healthy weight, had lower performance 
status, poorer self-assessed and actual function, increased anxiety and depression, more 
dyspnoea and reduced appetite compared to the group with follow-up. It is likely, 
therefore, that weight-losing patients are a group with more advanced disease than 
weight-stable patients.
The follow-up patients were reassessed after 6 weeks and those who had lost weight 
over that period were compared with those who had remained weight-stable. At 
baseline, those patients who subsequently lost weight had a lower performance status, 
performed less well in the functional tests and had a more marked inflammatory 
response. In longitudinal study there was an increase in mid-arm circumference in the 
weight-stable patients as well as an improvement in fatigue scores and in the functional 
tests. The weight-losing patients had a reduced mid-arm circumference and far fewer 
patients were able to complete the functional tests than in the weight-stable group. 
Performance status did not change over time, but performance in the various functional 
tests did, suggesting that the latter may be more sensitive indicators of a patient’s ability 
to function than performance status. Although fatigue scores improved in the weight- 
stable patients, there was no alteration in depression scores, suggesting that it is likely 
that fatigue precedes a lowering in mood rather than vice versa.
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In conclusion, this work has confirmed that weakness and fatigue are common problems 
in patients with advanced cancer who are not receiving active anti-cancer therapy. 
Patients tend to use the terms weakness and fatigue synonymously. Weakness/fatigue 
become more severe with increasing weight loss and illness progression. Weight-losing 
cancer patients are more unwell than weight-stable patients and lose muscle mass, 
muscle strength and are more functionally disabled. Weight-losers have poorer quality 
of life and more anxiety and depression. It is evident that these parameters change 
together, but the longitudinal relationships between strength, function, weakness/fatigue, 
weight loss and quality of life require further study. The relationship between depression 
and fatigue is strong and understanding the nature of this relationship merits further 
investigation.
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1. INTRODUCTION AND AIMS
1.1 Cancer and the Development of Specialist Palliative Care Services
One in three people will develop cancer in the United Kingdom and one in four will die 
of the disease (Richards, 1997). Many patients will, therefore, not be cured of their 
cancer.
Palliative care has been defined as “the active total care of patients whose disease is not 
responsive to curative treatment.” This includes the control of physical symptoms as 
well as dealing with psychological, social and spiritual problems. The ultimate goal of 
palliative care is to achieve the best quality of life possible for patients and their families 
(Doyle, Hanks and MacDonald, 1998).
The modern hospice movement has done much to promote a whole person orientated 
approach to patient care. In the United Kingdom, the Marie Curie Memorial Foundation 
and St. Christopher’s hospice were at the forefront of this movement (Saunders, 1998). 
It has been recognised that there are many important components to the provision of 
good palliative care, of which in-patient care is only part. Home care services, Day Care 
Units, hospital palliative care teams and bereavement care have all become integral to 
the provision of specialist palliative care. Palliative care services have developed in 
recent years and, as well as cancer care, are increasingly providing care for patients with 
other non-malignant, incurable conditions (Twycross, 1980; Addington-Hall, 1998).
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One of the cornerstones of specialist palliative care is good symptom control. However, 
there is comparatively little evidence-based research into the symptoms experienced by 
patients with advanced cancer (Wilkinson, 1993).
The ethics of research in this patient group has been a matter of some debate, with some 
claims that research in a vulnerable patient population is not desirable, and that many 
patients may feel obliged to participate in a project even though it will not directly 
benefit themselves (de Raeve, 1994).
There are, however, compelling counter arguments in favour of research in this patient 
group. Speck (1996) argues that there is an ethical obligation to undertake clinical 
research in order to improve the knowledge base against which clinical decisions are 
made. Bruera (1994) argues that we cannot afford not to perform research, given the 
increasing number of patients dying with cancer and the fact that many of the symptoms 
which cause patients significant distress have, as yet, no effective treatment.
It is, of course, important that patients understand the nature of any research in which 
they participate, so that consent is properly informed. Patients also need to be assured 
that they are free to withdraw from the study at any time, without prejudicing their 
future care (Wilkinson, 1993; Bruera, 1994; Speck, 1996). There is often a high attrition 
rate in studies involving patients with advanced cancer, because patients become too 
unwell or die before study completion (Loprinzi et al., 1990).
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1.2 The Problem of Weakness and Fatigue
In a survey of 1000 patients with advanced cancer, Donnelly and Walsh (1995) reported 
that the ten most frequently observed symptoms were pain, fatigue, weakness, anorexia, 
weight loss, lack of energy, dry mouth, constipation, dyspnoea and early satiety. When 
these symptoms were present, 60-80% of patients rated them as moderate or severe. In 
this study, pain was reported to be the commonest symptom. However, recently, some 
researchers have concluded that weakness and fatigue are actually the commonest 
symptoms faced by this patient group (Lichter, 1990; Glaus, Crow and Hammond, 
1996; Vogelzang et al., 1997; Pater et al., 1997).
Although there has been a significant amount of research into pain control in cancer 
patients, there has been comparatively little research into weakness and fatigue. One 
study of weakness in the elderly suggested that weakness was often a symptom that was 
accepted as inevitable (Gordon, 1986). It has been suggested that pain and pain control 
gain much more attention from oncologists than fatigue, perhaps because effective 
treatments exist for pain control (Vogelzang et al., 1997). The very vagueness of the 
concepts of weakness and fatigue, and the fact that patients often use different terms 
such as tiredness, exhaustion, lethargy and loss of energy to describe how they are 
feeling, make them difficult symptoms to research (Lichter, 1990; Regnard and Mannix, 
1992). Many researchers agree that weakness and fatigue are difficult terms to define 
clearly (Dunlop, 1989; Nail and Winningham, 1995). The different prevalences noted in 
the literature for weakness and fatigue may be due to inconsistent definitions, variable 
patient populations or the lack of appropriate control groups (Richardson and Ream, 
1996; Loge and Kaasa, 1998).
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Published studies suggest that between 40 and 82% of hospice or hospital patients with 
advanced cancer experience weakness (Dunlop, 1989; Donnelly and Walsh, 1995). 
Copp and Dunn (1993) reported that hospice and community nurses found weakness to 
be the most difficult symptom to manage in dying patients. Rhodes, Watson and Hanson 
(1988) reported that tiredness and weakness were the two symptoms that interfered most 
with patients’ abilities to care for themselves. They also observed that it was difficult to 
disentangle the two concepts of tiredness and weakness. Dunlop (1989) reported that 
weakness was not only the commonest symptom experienced by cancer patients 
(reported by 82% of patients), but was also their most distressing symptom. Pater and 
colleagues (1997) cited fatigue as the commonest and most distressing symptom faced 
by patients with cancer. Meyerowitz, Sparks and Spears (1979) reported that, in a study 
of 50 patients with breast cancer, 96% of patients experienced fatigue related to 
chemotherapy. However, this study had no control group. It has been suggested that up 
to 100% are fatigued after radiotherapy (Nail and King, 1987). More recently, 
Richardson (1995) commented that fatigue was the most distressing side effect of 
chemotherapy.
The terms weakness and fatigue are often used interchangeably by staff and patients 
alike (Piper, Lindsey and Dodd, 1987) and it has been suggested that they may well be 
aspects of the same phenomenon (Morant et al., 1993; Nail and Winningham, 1995). 
Some researchers prefer to use the term asthenia to describe the combination of 
weakness and fatigue thought to co-exist in many patients (Bruera and MacDonald, 
1988; Morant, 1996). However, some effort has been made to discriminate between 
these two concepts.
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1.2.1 Definition of Weakness
The term weakness has, in the past, often been associated with strokes, neuromuscular 
disorders and immobility (Nail and Winningham, 1995) and some suggest that weakness 
is predominantly a neurological problem (Pickard-Holley, 1991). Various definitions in 
the cancer and palliative care literature include both subjective and objective 
dimensions. Weakness has been defined as a deficiency in strength or power (Lichter,
1990) or a reduction in muscle strength or endurance below a baseline level (Nail and 
Winningham, 1995). Other definitions include; an inability or difficulty in starting an 
activity (Morant et al., 1993) and physical inability to perform a task (Dunlop, 1989; 
Barnish, 1994).
Glaus and colleagues (1996), reporting on a study of subjective experiences of 
fatigue/tiredness, suggested that weakness is a pathological component of tiredness, not 
found in the healthy subjects, and reported that tiredness was often expressed as a 
reduction in physical strength or reduced physical performance, for example an inability 
to walk as far as before. These researchers hypothesised that strength might be a key 
dimension to be isolated and studied further. In this study, weakness was defined as “an 
anticipatory, subjective sensation of difficulty in initiating a certain activity” which did 
not include localised or regional weakness from neurological or muscular disorders, thus 
distinguishing between weakness from neurological damage and weakness with normal 
neurological function.
1.2.2 Definition of Fatigue
On the other hand, fatigue has, primarily, been described as a subjective, 
multidimensional phenomenon which is variable in severity and has physical,
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emotional, mental, functional and spiritual components (Irvine et al., 1991; Irvine et al., 
1994; Nail and Winningham, 1995; Glaus et al., 1996). A recent study developed a 
definition of fatigue from analysis of concepts raised by cancer patients at interview: “a 
subjective, unpleasant symptom which incorporates total body feelings ranging from 
tiredness to exhaustion, creating an unrelenting overall condition which interferes with 
individuals’ ability to function to their normal capacity” (Ream and Richardson, 1996). 
Other patient complaints are of a complete lack of energy, lethargy, tiredness and sheer 
exhaustion, feeling “slowed down”, cognitive problems such as loss of motivation and 
poor concentration, and also a decreased ability to perform simple tasks (Meyerowitz 
et al., 1979; Rhodes et al., 1988; Pickard-Holley, 1991; Winningham et al., 1994; 
Irvine et al., 1994; Ream and Richardson, 1997). Many patients complain of associated 
low mood, loss of control of their lives and loss of independence (Irvine et al., 1991; 
Ream and Richardson, 1997). It has also been suggested that depression, as well as 
resulting from fatigue, can also be a cause of fatigue (Vogelzang et al., 1997).
In the study carried out by Vogelzang and colleagues (1997), patients reported that 
fatigue was something they had “to endure”. One third of patients reported that fatigue 
affected their hope of fighting their illness, or of survival, and 12% felt that they would 
rather die than face fatigue.
Some researchers distinguish between acute and chronic fatigue. Ream and Richardson 
(1997) describe acute fatigue as a phenomenon experienced by normal individuals as a 
response to physical activity, mental effort or lack of sleep. It is transient and will 
generally respond to rest or a change of lifestyle, hence the term acute fatigue. It appears 
to be part of normal body functioning, protecting the individual from various stresses,
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physical, emotional, mental and spiritual (Piper et al., 1987; Nail and King, 1987; 
Bamish, 1994).
Chronic fatigue, however, is not present in normal individuals and is present in a variety 
of disease states, particularly in malignancy and chronic infection (Morant et a l, 1993). 
Tiredness occurs with only mild or moderate physical or mental effort and rest fails to 
adequately relieve this symptom, which may relate to chronic stress, either directly or 
indirectly related to the disease process. This may lead to avoidance of activity (Aistars, 
1987; Piper et a l, 1987; Bamish, 1994; Ream and Richardson, 1997).
Fatigue is particularly reported in relation to cancer therapy, such as chemotherapy, 
radiotherapy and biological response modifiers, such as interferon. Many patients 
discontinue treatment as a result of distressing fatigue (Winningham et a l, 1994; 
Richardson, 1995). However, the prevalence estimates for fatigue in many studies need 
to be interpreted with caution, as fatigue is present in the healthy population and a lot of 
studies do not include a healthy control group.
1.2.3 Comparison of Weakness and Fatigue
Is there a relevant and useful difference between weakness and fatigue? In the study by 
Glaus and colleagues (1996), the patients stated that there was a physical dimension to 
their experience of tiredness, often describing this as loss of strength. It was 
hypothesised that it might be possible to isolate the physical component of tiredness and 
that, perhaps, this could be regarded as weakness as opposed to fatigue.
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Morant and co-workers (1993) hypothesised that there was a difference between 
weakness and fatigue by suggesting that weakness constituted difficulty in initiating 
activity, but that fatigue was a lack of strength to continue activity once started. Many 
patients find that they are able to perform activity during a crisis or given the appropriate 
stimulus, that they would otherwise have found difficult to do (Nail and Winningham, 
1995). Glaus and co-workers suggested that there must be a voluntary component to 
fatigue, since an individual can still push himself/herself to perform certain tasks (Glaus 
et al., 1996). Motivational factors may therefore be important in distinguishing between 
fatigue and weakness, fatigue having a motivational component, but weakness a 
disability which cannot be overcome by mental effort. The presence of an anxiety 
disorder or depression may, however, affect the mental effort needed for activity (Glaus 
et al., 1996). It is, therefore, likely to be difficult to disentangle the physical and 
emotional factors involved in the performance of activity.
Weakness could, therefore, be regarded as a difficulty or absolute inability in initiating 
activity, which cannot be overcome by mental effort, making it a largely objective and 
physical problem. Fatigue could be considered to be an inability to continue activity 
once started, due to tiredness, but which has a motivational component, i.e., the patient 
can keep going, given the appropriate stimulus or mental effort.
The difficulties in separating these two symptoms are multiplied by the fact that 
weakness and fatigue are likely to co-exist and may interact with each other. Patients 
who are tired are likely to reduce their activity levels, leading to muscle disuse and 
muscle weakness. Patients who are weak are likely to have more difficulty in 
performing activity: more strength will be needed to perform that activity and they will
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tire more easily. A downward spiral may be difficult to arrest (Nail and Winningham, 
1995; Glaus et ai., 1996).
Although, theoretically, it may be possible to distinguish between weakness and fatigue, 
it has to be acknowledged that patients are likely to use the terms synonymously to mean 
either an objective difficulty in doing something or a subjective experience of tiredness. 
It is likely that weakness and fatigue represent two overlapping components of a bigger 
problem, which has been termed asthenia. However, there is value in trying to tease out 
these components if it will influence management of the patient’s symptoms. What is, 
therefore, most important is not which words the patient is using to describe how they 
are feeling, but the problems that the patient is experiencing which prevent him/her 
from functioning normally.
Although there are studies which have considered the subjective experience of patients 
with weakness/fatigue (Dunlop, 1989; Glaus et al., 1996; Krishnasamy, 1997), there are 
no prospective studies to date which have attempted to investigate the relationship 
between these subjective elements and objective physical strength and performance in 
daily activities. There are also no prospective controlled studies to date which have 
investigated the experiences of weakness/fatigue in cancer patients who are not 
receiving active cancer treatment.
In the subsequent sections of this chapter, possible aetiological factors in the 
pathogenesis of weakness/fatigue will be considered, paying particular attention to 
possible causes of muscle weakness and dysfunction in cancer patients. The terms
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weakness, fatigue and asthenia will be used, where this is the term used by the author 
quoted.
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1.3 Cancer Cachexia
The syndrome of cancer cachexia is often suggested as an aetiological factor for the 
symptoms of weakness and fatigue (Theologides, 1979; Lichter, 1990; MacDonald, 
Alexander and Bruera, 1995; Billingsley and Alexander, 1996). An often profound 
weight loss, with consequent loss of muscle mass and adipose tissue, is the major 
feature of this debilitating syndrome (Nelson, Walsh and Sheehan, 1994a; Toomey, 
Redmond and Bouchier-Hayes, 1995). It is hypothesised that the loss of muscle mass 
leads to loss of muscle strength, hence weakness (Lichter, 1990).
1.3.1 Weight Loss in Cancer Patients
It has been recognised for many years that cancer patients who lose weight have a poorer 
prognosis than those who remain weight-stable (DeWys et al., 1980; Kern and Norton,
1988). As well as having a shorter survival time, patients who have lost a considerable 
amount of weight tolerate anticancer therapies, such as chemotherapy or radiotherapy, 
less well than weight-stable patients (Loprinzi, 1995).
The majority of patients with advanced cancer lose weight (Nixon et al., 1980), 
although this varies according to tumour type. Patients with lung and gastrointestinal 
cancers tend to lose large amounts of weight early on in their illness, whereas patients 
with breast and haematological malignancies frequently maintain their weight until late 
in the illness (MacDonald et al., 1995; Billingsley and Alexander, 1996).
The syndrome of cancer cachexia is not merely weight loss, but includes anorexia, and 
often early satiety and nausea (possibly secondary to gastric stasis caused by autonomic
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insufficiency) (Brennan, 1977; Theologides, 1979; Caiman, 1982; Nelson et al., 1994a; 
Falconer et al., 1994).
Patients with cachexia are more prone to infection, and infection is probably a common 
cause of death in those cancer patients who have lost a substantial amount of weight 
(Klastersky, Daneau and Verhest, 1972). However, Warren (1932), in a large post­
mortem study, concluded that cachexia, in the absence of other factors, was the sole 
cause of death in 22% of patients. Other researchers have concluded that cachexia is a 
major factor in the death of up to 50% of cancer patients (Toomey et al., 1995; Espat, 
Moldawer and Copeland, 1995; Billingsley and Alexander, 1996).
It is important to know the nature of the tissue being lost in weight-losing cancer 
patients. There is loss of both skeletal muscle and adipose tissue, and one group of 
researchers found a reduction in total body fat of 85%, and in muscle tissue of 75%, in a 
group of lung cancer patients who had lost 30% of their original pre-illness weight 
(Preston et al., 1995). Although both adipose tissue and muscle mass are lost, it is 
suggested that the loss of muscle accounts for most of the morbidity and mortality 
(Nelson et al., 1994a; Toomey et al., 1995). In cachectic patients, muscle protein 
synthesis appears to be reduced and muscle breakdown increased (Emery et al., 1984; 
Toomey et al., 1995). In a study by Heymsfield and colleagues (1985), it was noted that 
in weight-losing cancer patients there was no alteration in visceral tissue and non­
muscle protein. In contrast, in a group of patients with anorexia nervosa, there was a 
reduction in the weight of these tissues. These results were later confirmed by Preston 
and colleagues (1995). This suggests that the weight loss in cancer patients is not merely 
due to starvation.
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1 .3 .2  A etio logy  o f  Cancer C achexia
Weight loss does not appear to be related merely to altered digestion or mechanical 
disruption, e.g., in oesophageal or gastric tumours, as patients with lung cancer often 
lose significant amounts of weight (Stanley, 1980). The degree of weight loss does not 
appear to correlate with the cancer type or site, or the tumour bulk (Kern and Norton, 
1988; Tisdale, 1991).
Weight loss results from an energy imbalance between energy intake and energy 
expenditure. This negative energy balance may, thus, be related to a reduced food 
intake, increased energy expenditure, or a combination of both.
Food intake does appear to be reduced in cachectic cancer patients, and anorexia is a 
common symptom in cancer patients (DeWys, 1979; Bruera, 1997; O'Gorman, 
McMillan and McArdle, 1998). Although some patients do have mechanical causes for 
reduced food intake, and some patients complain of nausea and altered taste sensation 
(Theologides, 1972; Caiman, 1982; Kern and Norton, 1988), many patients lose weight 
disproportionately to their reduction in food intake (DeWys et al., 1980).
Studies of resting energy expenditure in cancer patients have found that in weight-losing 
patients resting energy expenditure is inappropriately high. The body’s normal adaptive 
response to weight loss is a reduction in energy expenditure, yet many studies have 
found either normal, or increased, resting energy expenditure, suggesting that 
metabolism in these patients is abnormal (Theologides, 1979; Caiman, 1982; Fearon and 
Carter, 1988). Falconer and colleagues (1994) found that an elevated energy expenditure
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in pancreatic cancer patients was associated with the presence of an acute phase 
response.
It has been suggested that cytokines such as the interleukins 1 and 6 and tumour 
necrosis factor are mediators of cancer cachexia (Scott et al., 1996; Billingsley and 
Alexander, 1996). Cytokines are polypeptide molecules produced by inflammatory cells, 
in particular macrophages, monocytes and lymphocytes, in response to tumour growth, 
infection and trauma (Billingsley and Alexander, 1996). Cytokines redirect protein 
metabolism away from the peripheral tissues to the liver, with a consequent increase in 
hepatic acute phase protein synthesis. Acute phase proteins, such as C-reactive protein, 
are produced by the liver in response to inflammation and appear to be a reliable 
measure of the acute phase response (Thompson, Milford-Ward and Whicher, 1992). 
Tumour necrosis factor and interleukin-1 are not consistently found in the serum, but 
may act at a tissue level (Billingsley and Alexander, 1996). However, raised serum 
levels of interleukin-6 have been frequently detected in the serum of some groups of 
weight-losing cancer patients (Espat et al., 1995; Scott et al., 1996).
Increasing C-reactive protein levels have been associated with disease progression 
(Milano et al., 1978) and a correlation between C-reactive protein and fatigue severity 
has been previously reported (Morant, 1996). Elevation of C-reactive protein 
concentrations have been reported in association with weight loss in non-small cell lung 
cancer patients (Scott et al., 1996). Although not all weight-losing cancer patients have 
elevated C-reactive protein levels (Fearon, 1992; McMillan et al., 1994a), some studies 
have reported that elevated C-reactive protein is a strong predictor of reduced survival 
(Fearon, 1992; Falconer et al., 1995). Fearon (1992) has reported that an acute phase
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response is associated with a reduction in body cell mass, the component of body fat 
free mass where most of the important metabolic processes, such as energy production, 
are carried out (Heymsfield, Tighe and Wang, 1994). It has also been reported that a 
reduction in the acute phase response in animals can improve anorexia and lead to 
weight gain (Gelin and Lundholm, 1992).
1.3.3 Treatment of Cachexia
Given that cancer cachexia is such a significant problem in cancer patients in terms of 
morbidity and mortality, the reversal of this process would seem to be of considerable 
importance. However, the definitive method of treating cachexia, i.e., removal, or other 
curative treatment of the tumour (Kern and Norton, 1988; Fearon and Carter, 1988), is 
not an option in a large number of patients.
Supplementary nutrition has been considered as a means of increasing caloric intake 
(Burke, Bryson and Kark, 1980). It has been suggested that supplementing nutrition by 
intravenous (parenteral) or enteral routes may improve the outlook in this patient group, 
particularly in terms of responsiveness to cancer therapy (Copeland et a l, 1975).
However, a meta-analysis of 28 randomised trials of total parenteral nutrition (TPN) has 
reported no significant improvement in tolerance of, or response to, anti-neoplastic 
therapy, nor in survival for those receiving TPN (Klein, Simes and Blackburn, 1986), 
although some trials have reported patient weight gain (Popp et a l, 1981). There have 
also been significant complications in some patients, including thrombosis and 
infection. An increase in weight following enteral feeding via nasogastric or 
gastrostomy tube has previously been reported (Keymling, 1994; Bozzetti, 1994).
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However, it would appear that the increase in weight was due to a disproportionate 
increase in body fat compared with lean body tissue (Bozzetti, 1994).
Given that cancer cachexia appears to be the result of complex metabolic processes 
(Billingsley and Alexander, 1996), it is likely that the solution to weight loss in cancer 
patients will involve more than simply increasing the calorie intake (DeWys and 
Kubota, 1981).
There have been many attempts to influence cancer cachexia through pharmacological 
measures, using drugs such as cyproheptadine, pentoxifylline and hydrazine sulfate. 
However, few controlled trials exist and there is little objective evidence to support their 
use (Kardinal et al., 1990; Loprinzi et al., 1994a; Loprinzi et al., 1994b; Loprinzi, 
1995 ; Goldberg et al., 1995).
Other drugs such as thalidomide, melatonin, (3-2 adrenoceptor agonists and the 
cannabinoids have been suggested as possible therapies for cancer cachexia, but no large 
trials have yet been published (Nelson et al., 1994b; Gagnon and Bruera, 1998). 
However, there is some evidence that the use of the polyunsaturated fatty acid 
eicosapentanoic acid may affect the acute phase response and lead to weight gain in 
pancreatic cancer patients (Wigmore et al., 1997).
Corticosteroids are widely used as appetite stimulants (Willox et al., 1984), but there is 
no clear evidence of muscle mass gain, or improved survival, and they have significant 
side-effects. The role of steroids in cancer patients is further discussed in section 1.9.
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Megestrol acetate is a synthetic progestogen which has been used in the treatment of 
breast cancer. It had also been noted to cause an increase in appetite and weight in some 
patients unrelated to tumour response (Ansfield et al., 1974; Ansfield et al., 1976). 
Several randomised double-blind placebo-controlled studies in cancer patients of mixed, 
mainly non-hormone responsive tumour types have shown increased appetite, some 
weight gain and improved mood (Loprinzi et al., 1990; Bruera et al., 1990; 
Tchekmedyian et al., 1992; Strang, 1997). However, weight gain in cancer patients 
receiving megestrol acetate appears to be mainly fat with little increase in fat free mass 
(Loprinzi et al., 1993).
Medroxyprogesterone acetate is a progestational agent with additional endocrine effects. 
Johnson and co-workers (1984) reported weight gain in 53% of patients with advanced 
breast cancer, although it is possible that this is because the medroxyprogesterone 
acetate was acting as an anti-tumour agent. Downer and colleagues (1993) studied a 
group of cancer patients, with non-hormone responsive tumours, in a randomised double 
blind placebo controlled trial and found no evidence of weight gain, although there was 
a significant improvement in appetite.
Ibuprofen is a non-steroidal anti-inflammatory drug which has been reported to 
moderate the acute phase response and reduce the circulating concentrations of acute 
phase proteins (Preston et al., 1995; McMillan et al., 1995). It has also been reported to 
reduce resting energy expenditure in pancreatic cancer patients (Wigmore et al., 1995). 
A recent study has suggested a role for ibuprofen, in combination with megestrol 
acetate, in promoting weight gain in weight-losing patients with an acute phase response 
(McMillan et a l, 1997).
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It is clearly important that further study of the acute phase response, in relation to 
cachexia and fatigue, is carried out.
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1.4 Neuromuscular Disorders
The term weakness has often been used to denote a neurological or neuromuscular 
problem (Nail and Winningham, 1995). Indeed, there are a number of reasons why these 
problems occur in cancer patients. Focal limb weakness may be the result of a 
cerebrovascular accident, a haemorrhage into a primary or secondary brain tumour, or 
directly related to cerebral métastasés. Clinicians should also be wary of the patient 
complaining of being “off his legs”, or reporting leg weakness, as this may represent a 
potentially treatable spinal cord compression .
Radiculopathies, due to spread of the primary tumour - particularly breast, lung, gastric, 
melanoma and lymphoma - to the leptomeninges, may present with a variety of motor 
and sensory deficits, particularly a lower motor neurone type weakness (Chad and 
Recht, 1991).
Brachial plexopathy is due to damage to the brachial plexus from disease spread to the 
axillary lymph nodes - usually from a breast or lung carcinoma - or due to previous 
radiotherapy, often many years before. Weakness is, however, far less common than 
pain. The distribution of the weakness will relate to the part of the brachial plexus 
involved. Lumbosacral plexopathy may relate to direct invasion of the lumbosacral 
plexus from an intra-abdominal neoplasm or, less commonly, due to metastatic spread - 
usually from a primary breast carcinoma - or previous radiotherapy. Pain and weakness 
co-exist, although weakness is the more prominent in radiotherapy induced lesions and 
is usually bilateral, symmetrical and distal in distribution (Chad and Recht, 1991; 
Stubgen, 1995).
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Paraneoplastic syndromes are uncommon, but should be considered as a cause of muscle 
weakness. Symptoms can precede the cancer diagnosis by a period of months to years 
and many of these syndromes can be partially reversible with treatment of the tumour 
(McEvoy, 1994). Table 1.1 lists some of the paraneoplastic syndromes which may 
present with muscle weakness (Richardson, 1982; Chad and Recht, 1991; Dalmau et al., 
1992; Stubgen, 1995). The commonest of these is the Lambert-Eaton myasthenic 
syndrome (LEMS) which is present in about 3% of patients with small cell lung cancer 
(McEvoy, 1994; Stubgen, 1995). LEMS is caused by antibodies against voltage-gated 
calcium channels, which prevent the release of acetylcholine from peripheral nerve 
terminals, and presents with predominantly proximal muscle weakness. Weakness tends 
to affect the lower limbs and is associated with easy muscle fatiguability, hyporeflexia 
and autonomic dysfunction (McEvoy, 1994; Anderson, 1995; Stubgen, 1995).
Myasthenia gravis is associated with thymoma in 30% of patients. When thymoma is 
present it is generally poorly responsive to thymectomy (Stubgen, 1995).
Drugs used as anti-cancer therapy can also lead to iatrogenic muscle weakness, notably 
vincristine and other vinca alkaloids, etoposide, paclitaxel and cytosine (Stubgen, 1995).
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Table 1.1 Paraneoplastic Syndromes Which May Present With Muscle Weakness
Paraneoplastic syndrome Associated malignancy
Motor neurone disease: 
Amyotrophic lateral sclerosis Non-Hodgkin’s lymphoma
Subacute motor neuronopathy Hodgkin’s disease
Lambert-Eaton myasthenic syndrome Small-cell lung cancer in up to 80% of 
patients
Myasthenia gravis Thymoma
Polymyositis/dermatomyositis Lung, breast, gastrointestinal and ovarian 
malignancies are most common
Carcinoid myopathy Carcinoid syndrome
Acute necrotising myopathy Small-cell lung cancer, breast, 
gastrointestinal and bladder malignancies
Paraneoplastic encephalomyelitis Mainly small-cell lung cancer 
(Anti-Hu antibody associated)
Sensorimotor polyneuropathies: 
Acute inflammatory demyelinating 
(Guillain-Barre syndrome)
Hodgkin’s disease, lung cancer
Chronic inflammatory demyelinating Lymphoma
Acute/chronic axonal Lung cancer
Carcinomatous myelopathy Mainly lung cancer (very rare)
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1.5 Aetiology of Impaired Muscle Function
Cachexia causes a reduction in muscle quantity. In the review of weakness in cancer 
patients by Lichter (1990), cachexia was considered to be the major cause of muscle 
weakness. However, not all patients who complain of feeling weak have lost weight 
and Theologides (1982) speculated as to why some patients with asthenia maintained 
their muscle bulk and strength until death. Most clinicians will have known patients 
who were able to self-care despite their marked cachexia, and some who became 
dependent and were unable to function despite maintaining their weight.
1.5.1 Inactivitv
Many cancer patients are far less active than their healthy counterparts and some 
researchers have commented on the role of inactivity in the production of muscle 
weakness in cancer patients (Winningham et al., 1994; Nail and Winningham, 1995). It 
has been estimated that a third or more of the reduction in ability to carry out physical 
activity in cancer patients can be attributed to prolonged physical inactivity (MacVicar, 
Winningham and Nickel, 1989). Excessive bedrest is thought to be partly responsible 
for weakness and reduced exercise tolerance (Lichter, 1990). Immobility is known to 
reduce muscle strength more than muscle area, with the quadriceps being the muscle 
most severely affected (Norregaard et al., 1994). The quadriceps muscle is functionally 
very significant and is used in many important daily activities, such as rising from a 
chair and stair climbing (Bassey et al., 1992).
Inactivity may be an inevitable result of advancing cancer and increasing ill-health. It 
may, however, be partly related to altered role. Tasks previously performed by the
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patient may become delegated to carers, either at the patient’s instigation or by the well- 
meaning intervention of carers. This may have knock-on effects and the patient may 
suffer from loss of role, poor self-esteem and greater dependence (Aistars, 1987). It is 
not clear whether the previous fitness or activity level of the patient affects the rate of 
any subsequent decline.in muscle function or strength.
1.5.2 Cytokines and Muscle Metabolites
It has been hypothesised that circulating humoral factors may cause changes to muscle 
and its function (Theologides, 1982). More recently fatigue has been associated with the 
local and circulating effects of cytokines on muscle function. St. Pierre, Kasper and 
Lindsey (1992) hypothesised that tumour necrosis factor, either produced by the body in 
response to the cancer, or used as anti-cancer therapy, may contribute to generalised 
muscle weakness via reduced muscle protein stores, leading to reduced muscle bulk and 
metabolic abnormalities within the muscle. It is thought that this may lead to reduced 
contractile ability in the muscle and impaired neuromuscular transmission. It is 
suggested that both the qualitative and quantitative effects on muscle will limit the 
patient’s ability to exercise and that increased effort will be required to generate 
adequate contractile force. Ability to exercise may, therefore, be impaired in cachectic 
cancer patients because of increasingly abnormal skeletal muscle metabolism.
During exercise, particularly in those who are inactive, like many cancer patients, there 
may be an accumulation of some muscle metabolites, such as hydrogen ions, and a 
reduction in others, such as muscle phosphocreatinine. These changes may contribute to 
the patient’s experience of fatigue (Newsholme, Blomstrand and Ekblom, 1992; 
St. Pierre et al., 1992).
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1.5.3 Other Causes of Impaired Muscle Function
Muscle biopsies have shown that cancer patients, even those who have not lost weight 
tend to lose type 2 muscle fibres preferentially to type 1 fibres. Type 2 fibres are used 
more in short duration activity, e.g., stair climbing, and this may explain some of the 
functional problems faced by non weight-losing cancer patients (Gomm et al., 1990; 
St. Pierre et al., 1992).
Vitamin D deficiency (osteomalacia) is common in medically ill patients, and one study 
of 290 consecutive patients on a general medical ward reported that 57% were vitamin 
D deficient (Thomas et al., 1998). One feature of vitamin D deficiency is proximal 
muscle weakness, which can be marked (Forbes and Jackson, 1993). Vitamin D 
deficiency relates to a combination of dietary deficiency and lack of sunlight exposure 
(Ainsleigh, 1993; Forbes and Jackson, 1993). Vitamin D concentrations have not 
previously been studied in patients with advanced cancer.
1.5.4 Muscle Electrical Activity
It can often be difficult to determine how much of an apparent muscle weakness is truly 
organic (has a physical cause) and how much Is functional (no obvious physical cause) 
(McComas, Kereshi and Quinlan, 1983). Patients may complain of muscle weakness 
and the reduced strength could be related to a loss of muscle tissue, a change in muscle 
function, or an inability or reluctance to activate fully all of the muscle (Rutherford, 
Jones and Newham, 1986).
The technique of twitch interpolation by electrical stimulation has a long tradition in the 
scientific literature. It has been used to study the electrical activity of muscles and to try
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and distinguish between the voluntary and involuntary components of muscle force 
production (Denny-Brown, 1928; Merton, 1954). The principle is that if a subject can 
activate a muscle fully during a muscle contraction then a superimposed electrical 
stimulus will not produce any additional force (Merton, 1954; McComas et al., 1983).
It has been shown that by stimulating the quadriceps muscle, the extra force generated 
by the interpolated twitch decreases with increasing levels of voluntary muscle force, 
(Chapman et al., 1984). This has been confirmed in other muscle groups (Belanger and 
McComas, 1981). Thus, an electrical stimulus delivered when the subject is producing a 
sub-maximal effort will produce a twitch tracing, the height of which is inversely related 
to the strength of the muscle contraction. The size of the superimposed twitch falls off 
linearly with increasing muscle tension and when the muscle is fully activated, i.e., true 
maximum voluntary contraction, then no twitch will be visible. A series of twitches 
related to muscle contractions of varying strengths may be graphed and the extrapolated 
value of muscle force for zero twitch corresponds to the maximal voluntary muscle 
force achievable (Merton, 1954; Chapman et al., 1984; Norregaard et al., 1994).
The technique can be used to decide whether a subject, when asked to produce a 
maximum voluntary muscle contraction has in fact done so (Chapman et al., 1984). 
One study reported a large functional component to reported muscle weakness in two 
patients. Large twitches were observed, superimposed on the force tracing, indicating 
that both patients had performed sub-maximal efforts (McComas et al., 1983). 
Sub-maximal efforts may be related to poor motivation, pain, fear of pain and 
psychological factors (Rutherford et al., 1986). It is possible that subjects may feel 
“weak”, without any detectable, objective muscle weakness.
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Rutherford, using this technique to study quadriceps muscle activation, was able to 
identify three patient groups: those with pain and incomplete activation of muscle due to 
pain, those with no pain and incomplete activation and those with loss of muscle tissue 
and full activation. (Rutherford et al., 1986).
Several groups have studied muscle strength and activation in patients with chronic 
fatigue syndrome. Two studies reported muscle strength to be normal in this patient 
population and similar to that of the healthy controls (Lloyd, Hales and Gandevia, 1988; 
Stokes, Cooper and Edwards, 1988). Stokes and colleagues commented that 
abnormalities in performance occurred only during voluntary activity and concluded that 
central impairment causing a sub-maximal effort was the cause of weakness, rather than 
intrinsic muscle weakness. Lloyd and co-workers (1988), however, suggested that the 
problem was an abnormality of perception of muscle force by the subject rather than of 
actual force production, i.e., the subject was unable to tell he had produced a 
sub-maximal effort. In contrast, Norregaard’s study reported that muscle strength was 
reduced per unit area of the quadriceps muscle in patients with fibromyalgia - which is 
related to chronic fatigue syndrome - and found no difference in central activation 
between patients and controls (Norregaard et al., 1994).
The clinical studies involving twitch interpolation have generally studied isometric 
muscle contractions (see section 1.6) in different patient groups, although one study has 
looked at isokinetic contractions (Westing, Seger and Thorstensson, 1990).
The above principles may well be applicable to cancer patients. Although a few studies 
have reported abnormal muscle electrophysiology in cancer patients (Bruera et al.,
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1988; Monga et a l, 1997), there appear to be no studies of twitch interpolation in cancer 
patients. Many patients will have lost muscle quantity, but may be able to fully activate 
their muscles and may be weak purely due to loss of muscle bulk. However, some 
patients may have normal muscle bulk and still have reduced strength due to failure to 
use their muscles properly. Some cachectic patients may also have an element of 
abnormal muscle function. More work needs to be done in looking at the involuntary 
and voluntary components of muscle strength in cancer patients.
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1.6 Strength and Functional Ability
Although weakness has been defined as a reduction in muscle strength, and many have 
commented at the difficulty cancer patients with weakness or fatigue have in the 
performance of ordinary activity, to date there appear to be few studies which have 
measured strength and quantified functional ability in cancer patients, or have examined 
their relationship. Having concluded that muscle function and muscle electrophysiology 
were abnormal in cancer patients, Bruera and co-workers hypothesised that abnormal 
muscle function may be a major component of asthenia/fatigue. It was suggested that 
attempts should be made to correlate the severity of asthenia with muscle function 
(Bruera et al., 1988, 1989).
In physiological terms, strength is the ability of a muscle to generate force. Force is 
more difficult to define as in itself it cannot be seen. What can be seen is the effect of 
that force, for example an object falling to the ground under the effect of gravity. If a 
force is applied to an object it will move and accelerate, unless an opposing force acts 
upon it (Jones and Round, 1990a). Measurement of muscle force has been important for 
exercise scientists and for those involved in rehabilitation medicine, to assess the effects 
of exercise or training programmes (Perrin, 1993a).
The capacity of a muscle to generate force can be assessed through either static or 
dynamic contraction. Isometric (constant length) contractions are static muscle 
contractions. In isometric assessment, the amount of force a muscle can generate against 
a resistance permitting no overall joint movement is measured. The resistance is in 
direct ratio to the force applied (Perrin, 1993a).
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Testing of isometric force has traditionally been performed with techniques such as 
handgrip dynamometry (Perrin, 1993a). Handgrip dynamometry has been used 
extensively in a variety of patient settings (Kallman, Plato and Tobin, 1990; Watters 
et al., 1993; Cress et al., 1995). The main advantage of isometric resistance is that it 
can be used to test muscles around a joint which cannot move, for example due to joint 
pathology (Perrin, 1993a). It is also an easy concept for the patient to understand. The 
major disadvantage of isometric strength assessment is that it allows measurement only 
at a specific point in a joint’s range of motion and, therefore, does not directly relate to 
usual daily activities.
Isotonic (constant load) assessment is a dynamic method of measuring muscle force and 
involves the application of force through all or part of a joint’s range of movement. A 
muscle can produce dynamic tension whilst either shortening or lengthening (Perrin, 
1993a). In isotonic muscle contraction the level of resistance against joint movement 
remains constant (Thistle et al., 1967). If the joint movement is in a direction opposite 
to that of gravity and the force produced by the muscle exceeds the external resistance 
encountered, the contraetion is described as shortening (or concentric) in nature (Perrin, 
1993b). If the joint motion is in the direction of the gravity and the external resistance 
encountered exceeds the muscle’s ability to generate force, the contraction is described 
as lengthening (or eccentric) in nature. Isotonic force can be measured using dumbbells 
or weight machines and force is often measured by testing the amount of weight that can 
be lifted through a joint’s range of movement for a number of repetitions. Isotonic 
measures have the advantages of being able to assess multiple joints simultaneously and 
of assessing a more natural form of movement. However, isotonic assessment is limited 
in that the muscle can be overloaded only by the amount of weight that can be lifted
51
through the weakest part of the exercised range of motion. There may also be difficulties 
in isolating a specific muscle group without contribution from accessory muscle groups.
An isokinetic contraction is also a dynamic contraction, but the angular velocity of joint 
motion is held constant. The concept of isokinetic contraction and exercise is a 
relatively recent development (Thistle et al., 1967; Hislop and Perrine, 1967). Isokinetic 
dynamometers allow individuals to exert as much force and angular movement 
(movement through a joint’s natural range of motion) as they can up to a predetermined 
velocity and through a pre-determined range of movement (Perrin, 1993a). When a 
limb’s angular rate of movement equals or exceeds the pre-set velocity limit, the 
dynamometer produces an equalling counterforce to ensure constant movement rate 
(Thistle et ah, 1967; Perrin, 1993a). The limb being studied is attached to the lever arm 
of the dynamometer. As force is being measured about a joint’s axis of rotation it is 
technically known as torque (Perrin, 1993b). Measurement of isokinetic resistance has 
the advantage that a muscle group can be exercised to its maximum potential throughout 
a joint’s entire range of motion and therefore it more closely mimics ordinary daily 
activity (Thistle et al., 1967). It is also safer than isotonic exercise because the 
dynamometer’s resistance mechanism disengages when pain or discomfort is 
experienced by the patient. As in isotonic assessment, it can be difficult to isolate one 
muscle group, without contributions from accessory groups.
Although what is measured in strength testing is muscle force or torque, because 
strength is a term often used interchangeably with force (Jones and Round, 1990a) and 
because strength is the more commonly used term in general speech, the word strength 
will generally be used throughout this thesis.
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1.6.1 Strength and Ageing
In contrast to the lack of cancer literature, there is a wealth of literature regarding the 
measurement of strength and function in the healthy population and in particular in the 
elderly population. Muscle strength is known to decline with age and appears to be 
related to muscle mass and fat free mass (Larsson, Grimby and Karlsson, 1979; Kallman 
et al., 1990; Frontera et al., 1991; Fiatarone et al., 1994). Fiatarone and colleagues 
(1990, 1994) suggest that the deeline in muscle strength and mass during ageing is 
related to physical frailty, functional decline and impaired mobility.
Kallman and co-workers (1990) reported that although handgrip strength correlated with 
muscle mass, there was a stronger association with age and suggested that other factors, 
such as ageing effect on the muscle, or reduced activity might be important. However, ' 
Frontera and colleagues (1991) found no significant difference between strength in 
patients of different ages when controlled for muscle mass (measured by urinary 
creatinine excretion) and fat free mass (measured by hydrostatic weighing) and 
concluded that muscle mass was the major determinant of age related skeletal muscle 
strength. It has also been reported that reduction in muscle strength is related to type 2 
muscle fibre atrophy, which is found in the elderly (Gomm et al., 1990).
1.6.2 Relationships Between Strength and Function
Although the cancer literature does comment on the role of the multidisciplinary team in 
the rehabilitation of cancer patients and in particular on the role of the physiotherapist in 
maintaining muscle strength and function, or in providing aid to activity (Fulton and 
Else, 1998), there appear to be no studies which have specifically examined the 
relationship between muscle strength and the ability to carry out daily activities in
53
cancer patients. However, a relationship between self-perceived fatigue and self­
perceived function - as measured using the Sickness Impact Profile (Bergner et a l, 
1981) - has previously been reported in cancer patients (Irvine et al., 1994).
Much more work has been done in care of the elderly research in the last 20 years, 
although as recently as 1986, Young commented that few studies had attempted to 
correlate measures of muscle strength, or of exercise tolerance, and performance in the 
activities of daily living. However, subsequent to this, it has been reported that in the 
elderly there is a correlation between self-perceived physical function - using the 
Sickness Impact Profile physical dimension summary score - and handgrip strength, as 
well as with physical performance measures such as time to stand from a chair and 
walking gait speed (Cress et al., 1995).
One study reported correlations between muscle strength, climbing onto variable step 
heights and walking speed in healthy 70 year old men and women, and also reported a 
relationship between strength in gripping a key and manual dexterity (Aniansson, 
Rundgren and Sperling, 1980). Bassey and colleagues (1992) reported a positive 
correlation between leg extensor power and short-term performance measures: speed of 
stair climbing, rising from a chair and walking. Power is the amount of work done by a 
muscle producing force over a period of time (Jones and Round, 1990a).
1.6.3 The Role of Strength and Functional Training
Several studies in various patient groups have looked specifically at trying to improve 
strength and ability to perform functional activities.
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Fulcher and White (1997) reported that, in a patient population with chronic fatigue 
syndrome, isometric quadriceps strength and aerobic capacity - as measured by time on 
a treadmill - could be increased using a graded exercise programme.
Several trials have been carried out in the healthy elderly. Using an exercise programme 
McMurdo and Burnett (1992) reported improvements in perceived health status and life 
satisfaction, increased physical exertion levels and improved spine flexion. However, no 
significant improvement in handgrip strength was found. In another study of strength 
training in nonagenarian females, increased mid-thigh muscle area and increased 
walking speed were reported, but there was no improvement in stair climbing (Fiatarone 
et al., 1990). A later study by the same group, a randomised placebo-controlled trial of 
progressive resistive exercise in the elderly, reported that muscle strength increased by 
13% in the training group and only 3% in the control group who participated in ordinary 
recreational activities (Fiatarone et al., 1994). Walking speed and stair climbing power, 
as well as the level of spontaneous activity, were also found to improve significantly. 
They found no relationship between the degree of muscle hypertrophy and the relative 
strength gains and concluded that some of the strength gain related to improved neural 
recruitment pattern within the muscle rather than merely improved muscle bulk.
Another group studied stair climbing as a means of improving quadriceps strength in 
middle-aged women, the rationale being that climbing stairs required an individual to 
vertically lift body weight and thus might improve leg strength. It was reported that 
those who took part in the stair climbing exercises developed increased isokinetic 
quadriceps strength (Loy et al., 1994).
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One randomised trial of strength training in elderly women to try and improve 
functional ability reported only an improvement in highest step height achievable and 
time to rise from a kneeling position - but not other functional tests - despite an 
improvement in Icnee extensor and elbow flexor muscle strength (Skelton et al., 1995). 
It was concluded that task dependent increases in strength and power can only produce 
limited improvement in functional ability. It is thought that gains from strength training 
may be specific to the type of exercise used during a training programme and that 
isolation of one muscle, e.g. the quadriceps, will not necessarily lead to functional 
improvement. Training may improve performance by increasing neural activation of the 
muscle units, leading to better muscle co-ordination and more skilful execution of 
activity (Gillies et al., 1999). The study by Gillies and colleagues set out to test the 
hypothesis that elderly patients could improve their ability to perform simple daily 
functional activities by practising those activities. They speculated that muscle decline 
might in part be due to lack of practice. The exercise group improved in stair 
ascent/descent, chair rise, triple chair rise and walking, and controls in only stair ascent 
and chair rise. Only the walking test was significantly different between the two groups, 
but study numbers were small (n=20) (Gillies et al., 1999).
As poor functional ability is often a factor in patients with advanced cancer, there is a 
need for studies to examine the relationship between strength and function in cancer 
patients. Formal assessment of ways of improving ability to perform daily activities is 
also needed.
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1.7 Exercise and Fatigue
The traditional approach to the management of fatigue/tiredness in cancer patients has 
been to advise patients to rest as much as possible. It has previously been assumed that 
cancer patients would be unable to tolerate exercise (Aistars, 1987; Mac Vicar et al.,
1989). However, there is some evidence that regular aerobic exercise may have 
important physiological and psychological benefits, including reduced fatigue (Aistars, 
1987). Graydon and colleagues (1995) reported that sleep and exercise were the two 
most effective patient-reported strategies for the relief of fatigue in patients receiving 
chemotherapy or radiotherapy for cancer.
In a review of the role of exercise in the rehabilitation of cancer patients, Friedenreich 
and Courneya (1996) identified nine studies of exercise in cancer patients, including 
four randomised controlled trials, three quasi-experimental studies and two retrospective 
studies. All of the studies involved breast cancer patients, mainly those of good 
performance status and mostly patients who were receiving active anti-cancer therapy. 
In most of the studies exercise was carried out on a bicycle ergometer in a controlled 
laboratory setting. Overall, it was concluded that exercise produced improvements in 
functional capacity, defined as improvement in the body’s maximal uptake of oxygen. It 
was also concluded that exercise led to increased lean tissue, decreased body fat, 
reduction in nausea and fatigue and improved psychological well-being and quality of 
life.
The rationale for aerobic exercise is that, because there is a direct relationship between 
oxygen uptake and the performance of physical activity, aerobic exercise will improve
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oxygen uptake by skeletal muscle (Mac Vicar et al., 1989). Mac Vicar and co-workers 
(1989) suggested that, even in advanced disease states, an exercise programme may 
minimise loss of functioning and prevent muscle disuse in cancer patients.
The role of exercise has been challenged by St. Pierre and colleagues (1992) who feel 
that exercise may increase muscle weakness in cachectic cancer patients. It is certainly 
true that studies to date have included mainly breast cancer patients at early stages of 
disease and it is difficult to extrapolate from the findings in these studies to patients 
with advanced disease. A recent study has suggested that exercise may reduce fatigue in 
patients with different cancer types (Dimeo, Rumberger and Keul, 1998), but this study 
included only five patients. Larger studies of the role of exercise in cancer patients - 
both weight-stable and weight-losing - are needed.
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1.8 Anaemia
Anaemia has been implicated as a cause of weakness, fatigue and asthenia (Lichter, 
1990; Morant, 1996; Celia, 1997). One study reported a correlation between the level of 
weakness, as measured on a linear analogue scale, and the haemoglobin concentration, 
and a later study by the same researcher found a weak correlation between haemoglobin 
concentration and a linear analogue scale measurement of fatigue (Morant et al., 1993; 
Morant, 1996).
In a study of transfusion in anaemic cancer patients, weakness was one of the reasons 
for transfusion in 91% of patients (Gleeson and Spencer, 1995). A significant 
improvement in patient-rated weakness score - as scored on a linear analogue scale - 
was found after transfusion as well as improvements in dyspnoea and general well-being 
scores. The researchers’ definition of weakness equated with loss of strength. Not all 
patients benefited from transfusion. The absolute level of haemoglobin did not appear to 
correlate with the level of weakness, nor was there more benefit from transfusion in 
those with the lowest initial haemoglobins.
In 2 studies, Irvine and colleagues (1991, 1994) found no consistent relationship 
between the level of fatigue and haemoglobin concentration. Bruera and colleagues 
(1989) found no correlation between haemoglobin level and an asthenia score and 
concluded that anaemia was probably not that important as an aetiological factor for 
weakness and fatigue in patients with advanced cancer.
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However, a recent study using the Functional Assessment of Cancer Therapy Fatigue 
(FACT-F) questionnaire (Yellen et ah, 1997) has reported that patient scores of fatigue 
were able to distinguish between different haemoglobin categories (< 11.0 g/dl,
11.0-13.0 g/dl and > 13.0 g/dl). A further study has reported that administration of 
erythropoietin to non-haematological cancer patients caused an increase in haemoglobin 
and also in quality of life and ability to carry out daily activity (Demetri et al., 1998).
Weakness and fatigue, therefore, would appear to be associated with anaemia, but there 
has been no consistent, strong, linear relationship established between degree of 
anaemia and the severity of weakness and fatigue.
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1.9 Other Abnormalities
Various biochemical abnormalities may contribute to the aetiology of generalised 
weakness in cancer patients, some of which are potentially treatable, such as 
hypercalcaemia and hypokalaemia, uraemia and hypomagnesaemia (Regnard and 
Mannix, 1992). Hyponatraemia may be related to the syndrome of inappropriate anti­
diuretic hormone secretion, which is a feature of some cancers, such as small cell lung 
cancer and can relate to drug therapy, such as opioids and antidepressants (Regnard and 
Mannix, 1992; Morant, 1996; Bower, Brazil and Coombes, 1998). Low albumin levels 
are often found in patients with advanced cancer and Morant and colleagues (1993) 
reported a correlation between albumin levels and patient-rated weakness.
Drug therapy is thought to contribute to the aetiology of weakness and fatigue, in 
particular opioids, anti-emetics, benzodiazepines, diuretics and psychotropic drugs, all 
of which are widely used in cancer patients (Bruera and MacDonald, 1988; Lichter, 
1990; Regnard and Mannix, 1992; Barnish, 1994).
Endocrine abnormalities are a less common cause of weakness. They may predate and 
not be related to the cancer, for example diabetes, Addison’s disease or hypothyroidism, 
or may be directly related to the cancer, such as Cushing’s syndrome, hypopituitarism or 
hypoadrenalism secondary to adrenal métastasés (Bruera and MacDonald, 1988; Lichter,
1990). Infection may also contribute to weakness in patients, who are often 
immunosuppressed as a result of progressive disease or chemotherapy (Bruera and 
MacDonald, 1988; Regnard and Mannix, 1992).
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1.10 Corticosteroids
Corticosteroids (steroids) are one of the most frequently used groups of drugs in the 
palliation of the symptoms of advanced cancer and may be used in up to two-thirds of 
in-patients in cancer or palliative care units (Hanks, Trueman and Twycross, 1983; 
Batchelor et ah, 1997).
Indications for the use of steroids include spinal cord compression, raised intracranial 
pressure secondary to primary or metastatic cerebral malignancy and superior vena caval 
obstruction. Steroids are also sometimes used as co-analgesics to reduce pain in 
association with hepatic métastasés or due to nerve compression. They are also 
frequently used in the treatment of anorexia, to improve mood and promote feelings of 
general well-being, particularly in those who complain of feeling weak or tired (Hanks 
et al., 1983; Popiela, Lucchi and Giongo, 1989; Robustelli Della Cuna, Pellegrini and 
Piazzi, 1989; MacDonald, Hagen and Bruera, 1994; Batchelor et al., 1997).
Little is yet known about the mode of action of steroids when used for treatment of 
anorexia and to enhance well-being. They may work partly through a central euphoriant 
effect and partly through effects on prostaglandins and pro-inflammatory cytokines 
(Bruera et al., 1985; Yanagawa et al., 1996; Gagnon and Bruera, 1998).
There have been few randomised controlled trials investigating the value of steroids in 
cancer patients. The Methylprednisolone Pre-terminal Cancer Study Group reported on 
two trials studying the efficacy of an eight week, 125mg/day intravenous course of 
methylprednisolone sodium succinate (MPSS), compared to placebo, in a heterogeneous
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group of patients with advanced cancer (Robustelli Della Cuna et al., 1989; Popiela 
et al., 1989). The first study reported that the patients receiving MPSS had significantly 
higher quality of life ratings than the placebo group, although this was rated by the 
health professionals and not by the patients (Robustelli Della Cuna et al., 1989). They 
also reported a significant improvement in patient-rated appetite, pain, vomiting and 
general well-being over the study period in the steroid treated group. However, there 
was no improvement in weakness scores and there was a significantly higher death rate 
in female patients receiving MPSS. In light of this, Popiela and colleagues performed a 
similar study in female cancer patients (Popiela et al., 1989). In this study, there was a 
non-significant trend towards earlier death in the steroid treated patients. They did, 
however, report an improvement in appetite, well-being, nausea and anxiety scores 
throughout the study period and also a significant improvement in weakness scores in 
the first two weeks of the study.
Steroids do, however, have significant side effects. Gastrointestinal symptoms are 
probably the commonest side effects, including dyspepsia, oropharyngeal candidiasis 
and upper gastrointestinal haemorrhage (Hardy, 1998). Steroid treated patients are 
generally more prone to infection. Raised serum glucose is also common and some 
patients develop psychiatric complications, including frank psychosis. (Hanks et al., 
1983; MacDonald et al., 1994; Batchelor et al., 1997).
A recent small study of fifteen cancer patients treated with dexamethasone (a synthetic 
steroid) reported that nine (60%) developed clinically detectable proximal muscle 
weakness (myopathy), which in five patients was severe enough to interfere with the 
activities of daily living (Batchelor et al., 1997). All patients were receiving high doses
63
of dexamethasone (16-100 mg/day of dexamethasone in those most disabled). The 
development of myopathy was significantly related to the cumulative dose of steroid, 
although not with the duration of steroid treatment. A decline in respiratory function 
was also reported, mainly affecting the group with proximal myopathy, and was thought 
to be due to respiratory muscle weakness.
The incidence of steroid myopathy has been reported as 10-60% (MacDonald et al., 
1994). However, one study documented myopathy in only 2% of patients (Hanks et al., 
1983), although in this study steroid doses were lower (starting dose of 10-30 mg of 
prednisolone or 4-16 mg of dexamethasone) than in the study by Batchelor and co­
workers (1997).
The muscle damage caused by steroids is thought to be related to alterations in muscle 
protein metabolism, with increased protein breakdown and reduced synthesis. Atrophy 
of type 2 muscle fibres has been found even in patients on low doses of corticosteroids, 
although this finding has also been reported in cancer patients generally (Warmolts 
et al., 1975; Gomm et al., 1990; St. Pierre et al., 1992; MacDonald et al., 1994). 
Anecdotal reports suggest that the incidence of steroid myopathy is highest in those 
treated with fluorinated steroids, such as dexamethasone, and that muscle weakness may 
improve over time with stopping the steroids, reducing the steroid dose or changing to a 
non-fluorinated steroid, such as prednisolone or hydrocortisone (MacDonald et al., 
1994; Batchelor et al., 1997). Isometric exercise may help to preserve muscle bulk 
(Horber et al., 1985; MacDonald et al., 1994).
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Steroids, therefore, although having some beneficial effects in cancer patients, have 
significant side effects, including steroid myopathy, which may lead to muscle weakness 
and may interfere with daily activities.
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1.11 Quality of Life
The World Health Organisation (1947) defined health as “a state of complete physical, 
mental and social well-being and not merely the absence of disease.” However, in the 
care of patients with cancer, traditionally the primary outcome variables have been 
tumour response to treatment and disease free survival (Aaronson et al., 1993; 
Hjermstad et al., 1995).
It is increasingly accepted that a significant proportion of patients with cancer will not 
be cured and that to aim to improve patient’s well-being is a critical component of good 
patient care (Ahmedzai, 1990; Hjermstad et al., 1995). It has been stated that the 
primary aim of palliative care is to optimise the quality of life of patients with advanced 
incurable illness through the control of physical symptoms and attention to their 
psychological and spiritual needs (Richards and Ramirez, 1997).
Quality of life, or health related quality of life has been defined as “the extent to which 
one’s usual or expected physical, emotional and social well-being are affected by a 
medical condition and its treatment” (Celia, 1995). This definition is extended by 
Ahmedzai to include the impact of the disease and treatment on the patient’s family 
(Ahmedzai, 1993).
It is now widely accepted that a number of dimensions, or domains, contribute to quality 
of life, but that the relative importance of each dimension will vary between individuals 
and with time. The dimensions which are generally assessed are physical symptoms, 
emotional well-being, cognitive well-being, functional activity and social functioning.
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Also included in some assessment tools are family relationships, occupational 
functioning, spirituality, perception of the future, treatment satisfaction, sexuality and 
body image (Ahmedzai, 1990; Hjermstad et al., 1995; Richards and Ramirez, 1997).
A number of questionnaires have been developed specifically to measure quality of life 
and a number of articles review these different measurement tools (Clark and 
Fallowfield, 1986; Moinpour et al., 1989; Celia, 1995), Any questionnaire should be 
valid (i.e., it should measure what it claims to measure) and reliable (i.e., on re-testing it 
should give the same result). However, validity can only be assessed indirectly as no 
gold standard of quality of life exists for comparison. Clearly, each patient will define 
their own quality of life differently (Hjermstad et al., 1995; Richards and Ramirez, 
1997).
There has been debate as to who should measure quality of life. There is some 
consensus that because quality of life is subjective and individual for each patient, the 
patient should measure it where possible (Slevin et al., 1988; Richards and Ramirez, 
1997). In the study by Slevin and colleagues (1988) it was suggested that doctors failed 
to adequately assess patients’ quality of life. However, it has been suggested that there 
may be situations where it is necessary for others, whether professional carer or a 
relative, to measure quality of life when the patient, for whatever reason, is unable to do 
so themselves (Ahmedzai, 1990; Celia, 1995). It could be argued that all quality of life 
assessment tools are flawed in that they presuppose the relevant areas of quality of life 
to be studied (Ahmedzai, 1993). The SEIQoL (schedule for evaluation of individual 
quality of life) tool has been recently developed (Hickey et a l, 1996) and allows 
respondents to nominate the areas of life which are most important, rate their level of
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satisfaction with each area, and indicate the relative importance of each to their overall 
quality of life. However, to date, this tool has not been validated in cancer patients.
Given the importance of quality of life to patients with a short life expectancy, it is vital 
that studies involving this patient group include some measure or assessment of quality 
of life. In preference, any measure should be assessed by the patient, using simple tools 
which can be easily completed.
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SUMMARY
A significant proportion of patients with cancer will not have curable disease and, 
consequently, symptom control and improvement of all aspects of quality of life are 
priorities. Weakness and fatigue are two of the commonest symptoms in patients with 
advanced cancer, yet little is known about their aetiology and less about how to manage 
them. They are often felt to be merely an inevitable consequence of advancing disease.
It is known that patients with weakness and fatigue complain of reduced strength and 
ability to perform simple daily activities. It is clear, from studies comparing cancer 
patients with healthy controls, that patients often express a physical dimension to their 
feelings of tiredness, which could possibly be understood as “weakness”. There is very 
little research into the relationship between the subjective experience of weakness and 
actual measures of strength and functional ability in cancer patients.
Many patients with advanced cancer have lost weight and this is reported to be an 
aetiological factor in weakness and fatigue. However, the exact role of cancer cachexia, 
and the inflammatory response associated with cachexia, in the production of these 
symptoms, and in loss of physical strength and functional ability, is unclear.
Anaemia, biochemical abnormalities and certain drugs commonly used in cancer 
patients have also been implicated in the aetiology of weakness and fatigue, although the 
relative importance of these is not known. Psychological distress has also been reported 
to be related to weakness and fatigue.
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Clearly, weakness and fatigue are important symptoms in cancer patients, and a greater 
understanding of their aetiology and impact is important. The relationships of weakness 
and fatigue to strength, function, blood parameters, psychological distress and other 
aspects of quality of life require further investigation.
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AIMS OF THIS WORK
The aims of the work which follows were:
1. To investigate the importance of weight loss, altered body composition, the 
inflammatory response, haemato logical and biochemical parameters in patients with 
advanced cancer.
2. To examine the relationships between objective tests of strength and function, and 
measures of weakness and fatigue and patient-related quality of life in patients with 
advanced cancer.
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CHAPTER 2 ; METHODS ; BODY COMPOSITION
2.1 Introduction
2.1.1 Body Composition
As has previously been discussed in section 1.3, many cancer patients lose weight. 
Weight loss in itself in cancer patients confers a poorer prognosis, in terms of survival, 
and leads to significant morbidity (DeWys et al., 1980; Nixon et al., 1980). Certainly, 
weight is often used as a measure of nutritional status in cancer studies (Heymsfield and 
McManus, 1985; Heymsfield et al., 1994; Burman and Chamberlain, 1996). The 
severity of weight loss in an individual is determined by two factors: the rate of weight 
change over time and the total reduction in weight. It is important to note the patient’s 
usual weight by history or from previous measurements as obese patients may have lost 
weight and be malnourished, although they are still overweight compared to the average 
population (Heymsfield et al., 1994). Weight is simple to measure, but it does have its 
disadvantages as a measure of nutritional status. The presence of ascitic fluid or 
peripheral oedema, a large tumour mass or organomegaly can mean that a patient may 
well have lost little weight, but has lost significant amounts of fat and skeletal muscle 
(Heymsfield and McManus, 1985; Heymsfield et al., 1994; Burman and Chamberlain, 
1996).
Body mass index (BMÏ) is often used in diagnosis of both malnutrition and obesity 
(Garn, Leonard and Hawthorne, 1986). It is calculated by dividing the patient’s weight 
in kilograms by the square of their height in metres and is clinically more relevant than 
an absolute value of weight. However, body mass index also has some limitations.
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Although BMI has a relatively strong correlation with body fat, some athletic 
individuals may have a large skeletal muscle mass and a high BMI, but are not obese 
(Smalley, 1990). Weight and BMI are clearly important indicators of nutrition and 
prognosis, but as they have limitations, additional approaches to assessing body 
composition were employed in the present work.
Keys and Brozek (1953) pointed out that “the human body may be analysed in many 
ways; the best way will depend on the end sought and the practical possibilities”. The 
present work adopted this approach of using methods which were practical, simple and 
acceptable to patients.
The human body can be considered to be made up of several compartments and several 
models have been used to describe these components. The simplest of these is one 
which divides the body into fat and fat free mass, which contains muscle and visceral 
tissue, non-muscle lean tissue and minerals. Given that weight loss in cancer patients 
involves loss from both compartments (Cohn et al., 1981; Heymsfield and McManus, 
1985; Preston et al., 1995), then it should be possible to measure alterations in both. 
Previous work has reported that fat-free mass consists of approximately 73% water 
(Pace and Rathbun, 1945) and, consequently, if body weight and total body water are 
known, this percentage can be used to estimate both fat mass and fat-free mass. A 
number of methods have been used to measure these two compartments.
Underwater, or hydrostatic, weighing involves the complete submersion of the patient in 
water, the weight underwater being subtracted from that in air. The weight of the patient 
is then divided by their volume to calculate their density. This method involves the
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assumption that both fat and fat-free mass have known and constant densities (0.9 kg/1 
for fat and 1.1 kg/1 for fat-ffee mass) (Jones and Norgan, 1974; Dumin and Womersley, 
1974; Jebb and Elia, 1993). Although inexpensive and non-hazardous, this technique 
requires considerable patient co-operation and is generally not considered to be suitable 
for frail and elderly patients (Jebb and Elia, 1993). It was, therefore, not considered 
suitable for use in this work.
Body composition can also be assessed by isotope dilution (Moore, 1980; Shizgal, 1981; 
Hannan et al., 1995). This method involves the injection or ingestion of stable isotopes, 
such as deuterium oxide, 18-oxygen, or tritiated water. After a time to allow the isotope 
to disperse throughout body water, the concentration of the isotope is measured in 
blood, urine, breath or saliva and is used to calculate total body water (Moore, 1980; 
Jebb and Elia, 1993; Burman and Chamberlain, 1996). It is assumed that the isotope 
has the same distribution volume as water and that fat is anhydrous, although this may 
not be strictly true (Szeluga et a l, 1984). Fat-free mass is calculated from total body 
water by assuming that fat free mass is, on average, 73% water (Heymsfield et a l, 
1994; Burman and Chamberlain, 1996). Fat mass is calculated, by subtracting fat free 
mass from body weight. Disadvantages of the technique include possible exposure to 
radiation, lack of easy availability of isotopes, often complex analytical procedures and, 
in some cases, serial blood sampling. It was therefore not felt to be suitable for the 
patients in this work.
Measurement of skinfold thickness is a technique widely used for the estimation of body 
fat (Jebb and Elia, 1993; Burman and Chamberlain, 1996). A series of regression 
equations have been developed which allow prediction of total body fat and fat-free
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mass from a combination of four skinfold measurements (Womersley and Dumin, 
1973). Skinfold thickness is measured by pinching a fold of skin and subcutaneous fat 
between the jaws of a pair of calipers, which exert a standard pressure over a standard 
area (Burkinshaw, Jones and Krupowicz, 1973; Jebb and Elia, 1993; Burman and 
Chamberlain, 1996). The method makes the assumption that subcutaneous fat is a 
reflection of total body fat and that the average thickness of fat is the same as at the 
selected skinfold sites (Jebb and Elia, 1993; Burman and Chamberlain, 1996). It is an 
inexpensive and convenient technique, which requires minimal patient co-operation. 
However, it has been reported to have considerable potential for error with a variation of 
6-24% (Burkinshaw et al., 1973). Skinfold compressibility can vary according to age 
and with the presence of oedema, although the latter is likely to be minimal if only the 
upper arm is used. There can be substantial inter-observer variation in measurements, 
but with a single observer more reproducible results have been reported (Womersley and 
Durnin, 1973). It is recommended that for longitudinal studies the measurements should 
be made by the same observer and the average of three readings taken (Jebb and Elia, 
1993; Burman and Chamberlain, 1996). Despite some of the limitations of this 
technique, it has been used to detect differences between weight-losing and non weight- 
losing patients with and without malignant disease (Watson and Sammon, 1980; 
Bozzetti et ah, 1982; Hansell, Davies and Burns, 1986). Its ease and convenience make 
it ideal for use in frail cancer patients and it was adopted for use in this work.
Limb circumferences can also be used in conjunction with skinfold thicknesses to 
calculate limb fat and limb muscle area (Heymsfield et al., 1982, 1994). By themselves 
they may be useful in quantifying changes in an individual over time (Jebb and Elia,
1993). As they are very easy to measure, they were used in this work.
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Bioelectrical impedance has been used to estimate total body water, intracellular and 
extracellular water. In this technique a small alternating current (usually 800 
micro amps) is passed between electrodes on the hand and foot and the voltage drop 
allows calculation of resistance (impedance). The current passes through the water and 
electrolyte component of fat-free tissue; fat is a poor conductor (Jebb and Elia, 1993; 
Hannan et al., 1994; Burman and Chamberlain, 1996). At low frequencies (around one 
kilohertz (kHz)) the current is unable to penetrate the cell membranes and thus passes 
mainly through extracellular fluid, whereas at higher frequencies (500-800 kHz) it 
passes through the intra- and extracellular water and, thus, total body water can be 
calculated (Lukaski et al., 1985; Hannan et al., 1995). By assuming the hydration 
fraction of lean tissue to be 73%, fat free mass can be calculated (Burman and 
Chamberlain, 1996).
Multi-frequency bioelectrical impedance analysers have been developed which provide 
a simple, portable and non-invasive means of estimating body composition (Hannan et 
al., 1994; Hannan et al., 1995). Minimal undressing is required, and little patient co­
operation is needed. It is, therefore, a suitable technique for use in frail cancer patients. 
As with the other body composition measures, there is error involved with the use of 
this technique. Much of the data for the use of bioelectrical impedance comes from 
studies of healthy volunteers. Many ill patients retain fluid into the extracellular space 
and this expansion in total body water means that fat-ffee mass is over-estimated 
(Hannan et al., 1995). Simons and colleagues (1995) reported that total body water was 
significantly overestimated in cachectic cancer patients when compared with predicted 
values obtained through the use of isotope dilution. However, because of the simplicity
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of the technique and the absence of observer bias, this technique was also chosen for 
this work.
As weight-losing cancer patients tend to lose significant amounts of muscle, it would be 
useful to estimate the degree of rnuscle lost. Muscle circumference and area estimates 
can be derived from skinfold thickness and limb circumference (Heymsfield et al.,
1994). However, another indirect method of estimating muscle bulk is through 24 hour 
urinary creatinine excretion. Ninety eight per cent of urinary creatinine is derived from 
creatinine phosphate located in skeletal muscle. Therefore, muscle mass can be 
estimated by measuring 24 hour urine creatinine excretion (Heymsfield et al., 1983; 
Burman and Chamberlain, 1996). Heymsfield and colleagues (1982) reported a strong 
correlation between arm muscle area and creatinine excretion and Forbes and co­
workers (1976) reported a strong correlation between fat-free mass and creatinine 
excretion.
There are several factors which affect the validity of measuring creatinine excretion. 
Creatinine is filtered and secreted in the kidney and the patient must therefore have 
normal renal function. There is a large intra-individual variability in creatinine excretion 
and excretion is affected by ingestion of red meat (Heymsfield et al., 1983; Burman and 
Chamberlain, 1996). A dietary history is therefore important. The 24 hours must be 
accurately timed or a large margin of error is introduced (Forbes and Bruining, 1976) 
and, therefore, not all patients will be able to comply with the practicalities of the 
measurements. Three consecutive collections are recommended but are impractical for 
out-patients. It is, however, a non-invasive test and is cheap to perform.
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Dual photon absorptiometry (DPA) and dual energy X-Ray absorptiometry (DEXA) are 
now being used more frequently to evaluate body composition. Photons are generated 
either from a gadolinium source (DPA) or an X-Ray source (DEXA). These are scanned 
over the patient at 2 different energy levels and the differential absorption of photons is 
measured. These techniques can determine the percentage of fat in non-bone tissue and, 
thus, with the addition of appropriate computer software, the fat-free mass can be 
calculated (Burman and Chamberlain, 1996). Unfortunately, it is an expensive technique 
and involves a small exposure to radiation (Jebb and Elia, 1993). It was also not readily 
available for use by the patients in this work.
Computerised tomography, magnetic resonance imaging and ultrasound can directly 
visualise both fat tissue and non-fat tissue and allow quantification of fat and muscle 
(Heymsfield et al., 1982; Burman and Chamberlain, 1996). However, they require a 
significant amount of time and expense and would have been practically very difficult 
for this work.
In this work, body composition was estimated using the following techniques: height, 
weight, body mass index, skinfold thickness, limb circumference, bioelectrical 
impedance analysis and 24 hour urine creatinine excretion. Serum creatine kinase 
concentrations were also measured as another indirect guide to muscle mass (Giltay et 
al., 1999). These procedures were felt to be minimally invasive and most likely to be 
acceptable to a group of cancer patients. The techniques used are described in the 
following sections.
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2.1.2 Blood Tests
As previously discussed in section 1.8, anaemia has been reported to be an aetiological 
factor for weakness, fatigue and asthenia (Lichter, 1990; Morant, 1996; Celia, 1997) 
and Morant (1993, 1996) reported significant correlations between linear analogue scale 
measurements of weakness and fatigue and haemoglobin levels.
As discussed in section 1.9, different biochemical abnormalities have been suggested as 
causes for weakness or fatigue, including hypercaicaemia, hypokalaemia, 
hyponatraemia, uraemia and hypomagnesaemia (Regnard and Mannix, 1992; Barnish,
1994). Low albumin concentrations have also been associated with weakness (Morant, 
1996) and have been reported in weight-losing cancer patients (Scott et al., 1996). Low 
albumin may be related to the acute phase response (Fearon et al., 1998). C-reactive 
protein concentrations - a marker of the acute phase response - have been reported to be 
elevated in weight-losing cancer patients (Scott et ah, 1996) and correlations have been 
found between C-reactive protein and fatigue levels (Morant, 1996). White cell count 
has also previously been reported as elevated in weight-losing cancer patients with an 
acute phase response (Scott et al., 1996). It has been reported that in cancer patients 
serum zinc concentrations are often decreased and serum copper concentrations 
increased (Catalano et al., 1993; S attar et al., 1997). S attar and colleagues found a 
significant positive correlation between concentrations of C-reactive protein and copper 
in patients with non-small cell lung cancer (p < 0.001), and a significant negative 
correlation with zinc (p < 0.05). They concluded that alterations in trace elements were 
associated with the presence of an acute phase response.
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Vitamin D deficiency can be associated with proximal muscle weakness (Forbes and 
Jackson, 1993). Reduced vitamin D concentrations have also been reported in a large 
proportion of hospital inpatients (Thomas et al., 1998), although this has not previously 
been investigated in patients with advanced cancer.
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2.2 Body Composition Measurements
2.2.1 Height Weight and Body Mass Index
Height was measured with the patient standing upright in stockinged feet. In patients 
studied at Stobhill Hospital, a wall mounted stadiometer was used. In patients studied at 
Strathcarron Hospice, Hunter’s Hill Marie Curie Centre and at home, where there was 
no stadiometer available, the patient was asked to stand against a door or wall, their 
height marked and measured using a centimetre tape measure. Height in all patients was 
measured to the nearest 0.5 cm.
Weight was measured on a set of Seca scales (Seca, Vogel & Halke GmbH & Co, 
Hamburg, Germany), with patients wearing indoor clothing and no shoes. Weighing 
took place on a flat non-carpeted surface. Weight was recorded to the nearest 0.25 kg. 
Previous weights were recalled by the patient or, where appropriate, taken from the 
casenotes.
Body mass index was calculated using the formula:
Body mass index (kgm'^) = Weight fksl
Height(m)^
2.2.2 Skinfold Thicknesses and Limb Circumferences
Skinfold thickness was measured using Harpenden skinfold calipers (British Indicator 
Ltd., West Sussex, United Kingdom). A stretch resistant measuring tape was used to 
accurately measure limb circumference and to locate sites for skinfold thickness 
measurements. Traditionally, body fat has been estimated by using the four site method
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which uses equations developed by Dumin and Womersley (1974). The four skinfolds 
normally measured are biceps, triceps, subscapular and suprailiac. O’Gorman (1997) 
recently reported a significant direct correlation between the sum of biceps and triceps 
skinfold thicknesses and fat mass calculated from the four site method (p < 0.001). To 
minimise patient inconvenience, subscapular and suprailiac measurements were not 
used in this work. To provide an estimate of lower limb fat thigh skinfold thickness 
measures were also carried out. All skinfold thickness measurements and 
circumferences were measured on the right side of the body except in patients with 
lymphoedema, where the left side was used.
The triceps skinfold thickness was measured over the triceps muscle at the midpoint 
between the acromion process of the scapula and the olecranon of the ulna with the arm 
relaxed and extended (Figure 2.1). The biceps skinfold thickness was measured at the 
same level as the triceps skinfold thickness over the biceps muscle, again with the arm 
relaxed and extended. For each of the skinfold thicknesses, the average of three 
measurements was taken and rounded to the nearest 0.5mm. The mid-upper arm 
circumference was measured at the midpoint between the acromion process and the 
olecranon, i.e., at the same point as the skinfold thickness measurements. The tape was 
maintained in a horizontal position, touching, but not compressing, the underlying skin. 
Thigh skinfold thickness was measured on the anterior aspect of the thigh at the 
midpoint between the anterior superior iliac spine and the middle of the patella. Thigh 
circumference was measured at this point in a similar way to the upper arm. All 
measurements were carried out by the same investigator.
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2.2.3 Bioelectrical Impedance
Bioelectrical impedance measurements were carried out using a Xitron 4000B multi­
frequency bioimpedance analyser (Xitron Technologies, Inc., San Diego, California, 
USA). Before each set of patient measurements the analyser was calibrated using a test 
resistor (422 ohms) provided by the manufacturer. The patient was asked to lie supine 
on a bed, or couch if in their own home, or occasionally if lying down was not 
practicable then the measurement was completed with the patient semi-supine in a 
recliner chair. The patient was asked to lie with legs slightly apart and with arms and 
hands not touching the body. The leads connecting the patient to the analyser did not 
touch each other nor did they touch any metal. The electrodes were consistently placed 
according to the same anatomical landmarks (Figure 2.2). The current source electrodes 
were placed on the right foot and right hand across the metatarsophalangeal joints and 
metacarpophalangeal joints respectively. The detection electrodes were sited on the right 
ankle between medial and lateral malleoli and on the right wrist between the distal ends 
of the ulna and radius. The left side was used if the patient had lymphoedema. The 
electrodes were disposable, self-adhesive, pre-gelled electrodes designed for use with 
multi-frequency bioimpedance analysers (Bodystat Limited, Douglas, Isle of Man).
Resistance and reactance was measured at 50 frequencies between 5 kHz and 1 MHz. 
Analysis was performed by a computer modelling program provided by the 
manufacturer, on a laptop computer connected to the analyser. The program obtains the 
best fit to the data and predicts resistance (impedance) at frequencies zero and infinity, 
which correspond to the resistance of extracellular fluid and total body water, 
respectively. The program combines this data along with the patient’s height, weight and
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sex to calculate extracellular, intracellular and total body water volumes (Hannan et al.,
1995).
2.2.4 Twenty Four Hour Urinarv Creatinine Excretion
Urine was collected in a large plastic container, with a 2,500 ml capacity, and containing 
a small amount of thymol as a preservative. All urine passed in a period of 24 hours was 
collected in the container. If the container was filled, then the remainder of the 
collection was collected in a second container. The patients were asked to set a start 
time for the collection, e.g., 9 a.m. and asked to empty their bladder at that time but not 
collect that sample. Every time thereafter that the patient needed to go to the toilet, all 
urine passed was collected in the container. At the exact end of the 24 hour period, the 
patient was asked to empty their bladder and collect this urine in the container. To take 
into account the effect of diet on creatinine estimation, patients were asked to recall 
what they had eaten in the previous 48 hours prior to and during the urine collection. 
Urine creatinine was assayed ftom a 20 millilitre aliquot of the complete urine collection 
using a Roche Cobas Mira analyser (Hoffman-La Roche Ltd., Basel, Switzerland).
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2.3 Blood Tests
In this work, haemoglobin was measured using the Syanmet method on a SYSMEX NE 
8000 analyser (TOA Medical Electronics Co. Ltd, Kobe, Japan). White cell count was 
also measured by the SYSMEX NE 8000 analyser using direct current and 
radioffequency methods. Urea and electrolytes, albumin, calcium, creatine kinase and 
C-reactive protein were assayed on an OLYMPUS AU5200 analyser (Olympus Optical 
Ltd., Tokyo, Japan) using standard methods. Serum magnesium was assayed by Atomic 
Absorption Spectrophotometry on a Perkin-Elmer llOOB analyser (Perkin-Elmer Ltd, 
Norwalk, CT., USA). In this work, zinc and copper were assayed by Atomic Absorption 
Spectrophotometry on a Perkin-Elmer llOOB analyser (Perkin-Elmer Ltd, Norwalk, 
CT., USA). Serum 25-hydroxy-cholecalciferol (the major circulating metabolite of 
vitamin D (Marshall, 1988)) was assayed by an Equilibrium Radio-Immunoassay 
procedure using Incstar ^^^I-RIA Kit (Diasorin Ltd., Stillwater, Minnesota, USA) and a 
Packard Cobra 5005 y-counter (Packard Instrument Co., Meriden, CT, USA).
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Figure 2 .1 Anthropom etric  M easurements
a) Triceps Skinfold Thickness
b) Biceps Skinfold Thickness
c) M id-Arm Circumference
d) Thigh Skinfold Thickness
e) M id-Thigh Circumference
!Figure 2 .2  Bioelectrical Im pedance Analysis A pparatus
a) Patient C onnected  to X itron 4000B  M ulti-Frequency Analyser
b) Position o f Electrodes on R ight H and
c) Position o f Electrodes on  Right Foot
CHAPTER 3 : METHODS : STRENGTH AND FUNCTION
3.1 Introduction
As previously discussed in section 1.6, there have been many studies of strength and 
function in the elderly. However, there has been little published work examining these 
issues in cancer patients.
Although the literature suggests that handgrip strength has been used in studies 
involving cancer patients (Burman and Chamberlain, 1996), there appear to be no 
prospective controlled studies using this technique in this patient group. However, this 
is a simple technique which has been used extensively in other patient groups (Kallman 
et al., 1990; Watters et al., 1993; Cress et al., 1995).
As the quadriceps muscle is so important to daily activity, a measure of quadriceps 
strength was included in this work. To allow direct comparison of an isometric upper 
limb strength measure (handgrip) and a lower limb strength measure, isometric 
quadriceps strength was measured in patients fit enough to participate in the test. To 
study a strength measure more naturally related to ordinary activity, isokinetic 
quadriceps strength was also measured. A kinetic communicator (Kin-Com) 
dynamometer was used in this work. The mechanical reliability and the reliability and 
reproducibility of strength data obtained using the Kin-Com has previously been 
established (Farrell and Richards, 1986; Tredinnick and Duncan, 1988; Harding et al., 
1988). The Kin-Com has also been used to carry out isokinetic and isometric strength 
measures in cancer patients (Monga et al., 1997), although in other muscle groups other
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than the quadriceps. The quadriceps muscle has been tested on the Kin-Com in other 
patient groups (Tredinnick and Duncan, 1988; Harding et al., 1988).
The technique of twitch interpolation was used to study the voluntary and involuntary 
components of quadriceps strength, i.e., whether a “maximal effort” by the patient was 
in fact a true maximal effort. This technique was used during isometric testing to allow 
comparison to previous work (Gibson et al., 1993; Norregaard et al., 1994) and also 
during isokinetic testing.
Many cancer patients report difficulty in carrying out daily activities (Rhodes et al., 
1988; Dunlop, 1989). There are no prospective studies which have examined the ability 
of cancer patients to carry out the activities of daily living. Rising from a chair, stair 
ascent and descent and walking ability have all been used frequently as short term 
measures of performance in geriatric research, due to their importance in maintaining an 
independent lifestyle (Aniansson et al., 1980; Fiatarone et al., 1990; Cress et al.,
1995). Their usefulness in assessment of functional ability in other patient groups is not 
clear. However, clearly these activities are also important to cancer patients.
The chair stand test (ability to rise from a seated to standing position) appears to be a 
reliable and reproducible test, with a coefficient of variation of only 6.8% over ten trials 
previously reported in a group of healthy subjects of diverse ages (Csuka and McCarty, 
1985). This test has also been used by other investigators, studying the elderly 
population (Bassey et ah, 1992; Skelton et ah, 1995; Cress et ah, 1995) and has been 
used to distinguish between young, elderly and hemiparetic subjects (Yoshida, Iwakura 
and Inoue, 1983). Gillies and colleagues (1999) found, in their longitudinal study, that
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many patients produced single chair rise times which left little room for improvement 
and introduced a triple rise test (standing up from a chair three times in a row).
Stair climbing tests have been also been used as assessments of physical functioning in 
the elderly (Bassey et al., 1992; Gillies et al., 1999) and also as means of strength 
training (Loy et al., 1994). Bassey and colleagues (1992) used four stairs, each of 15 
centimetres in height with sturdy banister rails on each side and around the top platform. 
The test was repeated after a “short rest”. She studied only stair ascent, whereas Gillies 
and co-workers (1999) studied ascent and descent with a two minute seated rest at the 
top and in between tests. However, their stairs were slightly higher at 17 centimetres 
each.
Walking tests have often been used by investigators as measures of physical function. In 
a study in the elderly, subjects were asked to walk at a self-selected speed over distances 
which varied between 6 and 40 metres (Cress et al., 1995). It was reported that self­
selected walking gait speed was the greatest single predictor of self-perceived physical 
function. Aniansson and colleagues (1980) asked patients to walk at their comfortable 
walking speed over a distance of 30 metres in a corridor. Gillies and co-workers (1999) 
used a 15 second time period to assess how far patients could walk over a carpeted 6 
metre course.
Six and 12 minute walking tests have become part of standard exercise assessment for 
patients with chronic heart failure and chronic lung disease (Guyatt et al., 1985; Lipkin 
et al., 1986; Meyer et al., 1997). They measure distance covered in that time and are 
used because they are simple and inexpensive tests which are familiar to the patient. In
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this work, twelve minutes was felt to be too long a test for an advanced cancer patient 
grouping and, as well as a 6 minute test, a 2 minute test was used.
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3.2 Strength Measures
3.2.1 Handgrip Strength
Dominant isometric handgrip strength was measured using a Takei Kiki Kogyo grip 
dynamometer (Takei and Company, Tokyo, Japan). Handgrip strength was measured to 
the nearest 0.5 kilogram watts (kgW). The handle was adjusted according to the size of 
the patient’s hand. While standing, the patient held the dynamometer in the dominant 
hand, with the arm extended by their side (see Figure 3.1). In those unable to stand, the 
dynamometer was held out in front of them. The patient was asked to squeeze the 
handle as hard as possible. Three trials were allowed, with a 30 second rest between 
attempts. The highest of the three values obtained was recorded as the definitive value. 
Non-dominant handgrip strength was also recorded in later tests.
3.2.2 Quadriceps Strength and Twitch Interpolation Technique
Quadriceps peak force was measured in patients of good performance status (Kamofsky 
score > 70) in the physiotherapy department at Stobhill Hospital on a Kin-Com 
isokinetic dynamometer (Chattanooga Group, Inc., Hixson, Tennessee, USA; see Figure 
3.1). Both isokinetic and isometric quadriceps force were measured. Quadriceps torque 
was calculated by multiplying the measured force by the length of the lever arm from 
the centre of rotation to the attachment point at the ankle. Electrical stimulation of the 
quadriceps muscle, during both isokinetic and isometric testing, was carried out to try 
and distinguish between voluntary and involuntary muscle force.
Prior to testing, each patient warmed up for 2 minutes on an exereise bicycle with no 
external resistance, to allow patients to pedal at their own pace. They were then seated
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on the movable seat of the Kin-Com apparatus, with their dominant (kicking) leg 
adjacent to the central section of the machine. Seat back position was adjusted to allow 
for different statures. The knee joint was aligned with the axis of rotation of the 
dynamometer lever arm. To try to restrict the contraction to the quadriceps muscle, 
restraining straps were fastened about the patient’s waist and distal thigh. Patients were 
also asked to keep their arms folded during the testing to prevent the possible extra 
leverage obtained by pushing down with the arms on the seat. The tested leg was 
attached to the lever arm by means of a heavy duty strap, secured near the ankle, five 
centimetres above the medial and lateral malleoli.
Gravity compensation was included in each test, by weighing the leg while attached to 
the lever arm in a position as close to horizontal as the patient could comfortably allow. 
The stop angle - the angle measured from the horizontal position to which the patient 
could move the lever arm comfortably without assistance - was set to provide the limit 
for the upward movement of the lever arm during the test. The start angle was set at 90° 
from horizontal for each patient. The 90° was measured with a goniometer as the angle 
made by the leg in relation to the greater trochanter of the femur, with the lateral joint 
line of the knee as the central point. The central point was aligned with the point of 
attachment of the lever arm. The forward and backward speed was set at 60°/sec for 
each patient. In previous work (Horber et al., 1985), this was identified as the best 
single speed for assessment.
The purpose of the test was explained. The patient was instructed to push against the 
shin strap as quickly and smoothly as possible to move the lever arm to the stop angle 
(concentric contraction) and then to continue to push up against the strap to allow the
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machine to push the leg back to the start angle (eccentric contraction). The patient was 
frequently reminded of the need to push “fast and smooth” to prevent the machine 
hydraulics from cutting out. Several warm-up contractions were allowed to help the 
patient become accustomed to the machine. The patient was encouraged to experiment 
with different amounts of force in preparation for the actual measurements.
The patient was allowed a brief rest period after the warm-up on the machine. During 
this time the purpose of the electrical stimulation apparatus was explained. The voltage 
limit was set on the stimulator (Digitimer Stimulator, Welwyn Garden City, 
Hertfordshire, UK) to 400 volts, although in practice this voltage is rarely reached. The 
stimulator was connected to the trigger box. The stimulator was connected to two round 
patch electrodes which were fixed to the patient’s anterior thigh (see Figure 3.1), 
proximally and distally, to allow the stimulus to be given to the peripheral branches of 
the femoral nerve as they entered the muscle (Jones and Round, 1990b). The trigger box 
was connected to a small magnet, which was fixed to an adjustable metal retort stand 
positioned on the floor. Another magnet was fixed to the side of the lever arm adjacent 
to the centre of the machine. The two magnets were adjusted such that, during testing, 
the magnet on the lever arm passed close (about 0.5-1.0 cm) to the magnet on the retort 
stand - triggering the stimulus - at a fixed angle. This angle was originally set at 70° 
because of pilot work suggesting that the peak of the force curve would be reached at 
this angle. Test stimuli were given to the patient to assess the current required to 
produce a visible muscle twitch. The strength of the stimulus was limited by patient 
tolerance. For the test itself, the current was maintained at around 3 times this level as 
exercising muscles tolerate higher currents than resting muscles. The current used in the 
test varied between patients from 30.0 to 70.0 milliamps.
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The patient was asked to produce 4 efforts of varying strengths, increasing progressively 
from gentle (“about a quarter strength”) to half and three quarter strength then finally 
“as hard as you can”. The patient was reminded not to equate gentle with slow and to 
continue to produce efforts that were fast. There was a 30 second break between efforts. 
The patient was asked to judge the strength of their effort without visual feedback from 
the monitor screen, based on their experience in the warm-up. This was done to ensure 
that the patient produced what they believed to be a maximal contraction. If, when asked 
to push “as hard as you can”, the patient felt that they had not produced their best effort, 
they were allowed another attempt. Eccentric contractions were used to return the lever 
arm to the start angle, but were not included in the analyses as patients found it more 
difficult to produce consistent smooth eccentric contractions compared to the concentric 
contractions. Electrical stimuli were only used during the concentric contractions.
Following a brief rest, to allow the machine set-up to be changed, several graded 
isometric contractions were recorded (see section 1.6). The same gravity correction 
values as for the isokinetic testing were used. The test was set up for contractions at 
fixed lever arm angles of 90° and 60° from horizontal, as previously used in isometric 
testing (Aniansson et al., 1980). Several warm-up contractions of varying force were 
allowed, to familiarise the patient with the concept of isometric exercise. The patient 
was asked to produce three graded efforts (gentle, medium and “as hard as you can”) at 
both 90° and 60°. They were asked to hold that contraction, without relaxing, for 5 
seconds. No visual feedback was given as in the isokinetic contractions. An electrical 
stimulus, identical to that given in the isokinetic testing, was delivered by pressing by 
the stimulator button at a stable point in the contraction. A thirty second break was
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allowed between contractions. The highest force produced at either 90° or 60° was taken 
to be that patient’s peak force.
The data obtained during the Kin-Com tests was downloaded as ASCII (American 
Standard Code for Information Interchange) files onto pre-formatted floppy disks and 
analysed and graphed on a personal computer using Microsoft Excel version 7.0a 
(Microsoft Corporation, Redmond, Washington, USA).
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3.3 Functional Tests
3.3.1 Chair Tests
Chair-stand time was measured using a chair of square design, with a firm seat and arm 
rests. The seat height was 43 centimetres, which is one centimetre higher than the height 
of the average British toilet (Gillies et al., 1999) and is therefore a functionally 
significant height. The patient was asked to rise from a seated position to a fully upright 
position as fast as possible, without using the arm rests. The time taken to complete this 
manoeuvre was measured on a hand-held digital stopwatch (Lorus Watches, Austin, 
Texas, USA) to the nearest 0.01 seconds. If the patient was incapable of rising without 
using the arm rests, then they were allowed to use them and this fact noted. Three trials 
were allowed, with a 30 second break between attempts. The fastest of the 3 attempts 
was recorded as the patient’s definitive attempt. Sixty seconds after the third attempt, 
the patient was asked to complete the triple chair rise test. The patient was asked to 
stand up from the chair 3 times in a row, as fast as possible, and without a break in 
between each time, given the instruction “Up-down-up-dovm and finishing on the third 
up”. The time for this test was recorded to the nearest 0.01 seconds on the digital 
stopwatch. The test was omitted in those who felt unable to complete it. The chair was 
portable and was used at Stobhill Hospital, Strathcarron Hospice, Hunter’s Hill Marie 
Curie Centre and also in patients’ homes.
3.3.2 Stair Tests
A flight of four stairs with banisters on either side was used for this test. The stairs were 
each 15 centimetres high. For patients seen at home the test was omitted. The test was 
also omitted in those who were unable to complete the test.
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Patients were asked to stand at the foot of the stairs and to climb to the platform at the 
top of the stairs as quickly as possible, one step at a time. They were then immediately 
asked to turn around and descend the same stairs as quickly as possible, one at a time. 
The patient was allowed to use the banisters if they would normally use banisters at 
home. The time to complete the test was measured to the nearest 0.01 seconds using the 
same stopwatch as in the chair tests. The stair ascent and descent were performed three 
times with a thirty second rest between each ascent/descent. Previous studies have used 
“a short rest” (Bassey et al., 1992) between tests and thirty seconds was felt to be an 
appropriate rest period. The fastest ascent and fastest descent were recorded as the 
patient’s definitive attempt.
3.3.3 Walking Test
The walking test was performed in a carpeted corridor in which a 20 metre length had 
been measured off. Suitable corridors were found in all three sites, although this test was 
not possible in those patients seen at home. The patient was asked to start walking at 
their ordinary walking pace towards the end of the 20 metres and when they reached this 
point to turn and come back to the beginning. Patients were asked to continue to do this 
for as long as they could comfortably do so. They were allowed to stop if they became 
tired, breathless or had any other significant discomfort. The test was continued for a 
maximum of 6 minutes when the test was stopped. The distance walked in 2 minutes 
and 6 minutes was documented, to the nearest metre.
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Figure 3 .1 Equipment Used In Strength Testing and Electrical Stimulation Apparatus
a) Handgrip Dynamometer b) Kin-Com Isokinetic Dynamometer c) Digitimer 
Stimulator and Trigger Box d) Position of Magnets (M) on Lever Arm (LA) and Retort 
Stand (RS) as they pass each other e) Position of Patch Electrodes on Thigh for Electrical 
Stimulation
CHAPTER 4 : METHODS : QUALITY OF LIFE QUESTIONNAIRES 
4.1 Introduction
Quality of life is a critical component of good patient care (Ahmcdzai, 1990; Hjcrmstad 
ct a l, 1995). It is clear that any study of symptoms in patients with cancer would be 
incomplete without a consideration of how those symptoms affected quality of life. 
Many tools exist which assess different dimensions of quality of life. The following 
tools were chosen for the present work because they were valid and easy to complete.
4.1.1 Karnofsky Performance Status
In 1948, Karnofsky and colleagues developed a scale to quantify the functional ability of 
patients with advanced cancer. This is an 11 point numerical scale (0-100) which has 
become known as the Karnofsky Performance Status (KPS). This observational 
instrument was introduced as a measurement to assess the degree of patient 
independence and to establish the level of medical and nursing care required. This scale 
is among the most widely used scales for measuring functional ability in cancer patients 
(Yates, Chalmer and McKegney, 1980; Mor et al., 1984; Conill, Verger and Salamero, 
1990).
The KPS has been criticised because, as with all observational scales, it is subjective 
and therefore the potential exists for inter and intra-observer variability (Clark and 
Fallowfield, 1986). However, Mor and colleagues (1984), in a national hospice study, 
described a highly significant rate of agreement between different observers and 
concluded that the KPS was a valuable tool for assessment of functional ability.
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It has been suggested that a major disadvantage of the KPS is that, since it is normally 
scored by a physician, it does not reflect the patient’s own experience (Padilla and 
Grant, 1985; Clark and Fallowfield, 1986), However, Conill and colleagues (1990) 
reported significant correlations between physician and patient scores, as well as 
between scores by different physicians. They suggested that these results demonstrated 
that physicians measure performance status adequately using the KPS.
Yates and colleagues (1980) compared the KPS to several independent measures of 
physical functioning and reported strong correlations. Another study reported a strong 
relationship between the KPS and the Katz activities of daily living index (Katz et al., 
1963; Mor et al., 1984). These studies suggested that the KPS demonstrates construct 
validity, i.e., it measures what it claims to measure.
The KPS has also been shown to be a strong predictor of survival (Mor et al., 1984). 
Stanley (1980) reported the initial KPS score to be one of the three most important 
prognostic features affecting survival in inoperable lung cancer. A falling KPS score has 
also been reported to be a poor prognostic factor (Yates et al., 1980).
The KPS is simple to measure (Mor et al., 1984), is commonly used in cancer studies 
and seems a useful tool in measuring functional ability. However, it has its limitations in 
assessing quality of life as it is unidimensional and does not assess psychosocial factors.
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4.1.2 Method For Assessing The Karnofsky Performance Status
The Karnofsky Performance Status Scale is an 11-point rating scale, which ranges from 
100 (normal functioning) downwards in decrements of 10 to 0 (dead) (see appendix 1). 
It is completed by the observing clinician. To eliminate any possible problems of inter­
observer reliability, all of the assessments in this work were performed by the same 
person (the author). When the performance status did not entirely fit one of the 11 points 
then a score half-way between two points, e.g., between 60 and 70 = 65, was made.
99
4.2 The EORTC QLO-C30 Quality of Life Questionnaire
The European Organisation for Research and Treatment of Cancer (EORTC) was 
involved in the development of the EORTC QLQ-C30 quality of life questionnaire, 
which was originally designed to assess the quality of life of cancer patients 
participating in clinical trials (Aaronson et ah, 1993). This is a 30 item self-report 
questionnaire which assesses different aspects of a patient’s quality of life. It includes 
several subscales on patient function: physical function, role function, emotional 
function, cognitive function and social function. There is also a global health/quality of 
life scale. The questionnaire also includes several symptom measures with questions 
about fatigue, pain, nausea and vomiting, dyspnoea, sleep, appetite and bowel function 
as well as a question regarding financial problems. The EORTC QLQ-C30 core 
questionnaire was developed following the international field study on the initial 36 
item questionnaire (Aaronson et ah, 1993; Celia, 1995). The questionnaire has become 
widely accepted and is available in many different languages (Celia, 1995).
The original validity and reliability testing was performed in a multinational study of 
346 cancer patients. The EORTC QLQ-C30 questionnaire was shown to be reliable in 
assessing many dimensions of quality of life. Although correlations between all the 
component subscales were statistically significant, the correlations were moderate, 
providing evidence that the scales were assessing distinct components of quality of life 
(Aaronson et ah, 1993).
A test-retest reliability study was performed by Hjermstad and colleagues (1995). The 
scores obtained using the questionnaire were compared with scores obtained &om
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completion of the same questionnaire 4 days later. Correlations between scores on both 
days were found to be high.
The use of the EORTC QLQ-C30 is now widely established in cancer patients and 
provides information about diverse aspects of a patient’s quality of life. It has also been 
used in the healthy population and has been reported to provide a valid measure of 
health-related quality of life in this group (Hjermstad et ah, 1998). It is simple to 
complete, the average completion time being around 11 minutes (Aaronson et ah, 
1993). It is generally completed by the patient, but can also be completed by interview.
4.2.1 Completion of the EORTC 0L0-C3Q Version 2.0
At the time of starting this work the EORTC QLQ-C30 version 2.0 was the current 
version of the questionnaire.
The QLQ-C30 version 2.0 (see appendix 1) is composed of both multi-item scales and 
single item measures. These include five functional scales (physical, role, cognitive, 
emotional and social functioning), three symptom scales (fatigue, pain and 
nausea/vomiting), a global health status/quality of life scale, and six single items 
(dyspnoea, sleep, appetite, constipation, diarrhoea and financial). All questions are 
worded in terms of a statement and ask the patient to assess how true that statement has 
been over the preceding 7 days.
Patients were asked to complete the questionnaire by themselves, or in an interview 
format if they were unable to self-complete the questionnaire. In the latter case the
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investigator read aloud the questions and possible responses and recorded the patient’s 
answers without in any way trying to influence the patient’s answer.
The first five questions (the physical functioning scale) involve a simple choice between 
Yes and No. The subsequent 23 questions involve selection of the appropriate value on 
a numerical scale ranged between 1 and 4 ( 1 =  not at all, 2 = a little, 3 = quite a bit, 4 = 
very much). The last 2 questions (the global health/quality of life scale) are numerical 
scales ranged between 1 and 7 (from 1 = very poor to 7 = excellent).
Questionnaire scoring is carried out according to the scoring algorithms produced by 
EORTC (see appendix 1). All of the scales and single item measures range in score 
from 0-100. A high score for a functional scale represents a high/healthy level of 
functioning, a high score for the global health status/quality of life scale represents a 
high quality of life, whereas a high score for a symptom scale/item represents a high 
level of symptomatology/problems.
If items are missing from multi-item scales then, provided at least 50% of the items 
within the scales are completed, it is assumed that the missing values have values equal 
to the average of those items which are present for that respondent (EORTC QLQ-C30 
Scoring Manual).
The EORTC questionnaire is under copyright and permission, in writing, for use in this 
work was obtained via Christiane van Pottelsburghe of the EORTC Quality of Life 
Group, avenue E. Mounier 83 Bte I I , 1200 Brussels, Belgium.
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4.3 The Functional Assessment of Cancer Therapy Fatigue Subscale
The Functional Assessment of Cancer Therapy (FACT) series of questionnaires was 
also developed with the view that quality of life was a subjective (patient-rated) and 
multi-dimensional concept (Celia et ah, 1993). The FACT collaborators developed a 
28-item core (general) questionnaire (FACT-G) and several cancer site, symptom and 
treatment specific modules which could be added to the general questionnaire as 
appropriate. The FACT-G scale consists of physical, functional, social, emotional and 
“relationship with the doctor” subscales as well as a total score. The authors reported the 
questionnaire to be valid compared with other established measures of quality of life and 
that the FACT-G was reliable on re-testing after 3-7 days. Correlation co-efficients for 
validity and reliability were all found to be high.
The same researchers subsequently developed a symptom module to try and accurately 
assess quality of life in cancer patients suffering from fatigue and other anaemia-related 
symptoms (Yellen et al., 1997). The FACT-F consists of the FACT-G and a 13 item 
fatigue subscale (FACT-Ftg). The FACT-F was reported to accurately predict patient­
rated performance status and to stratify patients according to low or high haemoglobin 
level. It was also reported that the 13 item fatigue subscale also showed excellent 
internal consistency (i.e., all the questions measured part of the same phenomenon), test- 
retest reliability and predicted haemoglobin level and performance status. There were 
positive correlations with other measures of fatigue. The authors suggested that the 
fatigue subscale should prove useful as an independent, brief assessment of fatigue. It is 
short, takes only a few minutes to complete and like all FACT scales can also be 
completed by interview (Celia et al., 1993).
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4.3.1 Completion of the FACT-Ftg Scale Version 3
The Functional Assessment of Cancer Therapy Fatigue Subscale (FACT-Ftg) version 3 
was used in the present work (see appendix 1). All thirteen questions are rated on a 
numerical scale of 0-4 (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit and 
4 = very much) with a total range of possible scores of 0-52. Questions 1-6 and 9-13 are 
scored by subtracting each item response from 4. Questions 7 and 8 are scored by 
adding the item response to 0.
High total scores indicate a low level of fatigue and low scores a high level of fatigue. 
Where some questions are left unanswered - provided that more than 50% of the 
questions have been completed - the total score can be extrapolated by multiplying the 
sum of the subscale by the number of items in the sub scale (i.e., 13) and then dividing 
by the number of items actually completed, i.e.:
Final score = [sum of item scores] x 13 4- [number of items answered]
Permission for the use of the scale was obtained, in writing, from Kimberley Webster, 
M.A., Director of Communications, Center on Outcomes, Research and Education 
(CORE), Evanston Northwestern Healthcare, 1000 Central Street, Suite 101, Evanston, 
Illinois, 60201, USA.
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4.4 Linear Analogue Self-Assessment Scales
Visual analogue scales, or linear analogue self-assessment (LASA) scales, use a 100 
millimetre line with descriptors at each end and the length of which is taken to represent 
the continuum of a physical or emotional experience such as pain, anxiety or weakness 
(Clark and Fallowfield, 1986). Respondents are asked to mark the line at a point which 
they feel best represents how they are currently feeling. The score is measured in 
centimetres or millimetres from the 0 point on the far left (Celia, 1995).
LAS A scales were originally used in cancer patients by Priestman and Baum (1976) to 
study quality of life in patients with advanced breast cancer receiving chemotherapy. 
They used ten scales, including questions on symptoms, mood and activity levels. They 
reported relationships between LASA scores and treatment response and treatment 
toxicity.
Coates and colleagues (1983) reported an association between performance status and 
LASA scores for general well-being, dyspnoea and physical activity in ovarian 
carcinoma patients receiving anti-cancer therapy. More recently, Gleeson and Spencer 
(1995) found an improvement in LASA scores of weakness, dyspnoea and general well­
being following transfusion in anaemic cancer patients.
LASA scales are simple and readily reproducible (Clark and Fallowfield, 1986). They 
can provide a wide range of scores and are thought to be very sensitive and responsive 
to change over time (Girling, Hop wood and Ahmedzai, 1994; Celia, 1995). However, 
there has been some criticism of their use, in that it can be difficult to know what is the
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minimal clinically significant - as opposed to statistically significant - difference in 
scoring (Celia, 1995). Some patients find it difficult to grasp the concept of LASA 
scales, though they have been used successfully in 5 year olds (Clark and Fallowfield, 
1986).
4.4.1 Using Linear Analogue Self-Assessment Scales
Linear analogue self-assessment scales were used in this work because of their 
simplicity and because previous research has employed them to assess weakness and 
fatigue (Robustelli Della Cuna et al., 1989; Morant et al., 1993, Gleeson and Spencer, 
1995).
Two scales were used in this work, designed by the author. One measured the patient’s 
own perception of their level of weakness and has at its two extremes: “I don’t feel 
weak at all” and “I couldn’t feel any weaker” (see Figure 4.1). The other measured the 
patient’s perception of their level of strength and its two extremes were “I feel I have no 
strength” and “I feel my strength is normal” (see Figure 4.2). Patients were instructed to 
“Please mark with a vertical line which point on this line best represents how 
weak/strong you feel at this moment”. Patients were asked to imagine that the line was a 
scale of zero to ten, with zero at the left hand end and ten at the right hand end.
Each scale was scored by measuring the line with a ruler from the left hand end and 
measured to the nearest 1.0 mm.
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4.5 Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression (HAD) scale is a self-report questionnaire 
originally designed for use with medical patients (Zigmond and Snaith, 1983). It is a 14 
item scale made up of two 7 item subscales measuring anxiety and depression. Zigmond 
and Snaith (1983) conducted their initial studies on 100 patients with a wide variety of 
illnesses in a medical outpatient clinic. The patients were asked to complete the HAD 
scale while waiting to be seen by a clinician and were subsequently interviewed by a 
researcher, who independently assessed their levels of anxiety and depression. The 
authors found that the scale had satisfactory internal consistency and validity, 
determined by a comparison with a rating from the psychiatric assessment. The authors 
reported the HAD scale to be reliable in detecting states of anxiety and depression and 
found a very low incidence of false results. They also suggested that the scores for the 
subscales could detect the severity of the emotional disorder (Zigmond and Snaith, 
1983).
The HAD scale has been used in studies of cancer patients. Hopwood, Howell and 
Maguire (1991) studied a group of 81 patients with advanced breast cancer. They 
compared the HAD results with independent interviews by a psychiatrist. They 
concluded that the HAD scale performed well in detecting psychological problems, 
although more so with anxiety than with depression.
Ibbotson and colleagues (1994) compared the HAD scale with a psychiatric interview in 
284 cancer patients. They reported that the HAD scale performed well in detecting
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anxiety and depression in patients with stable disease and on anti-cancer treatment, 
compared to other questionnaires, though performed less well in progressive disease.
There has been some debate as to whether the HAD scale should be used as a single 14 
item scale to deteet psychological distress or as two distinct scales assessing both 
anxiety and depression. The study by Moorey and colleagues suggested that although 
anxiety and depression often co-exist, it is possible to distinguish between the two, at 
least early on in the illness (Moorey et al., 1991).
Although the usefulness of the HAD scale in patients with advanced cancer has been 
questioned (Moorey et al., 1991; Ibbotson et al., 1994), there are no other scales which 
have been successfully used on a regular basis in this patient group. The main advantage 
of the HAD scale is that it is quick to administer, taking on average 2 minutes to 
complete, is easily understood and easily scored (Clark and Fallowfield, 1986).
4.5.1 Completing The Hospital Anxiety and Depression Scale
Each of the 14 items of the HAD scale has four possible answers and patients are asked 
to tick the answer which comes closest to how they have been feeling in the previous 
week (see appendix 1). If the patient was unable to complete the questionnaire 
themselves, then the questions were read out to them by the investigator. Each question 
is scored from 0-3, therefore each scale is scored 0-21 (see appendix 1). Any score for 
either scale of 0-7 is regarded as “normal”, 8-10 is a borderline case and 11-21 a 
probable clinical case of anxiety or depression.
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4.6 Administering The Questionnaires
The questionnaires described above were administered at the beginning of this work, to 
avoid any influence of the other tests on the patient’s responses to the questions. The 
weakness linear analogue scale was administered first and the strength linear analogue 
scale last to avoid patients scoring the latter with reference to the former. As there was 
some overlap between the fatigue scale of the EORTC QLQ-C30 questionnaire and the 
FACT-Ftg scale, the EORTC questionnaire was administered next after the weakness 
scale and taken from the patient before they were given the FACT-Ftg questionnaire. 
The HAD scale was then administered. No prompting was given to the patients other 
than an explanation of what they were expected to do.
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CHAPTER 5: CHARACTERISTICS OF A HOSPICE POPULATION
5.1 Introduction
Patients with advanced cancer have a variety of medical and non-medical problems. 
They are a group with poor prognosis, who have varied symptoms and are treated with 
an array of drugs and potentially disease-altering therapies. Weakness and fatigue are 
common symptoms in advanced cancer (Donnelly and Walsh, 1995) and many patients 
have difficulty in carrying out the activities of daily living (Rhodes et al., 1988). Many 
have lost weight (Watson and Sammon, 1980). To establish a baseline prior to studying 
some of these issues prospectively, a retrospective audit of patients in a typical palliative 
care unit was carried out.
Strathcarron Hospice is an independent hospice serving a large area in central Scotland, 
including Stirlingshire, Clackmannanshire and North Lanarkshire. It has eighteen in­
patient beds and has a busy day unit (20 spaces/day; 3333 patient attendances in 
1995/1996). The majority of patients are cared for at home by general practitioners with 
the input of hospice medical staff and Specialist Palliative Care Home Care nurses. The 
majority of its patients have advanced cancer, with a small number having advanced 
neurological conditions, such as motor neurone disease and multiple sclerosis.
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5.2 Material and Methods
All cancer patients under the care of the hospice - in-patients, day-patients and home 
care patients - who died in a six month period June 1996-30^ *^  November 1996) were 
included in this retrospective audit. All the details were recorded from the casesheets.
Factors recorded were age, sex, diagnosis, site of métastasés, length of involvement with 
the palliative care services (including inpatient care, day care, home care), place of 
death, drugs prescribed and evidence of anorexia, weight loss, weakness, fatigue or 
tiredness during the illness.
Statistical analysis was carried out where appropriate using the Mann Whitney U Test 
and Fishers Exact Test (SPSS Inc., Chicago, Illinois, USA).
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5.3 Results
Two hundred and twenty nine patients with cancer died during the 6 month period 
(Table 5.1). There were similar numbers of men and women. There was a wide age 
range (35-94 years) in the patients involved with the palliative care services, although 
the majority of patients were over the age of 65. There was no significant difference in 
age between the males and females.
The largest group of diagnoses was of gastrointestinal cancers comprising colorectal, 
oesophageal, pancreatic, gastric, caecal, cholangiocarcinoma, small bowel and anal 
cancers, in order of frequency. The most common single organ affected was lung, the 49 
patients including non-small cell and small cell cancers, although for half of the lung 
cancer patients no histological diagnosis was documented in the casenotes and therefore 
the diagnosis was accepted on clinical grounds. The urinary tract cancers included both 
renal and bladder cancers and the gynaecological group contained ovarian, cervical and 
vulval cancers. The haematological malignancies included lymphoma, acute leukaemia 
and myeloma. The sites of the head and neck cancers included larynx, palate, tonsil and 
pharynx. The number of male and female patients for each cancer grouping was similar. 
The median age within the different cancer types was similar with the largest three 
groups - gastrointestinal, lung and breast - having median ages of 69, 70 and 71 
respectively. The youngest group was the haematological group (65) and the oldest the 
prostate group (73) (p < 0.05), although both of these groups were small.
Many of the patients had progressive metastatic disease. Bone (n=50), liver (n=42), 
brain (n=21) and lung (n=18) were the commonest sites of metastatic spread. Fifty four
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per cent of all the patients had the presence of weight loss documented in the notes 
(Table 5.2), although there were no actual weights documented in any of the patients. 
Eighteen per cent of patients had documented anorexia without weight loss and 35% of 
patients had both symptoms of anorexia and weight loss. Sixteen per cent of patients 
had no evidence of weight loss during their illness. The documentation within some of 
the notes was incomplete and, therefore, the presence of weight loss in some patients 
could not be confirmed or excluded.
Fifty one patients had documented generalised or muscle weakness (22% of total) and 
24 had documented tiredness, exhaustion, lethargy or fatigue (10%) (see appendix 2). 
Twenty patients were noted to be frail (9%) and 82 (36%) had documented difficulties 
with their mobility, such as difficulty in toiletting and rising from a chair.
Patients were involved with the palliative care service for varying lengths of time from a 
single day to nearly 3 years, although the median length of involvement was just over 5 
weeks. The majority of patients died in the hospice or in hospital (71%), although 25% 
died in their own home (Table 5.3).
This patient group were taking a large number of medications. The prevalence of usage, 
in this patient group, of drugs commonly used in palliative care is shown in Table 5.4. 
The commonest group of drugs used was the strong opioids (64% of patients), morphine 
sulphate being the commonest drug prescribed. Other commonly prescribed drugs were 
corticosteroids (54%), diuretics (31%), non-steroidal anti-inflammatory drugs (NSAIDs) 
(29%), benzodiazepines (22%) and anti depressants (21%).
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5.4 Discussion
The present retrospective study describes a cross-section of cancer patients involved 
with a palliative care service and is representative of all the main cancer types 
registered in Scotland (Scottish Cancer Co-ordinating and Advisory Committee, 1996). 
The three main cancer types were gastrointestinal, lung and breast in order of frequency. 
Donnelly and Walsh (1995) found a similar picture in their large survey of patients 
involved with palliative care services in Cleveland, USA, although in that study lung 
cancer was commoner than gastrointestinal cancer. The median age in the Strathcarron 
study was similar to that in the study by Edmonds and colleagues (1998), which also 
described a heterogeneous group of cancer patients. Donnelly and Walsh (1995) had a 
younger median age of 65 years, but their patient group included patients with childhood 
malignancies (youngest patient aged 12).
It is clear that lung and gastrointestinal malignancies are the commonest malignancies 
cared for at Strathcarron Hospice. Lung cancers comprised the largest single group of 
cancers registered in Scotland between 1990 and 1994 (Scottish Cancer Co-ordinating 
and Advisory Committee, 1996), although if all the different gastrointestinal cancers 
registered are taken together they exceed the lung cancers in number. When cancer 
registrations are broken down into regional statistics, the two main areas covered by 
Strathcarron Hospice - Forth Valley and Lanarkshire - show very similar distributions, 
except that in Lanarkshire lung cancer is commoner than all gastrointestinal cancer. 
Breast cancer was the fourth highest group in cancer registrations and the third highest 
at Strathcarron. The third highest group in the registration statistics - skin neoplasms.
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excluding melanoma - are cancers which are mainly curable and, therefore, are not 
usually cared for in hospice units.
The literature suggests that 50-70% of cancer patients wish to die at home (Carroll, 
1998; Karlsen and Addington-Hall, 1998). However, from this study, only a quarter died 
at home and the majority in hospital or hospice. Karlsen and Addington-Hall (1998) 
reported that in an inner London area only 21% of patients died at home and in a review 
of all cancer registrations in England between 1985 and 1994, Higginson, Astin and 
Dolan (1998) established that 27% of patients died at home, with only minor regional 
variation. A similar picture has also been reported in Belgium (Schrijvers et al., 1998). 
Palliative care services should take into account the wishes of patients about place of 
death and Carroll (1998) reported, in Kincardineshire, that when this is done the 
percentage of patients who die in their place of preference is increased significantly. 
However, it is not always practicable to ensure this as patients may require admission to 
an in-patient unit for symptom management or intensive nursing care that would be 
impossible at home (Carroll, 1998).
Weight loss and anorexia are clearly important issues for cancer patients and previous 
work has shown that weight loss adversely affects quality of life and survival (DeWys et 
al., 1980; Ovesen, Hannibal and Mortensen, 1993; O'Gorman et al., 1999). Half of the 
patients in the present audit had definite weight loss and 18% had anorexia without 
documentation of whether weight had been lost. It is thought that around two-thirds of 
cancer patients develop cachexia (Kern and Norton, 1988). Weight loss is generally 
commonest in lung and gastrointestinal cancers (Caiman, 1982). In this audit weight 
loss was documented in 54% of patients, although in 12% of patients there was
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insufficient information to determine whether or not the patients had lost weight. In the 
present audit 65% of the lung cancer patients and 61% of the gastrointestinal cancer 
patients had definite weight loss and were the commonest cancer sites for weight loss, 
except for the haematological group (66%). However, this latter group was small (n=9).
Weakness, fatigue and tiredness also feature as symptoms documented in this cancer 
group, although are not documented as frequently as weight loss. The percentage of 
patients documented with these symptoms is smaller than in prospective studies 
(Donnelly and Walsh, 1995). However, this study was retrospective and, therefore, is 
dependent on full documentation. Some subjective symptoms are not always 
documented and an accurate assessment of the prevalence of weakness and fatigue 
would require a prospective study. It is possible that weakness and fatigue are 
documented less often than other symptoms such as pain or dyspnoea, because it is often 
assumed that there is little or nothing that can be done to improve these symptoms or 
that they are an inevitable part of the illness (Gordon, 1986; Vogelzang et al., 1997). 
Many of these patients also had a documented reduction in mobility and function. The 
role of weight loss in the production of weakness, fatigue and reduced function is not 
clear and, although the literature suggests that there is a connection between cachexia 
and weakness (Lichter, 1990), this relationship has not been formally studied.
Polypharmacy is often an issue in palliative care patients, and this sample population is 
no exception. The majority of patients were taking strong or weak opioids, mainly for 
analgesia, although opioids are sometimes used for palliation of breathlessness 
(Ahmedzai, 1998). Corticosteroids feature prominently and are frequently used for the 
palliation of anorexia, weakness and fatigue (Robustelli Della Cuna et al., 1989;
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MacDonald et al., 1994). They do have the side effect of muscle weakness and the 
presence of proximal myopathy can seriously limit patients’ mobility and function 
(Batchelor et al., 1997). Non-steroidal anti-inflammatory drugs (NSAIDs) are also 
frequently used as analgesics in cancer patients. NSAIDs are thought to reduce pain 
partly through effects on inflammation. They are thus thought to be useful in musculo­
skeletal and bone pain and may have an opioid sparing effect (Pace, 1995; Rawlins, 
1998; Jenkins and Bruera, 1999). As discussed in section 1.3.3, NSAIDs have also been 
reported to have an effect in moderating the acute phase response which is present in 
many cancer patients with cachexia (Preston et a l, 1995; McMillan et a l, 1995). As 
patients with cachexia are often reported to be weak and fatigued, it is possible that 
these latter symptoms may be improved by effects on the acute phase response and there 
may be a role for NSAIDs here. Other drugs which may contribute to the aetiology of 
weakness include benzodiazepines, diuretics and antidepressants (Lichter, 1990), which 
also feature prominently in this group of patients. The prevalence of antidepressants - 
although some are used in treatment of neuropathic pain - and antipsychotics indicate 
that there are often psychiatric or mood disturbances present in this patient group.
In summary, in the present audit, this hospice sample population was representative of 
other palliative care populations previously studied and also of all the common cancer 
types. Weight loss was a common symptom in this patient group, particularly in patients 
with lung and gastrointestinal malignancies. Weakness, tiredness and fatigue were also 
common symptoms in this group, although probably incompletely documented. 
Polypharmacy was common in this patient group, with opioids, corticosteroids, diuretics 
and non-steroidal anti-inflammatories the commonest drugs prescribed.
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Table 5.1 Characteristics of Strathcarron Hospice Patients Who Died 
Between June 1®* and November 30^ ** 1996
Age at hospice involvement (years)* 
Age at death (years)*
Length of hospice involvement (days)*
Male
(n=117)
69 (36-91)
69 (36-91)
41.5(1-1017)
Female
(n=112)
69 (35-94)
69 (35-94)
32 (1-693)
p-value
NS
NS
NS
Cancer Diagnosis
Gastrointestinal
Lung
Unknown Primary 
Breast 
Prostate 
Urinary Tract 
Haematological 
Head & Neck 
Female GU 
Primary Cerebral 
Melanoma 
Others
27
30
15
13
6
5
7
3
1
10
30
19
11
25
4
4 
2 
7 
3 
2
5
NS
NS
NS
NS
NS
NS
NS
NS
NS
N S  = N o t S ign iflcan t
* Data presented as median and range
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Table 5.2 Presence of Weight Loss or Anorexia in Strathcarron Hospice
Patients
Number Percentage of Total (%)
Weight loss 124 54
No weight loss 37 16
Not known 27 12
Anorexia alone documented 41 18
Total 229  ^ 100
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Table 5.3 Place of Death of Strathcarron Hospice Patients
Number of deaths Percentage of Total (%) 
Hospice 94 41
Hospital 68 30
Patient’s Home 58 25
Nursing Home 4 2
Relative’s Home 1 <1
Not Known 4 2
Total 229 100
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Table 5.4 Drugs Prescribed in Strathcarron Hospice Patients
Number Percentage of Total (%) 
of patients
Strong Opioids 146 64
Corticosteroids 123 54
Diuretics 70 31
Non-steroidal anti-inflammatory drugs 67 29
Benzodiazepines 50 22
Antidepressants 49 21
Weak opioids 33 14
Antipsychotics 25 11
Anticonvulsants 17 7
Disease modifying drugs 13 6
Megestrol acetate 12 5
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CHAPTER 6: A STUDY OF THE IMPORTANCE OF WEIGHT LOSS. 
ALTERED BODY COMPOSITION, INFLAMMATION AND BLOOD 
PARAMETERS ON THE EXPERIENCE OF WEAKNESS AND FATIGUE IN 
PATIENTS WITH ADVANCED CANCER
6.1 Introduction
Weakness and fatigue are the commonest symptoms in patients with advanced cancer 
(Lichter, 1990; Glaus et a l, 1996; Vogelzang et al., 1997; Pater et a l, 1997). They are, 
however, poorly understood and are often regarded as an inevitable consequence of 
advancing disease (Lichter, 1990).
The relationship between weakness and fatigue is unclear and the two terms are often 
used interchangeably. They may be two components of a larger symptom complex, often 
called asthenia (Bruera and MacDonald, 1988; Morant, 1996). Morant (1993) suggested 
that it might be possible to distinguish between weakness and fatigue by hypothesising 
that weakness constituted difficulty in initiating activity and that fatigue related to 
difficulty in continuing activity once started. In a later study, Morant (1996) reported a 
significant correlation between linear analogue scale measures of weakness and of 
fatigue, suggesting that the two symptoms often co-exist. Glaus and colleagues (1996) 
suggested that weakness was a pathological symptom, while fatigue was found to some 
degree in the healthy population.
Many cancer patients lose weight and weight loss is known to be a poor prognostic 
factor (DeWys et ah, 1980; Kern and Norton, 1988). Cancer cachexia has often been
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suggested as an aetiological factor for weakness and fatigue (Theologides, 1979; 
MacDonald et ak, 1995; Billingsley and Alexander, 1996). The weight loss consists of 
loss of both fat and fat free mass, of which muscle is a large component (McMillan 
et al., 1994a). Measurement of total body water gives an estimate of fat free mass 
(Heymsfield et ah, 1994; Burman and Chamberlain, 1996). Twenty four hour urinary 
creatinine excretion is often used as a measure of muscle bulk (Heymsfield et al., 1983; 
Burman and Chamberlain, 1996) and has previously been found to correlate with fat free 
mass (Forbes and Bruining, 1976). Serum creatine kinase concentrations also give some 
indication of muscle mass (Giltay et al., 1999).
Raised C-reactive protein concentrations have previously been reported in weight- 
losing, compared with weight-stable cancer patients (Scott et ah, 1996), suggesting that 
inflammation has a role in the aetiology of cancer cachexia. C-reactive protein 
concentrations may also relate to the severity of weakness and fatigue (Morant, 1996). 
Low albumin has been associated with raised C-reactive protein concentrations 
(O'Gorman et ah, 1999) and may also relate to the level of weakness and fatigue 
(Morant, 1996). Low serum zinc and raised serum copper levels have also been 
reported to be associated with C-reactive protein concentrations in cancer patients 
(Sattar et ah, 1997), although it is not known if these are related to the experience of 
weakness and fatigue.
Anaemia has been reported to be an aetiological factor for weakness and fatigue, 
although contrasting views exist as to whether or not the level of haemoglobin relates to 
the level of weakness or fatigue (Bruera et ah, 1989; Gleeson and Spencer, 1995; 
Morant, 1996; Yellen et ah, 1997). Low blood sodium, potassium and magnesium
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concentrations, raised blood calcium concentrations and renal failure have all been 
reported as causes of weakness and fatigue (Regnard and Mannix, 1992; Barnish, 1994; 
Morant, 1996). It has been reported that Vitamin D concentrations are often low in 
medically ill patients (Thomas et ah, 1998), but this has not previously been studied in 
patients with advanced cancer. Vitamin D deficiency may lead to proximal muscle 
weakness (Forbes and Jackson, 1993).
The aim of the present study was to investigate the importance of weight loss, altered 
body composition, the inflammatory response, haematological and biochemical 
parameters in the experience of weakness and fatigue in patients with advanced cancer.
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6.2 Material and Methods
6.2.1 Patients
A cross-section of patients with advanced cancer was recruited from several palliative 
care centres - Strathcarron Hospice (Denny), Stobhill Hospital NHS Trust (Glasgow) 
and Hunter’s Hill Marie Curie Centre (Glasgow). Patients were identified as suitable for 
the study by medical or nursing staff in the wards at each centre, the 
Respiratory/Oncology outpatient clinic, the hospice day centres or by hospice home care 
sisters. The investigator visited each of the centres on a regular basis and approached 
those patients identified as eligible for inclusion in the study, either at the centre or at 
the patient’s own home.
Patients were included in the study if they had a firm clinical or histological diagnosis of 
cancer which was no longer amenable to curative treatment, if they were aged 18 years 
or more and if they were able to give full informed consent to the study. Patients were 
excluded from the study if they were under 18 years of age, if they had received surgery, 
chemotherapy or radiotherapy within the previous month, had an active connective 
tissue disease, a pre-existing neuromuscular disorder causing generalised muscle 
weakness, had uncontrolled pain, symptomatic angina, severe dyspnoea (breathless at 
rest), or were otherwise too ill to participate in the study.
Details of the patient’s illness, including evidence of metastatic disease, were obtained 
from their casenotes and from a careful history. Details of the patient’s drug history 
were recorded and they were questioned about their healthy weight and degree of 
weight loss. Previous weights documented in the casenotes were noted. Patients were
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divided into weight-stable and weight-losing groups. Weight loss was defined as loss of 
> 5% of body weight in the previous 3 months. If patients had lost weight earlier in their 
illness, but had remained weight-stable in the preceding 3 months, they were regarded as 
weight-stable for the purposes of the study. Patients were also asked about their pre­
illness, and current, activity levels. Activity levels were rated on a simple 4 point scale 
devised by the investigator (0 = Inactive; mainly bed or chair bound; 1 = Sedentary 
lifestyle, some walking; 2 -  Moderately active, walks a lot, light sporting activity; 
3 = Very active, training or sports).
A group of healthy volunteers (n=15) was recruited from Strathcarron Hospice 
volunteers and also through personal contacts at the University of Glasgow.
The study was approved by the local ethics committees in Forth Valley (covering 
Strathcarron Hospice), Stobhill Hospital (which covers Hunter’s Hill Marie Curie 
Centre) and in Lanarkshire (as some Strathcarron Hospice patients were from 
Lanarkshire). All patients and healthy subjects were aware of the purpose of the study 
and gave written, informed consent.
6.2.2 Questionnaires
Patient-rated levels of weakness and strength were obtained using two linear analogue 
scales (figures 4.1, 4.2) as described in section 4.4. The FACT-Ftg Version 3 scale (see 
appendix 1) was used as a validated measure of fatigue as described in section 4.3. The 
EORTC QLQ-C30 questionnaire version 2.0 (see appendix 1) was used as a general 
quality of life questionnaire as previously described in section 4.2; this questionnaire 
also includes a 3-item fatigue subscale (“Did you need to rest?”, “Have you felt weak?”.
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“Were you tired?”). The Karnofsky Performance Status was used as an observer-rated 
measure of functional ability as described in section 4.1.
Prevalence estimates for weakness and fatigue were calculated, by using a cut-off point 
of the 95% centile of the healthy scores. This means that 95% of the healthy scores were 
regarded as normal and any results poorer than these in the cancer patients were 
regarded as pathological. Thus, a prevalence for pathological weakness and fatigue was 
calculated. This technique has recently been used in a study by Stone and co-workers 
(1999).
6.2.3 Body Composition
Height and weight were measured and body mass index calculated as described in 
section 2.2.1. Current body mass index was then divided by 23 and multiplied by 100 to 
express it as a percentage of healthy body mass index. Triceps, biceps and thigh skinfold 
thicknesses and mid-arm and mid-thigh circumference were measured as described in 
section 2.2.2.
Arm muscle area (in cm^) was calculated using the equation:
[Mid-arm circumference - tcx Triceps skinfold thicknessf
4tu
Mid-thigh muscle area (in cm^) was calculated using the equation:
[Mid-thigh circumference - 7i x Thigh skinfold thickness)^
4n
(Heymsfield et al, 1994)
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Bioelectrical impedance analysis was carried out using the technique described in 
section 2.2.3. Twenty four hour urinary creatinine was measured using the technique 
described in section 2.2.4. A dietary history for the previous 48 hours was obtained, as 
the value obtained for creatinine excretion can be affected by red meat consumption.
6.2.4 Blood Testing
Haemoglobin, white cell count, sodium, potassium, urea, creatinine, albumin, creatine 
kinase, calcium, magnesium, zinc, copper, vitamin D and C-reactive protein 
concentrations were measured using the methods described in section 2.3.
6.2.5 Statistics
Data is presented as medians, with ranges. Comparisons were carried out, where 
appropriate, using Fisher’s Exact test and the Mann Whitney U test, and correlations 
were calculated using the Spearman Rank Correlation (SPSS Inc., Chicago, Illinois, 
USA). Correlations were only carried out for the cancer group.
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6.3 Results
One hundred and ten patients were approached about the study and given a full 
explanation of its purpose. However, only 68 patients actually participated in the study. 
Of the 42 patients lost to study, 16 patients subsequently declined to participate in the 
study, 10 became too unwell before the first measurement could be carried out and 
9 died. Three patients were subsequently felt to be inappropriate for entry into the study, 
due to confusion in one patient and failure to understand the study in the other two. Four 
patients were lost to study for other reasons.
Sixty eight cancer patients participated in the study. There was no significant difference 
in the proportion of men and women between this sample and the hospice population 
described in chapter 5. However, there was a significant difference in the ages of the 
two samples (p < 0.001), the study sample being younger than the Strathcarron Hospice 
population. There were significantly more lung cancer patients (p < 0.001) in this 
sample. There were no significant differences between the two samples for any of the 
other malignancies.
The majority of patients had either lung or gastrointestinal malignancies (Table 6.1). Of 
the 38 patients with lung cancer, 28 had non-small cell lung cancer, 6 had small cell 
lung cancer and 4 had no histology. Of the 13 patients with gastrointestinal malignancy, 
8 had colorectal cancer, 2 had pancreatic cancer, 2 had oesophageal cancer and one had 
gastric cancer. The patients with hormone dependent tumours (n=7) included 4 patients 
with breast cancer, 2 with ovarian cancer and one with prostate cancer.
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Thirty two patients had metastatic disease, some at multiple sites (results not shown, 
see appendix 3). The commonest sites were bone (n=12), liver (n=8), lung (n=6), lymph 
node (n=5) and brain (n=4). There was no significant difference in the prevalence of 
these sites of distant spread compared to the hospice population described in chapter 5. 
Other patients had peritoneal (n=3), renal (n=l) and bladder (n=l) metastatic disease.
The co-existing medical conditions in the patient groups included cardiac and vascular 
disease, chronic chest disease and diabetes. One patient had a co-existing superficial 
papillary bladder tumour, which was not felt to be linked significantly to his clinical 
condition. Six of the 15 healthy subjects reported high blood pressure, which was 
controlled on medication, compared to only 3 of the patient group (p < 0.01). There 
were no significant differences between the healthy and cancer groups for the prevalence 
of other medical conditions.
Fifteen healthy volunteers also participated in the study. The cancer and healthy groups 
were similar in terms of gender, age, healthy weight and healthy body mass index (Table 
6.1). The cancer group were significantly lighter at study entry (p < 0.01) and, compared 
to the control group, the Karnofsky Performance Status was significantly lower
(p<  0.001).
Total body water (p < 0.01), intracellular fluid volume (p < 0.05), the intracellular to 
extracellular fluid ratio (p < 0.05), limb circumferences (p < 0.001), limb muscle areas 
(p < 0.01) and 24 hour urinary creatinine excretion (p < 0.05) were all significantly 
reduced in the cancer patients (Table 6.2), indicating that the cancer group had lost lean 
body tissue. There were highly significant correlations between mid-arm circumference
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and arm muscle area (r -  0.91, p < 0.001) and mid-thigh circumference and thigh 
muscle area (r = 0.96, p < 0.001). There was also a significant correlation between 
24 hour urinary creatinine excretion and total body water (r = 0.75, p < 0.001). There 
were similar numbers of healthy subjects and cancer patients who had eaten red meat in 
the previous 48 hours. The cancer group had also lost body fat, as indicated by 
significantly lower skinfold thicknesses at all sites (p < 0.05), Nine patients had 
evidence of peripheral oedema or lymphoedema.
The majority of patients were moderately active prior to their cancer diagnosis, with 
most having an activity level of 2 (Table 6.3). However, the patients’ activity level at 
study entry was much reduced, with the majority of patients in activity level 1. Most of 
the volunteers were moderately to very active, with a similar picture to the patient group 
prior to their illness.
The cancer patients scored significantly higher on the weakness scale than the healthy 
subjects (p < 0.001, Table 6.4), and significantly lower on the strength scale (p < 0.001). 
They scored significantly lower on the FACT-Ftg scale (p < 0.001) and higher on the 
EORTC Fatigue scale (p < 0.001), indicating higher levels of fatigue. The weakness 
scale was correlated with both the FACT-Ftg scale (r = -0.50, p < 0.001) and the 
EORTC Fatigue scale (r = 0.47, p < 0.001). The FACT-Ftg and EORTC Fatigue scales 
were strongly correlated (r = -0.81, p < 0.001). There were correlations between the 
weakness scale and the individual questions within the EORTC Fatigue scale and the 
FACT-Ftg scale except for questions 7, 8 and 10 of the FACT-Ftg scale (“I have 
energy”, “I am able to do my usual activities” and “I am too tired to eat”). The
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relationship between subjective weakness and subjective strength linear analogue scales 
was weak (r = - 0.29, p < 0.05).
A cut-off point of the 95% centile of the healthy scores was taken for estimation of 
prevalence of weakness and fatigue as discussed in section 6.2.2. The prevalence for 
weakness in the cancer group in the present study was calculated as 64%. The 
prevalence for fatigue on the FACT-Ftg scale was calculated as 94%, and on the 
EORTC Fatigue scale as 72%.
There was no relationship between patient age or gender and the weakness score, nor 
with either of the fatigue scales. There were too few patients in most of the cancer 
diagnostic groupings to compare weakness and fatigue scores. However, there were no 
differences in these scores when the lung cancer group was compared with the 
gastrointestinal cancer group, nor between the lung cancer patients and the other patient 
groups combined. The weakness score was related to mid-thigh circumference 
(r = -0.25, p < 0.05), but not to mid-thigh muscle area. The FACT-Ftg scale was related 
to triceps skinfold thickness (r = 0.24, p = 0.05), mid-arm circumference (r = 0.28, 
p < 0.05) and mid-thigh circumference (r = 0.28, p < 0.05) and mid-thigh muscle area 
(r = 0.29, p <  0.05).
Many patients were taking drugs implicated in the aetiology of weakness and fatigue 
(data not shown, see appendix 3), including strong opioids (n=38), benzodiazepines 
(n=26), antidepressants (n=17) and diuretics (n=15). Twenty two patients were taking 
corticosteroids and 7 were taking megestrol acetate. Twenty two patients were also 
taking non-steroidal anti-inflammatory drugs. Those patients taking benzodiazepine
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drugs had higher scores on both the FACT-Ftg scale (p < 0.05) and the EORTC Fatigue 
scale (p < 0.01). This was not true for opioids, antidepressants, non-steroidal anti­
inflammatory drugs or steroids. There was no relationship between weakness or fatigue 
scores and either opioid dose or steroid dose.
Haemoglobin concentrations were significantly lower in the cancer group compared 
with the healthy group (p < 0.001; Table 6.5) and haemoglobin was correlated with the 
FACT-Ftg score (r = 0.29, p < 0.05). There was a trend towards lower FACT-Ftg scores, 
i.e., more fatigue, in those patients with haemoglobin concentrations less than 12.0 g/dl 
compared with those with concentrations of 12.0 g/dl or more (p < 0.10). White cell 
count was significantly higher in the cancer group (p < 0.001) and was correlated with 
the FACT-Ftg scale (r = -0.26, p < 0.05) and the EORTC Fatigue scale (r = 0.33, p < 
0.01).
Sodium (p < 0.01), albumin (p < 0.001), creatine kinase (p < 0.001), zinc (p < 0.001) 
and vitamin D (p < 0.01) concentrations were all significantly lower in the cancer 
patients (Table 6.5). Albumin concentrations were correlated with both the FACT-Ftg 
scale (r = 0.33, p < 0.01) and the EORTC Fatigue scale (r = -0.34, p < 0.01). Calcium 
(p < 0.05), copper (p < 0.01) and C-reactive protein (p < 0.001) concentrations were 
significantly higher in the cancer group. Calcium concentrations were correlated with 
the weakness scale (r = 0.38, p < 0.01) and the EORTC Fatigue scale (r = 0.26, 
p < 0.05). C-reactive protein concentrations were correlated with the weakness scale, the 
FACT-Ftg scale, the EORTC Fatigue scale, white cell count and albumin, zinc, copper 
and vitamin D concentrations (Table 6.6). There were no relationships between any of 
the other blood parameters and the weakness and fatigue scores.
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Dividing the cancer patients into weight-stable and weight-losing groups, the sex and 
age distributions were similar (Table 6.7). There were no significant differences in the 
numbers of patients of each cancer type between the two groups, except that all the 
patients in the “others” group were weight-stable (p < 0.05). There were similar 
numbers of patients with metastatic disease in each group. The healthy weight and body 
mass index were similar in both groups. However, the weight-losing group had lower 
Karnofsky Performance Status (p < 0.01).
In terms of body composition, there was no significant difference between the weight- 
losing and weight-stable patients in triceps, biceps and thigh skinfold thickness, nor in 
mid-arm circumference, nor any of the bioelectrical impedance parameters (Table 6.8). 
The mid-thigh circumference and thigh muscle area were, however, significantly lower 
(p < 0.05) in the weight-losers, as was the 24 hour urinary creatinine excretion 
(p < 0.01). Five weight-losing and 4 weight-stable patients had evidence of peripheral 
oedema or lymphoedema.
The number of patients with metastatic disease and with different pre-existing medical 
conditions were similar in both groups. Activity levels were also similar both pre­
diagnosis and at study entry in both groups (data not shown, see appendix 3). More 
patients in the weight-losing group were taking strong opioid drugs than in the weight- 
stable group (72% V 42%; p < 0.05), although the median equivalent morphine dose for 
each group was similar (see appendix 3). There was no significant difference between 
the two groups for any other medication.
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The weight-losing group scored higher on the weakness scale (p < 0.01) and rated as 
more fatigued on the FACT-Ftg scale (p < 0.05, Table 6.9). Degree of weight loss was 
related to both the weakness score (r = 0.25, p < 0.05) and the FACT-Ftg score 
(r =-0.36, p <  0.01).
There were significant differences between the two groups in scores for the individual 
questions in the two fatigue scales (see appendix 3). Weight-losers scored higher on the 
“Did you need to rest” EORTC scale question (p < 0.05) and on the FACT-Ftg scale 
they reported more difficulty in starting activity (question 5, p < 0.05), lower energy 
levels (question 7, p < 0.01), needing more help in doing their usual activities (question 
11, p < 0.001), increased frustration at their limitations (question 12, p < 0.05) and 
limitation of their social activities (question 13, p < 0.05).
The weight-losing group had lower sodium (p < 0.05), creatine kinase (p < 0.05) and 
albumin (p < 0.01) concentrations than the weight-stable group (Table 6.10). White cell 
count (p < 0.001) and C-reactive protein (p < 0.01) concentrations were significantly 
higher in the weight-losing group.
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6.4 Discussion
The present study examined a group of patients with advanced cancer. The majority of 
these patients had lung or gastrointestinal cancer. The lung cancer group forms a greater 
proportion of this group than in Scottish cancer registration statistics (Scottish Cancer 
Co-ordinating and Advisory Committee, 1996). However, all of the patients recruited at 
Stobhill Hospital were recruited via the Respiratory Oncology services and had either 
lung cancer or mesothelioma. It was of note, however, that many of the patients 
recruited from Hunter’s Hill Marie Curie Centre, a heterogeneous cancer population, 
also had lung cancer, which may be a reflection of the fact that Glasgow has a higher 
proportion of lung cancer patients than the national average.
Many of the patients approached for the study were unable to participate due to disease 
progression or death, which illustrates the frequent problem of attrition rates in studies 
involving palliative care patients (Loprinzi et al., 1990; Tchekmedyian et al., 1992; 
McMillan et al., 1999). The attrition rate prior to study entry in this study was 38%. For 
a variety of reasons not all patients were able to complete all the tests. Some 
questionnaires were left incomplete and some blood samples were haemolysed and 
inappropriate for certain analyses. The bioelectrical impedance analysis apparatus was 
occasionally unavailable. The 24 hour urine collection was not felt to be suitable for all 
patients, as this test involves significant patient co-operation to remember to use the 
container each time they need to pass urine. Therefore, those who were too frail or for 
whom the test would prove practically difficult did not collect a urine specimen.
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The study group was younger than the hospice population described in chapter 5. The 
reason for this is unclear. However, it was of interest that those patients approached 
about the study who declined to participate were of a similar age distribution to the 
hospice population (median 67.5 years (49-78)). Given the nature of the present study it 
may be that it was not attractive to the older patients.
It is clear that the cancer patient group were more unwell than the healthy subject group, 
with reduction in both fat and fat free mass. It was also clear that muscle mass was 
reduced, as there was a reduction in limb circumferences and limb muscle area, as well 
as a reduction in 24 hour urinary creatinine excretion and serum creatine kinase. The 
cancer patients had significantly more weakness and fatigue. The cancer group also had 
lower haemoglobin, sodium, albumin, zinc and vitamin D concentrations compared with 
the healthy group, as well as higher white cell count, calcium, copper and C-reactive 
protein concentrations.
The literature describes fatigue as a symptom present in normal individuals (Barnish, 
1994; Glaus et al., 1996), and suggests that weakness is a symptom that is pathological 
(Glaus et ah, 1996). The weakness and fatigue scores in this study were generally low 
in the healthy group. The prevalences for weakness and fatigue in this study have to be 
interpreted in the light of the small control group. However, they are consistent with 
previous estimates in uncontrolled studies (Dunlop, 1989; Donnelly and Walsh, 1995). 
Previous studies of fatigue have largely considered the role of chemotherapy and 
radiotherapy in the aetiology of fatigue (Meyerowitz et al., 1979; Nail and King, 1987; 
Richardson, 1995). In this study, patients in the baseline group had received neither of 
these treatment modalities in the previous month, suggesting that weakness and fatigue
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are also common symptoms in cancer patients not receiving anti-cancer treatment. These 
results are consistent with recent work by Stone and colleagues (1999), who reported a 
prevalence for fatigue of 75% in patients with advanced cancer not receiving 
chemotherapy or radiotherapy.
There were significant relationships between the weakness scale and the measures of 
fatigue (FACT and EORTC), and this is extended into individual questions within the 
fatigue scales: there were positive correlations between the weakness scale and all three 
components of the EORTC fatigue scale and with most of the questions of the 
FACT-Ftg scale. Although the weakness linear analogue scale measured weakness at a 
single point in time and the fatigue scales considered the patients’ experience over the 
previous seven days, these results suggest that fatigue, tiredness and weakness tend to 
coexist in cancer patients and may be components of the same phenomenon.
The cancer patients had clearly lost fat and fat free mass compared with the healthy 
subjects. This is consistent with the published literature, which has reported that cancer 
patients who lose weight lose both adipose tissue and muscle (Nelson et al., 1994a; 
Toomey et al., 1995). Although total body water was reduced in the cancer patients, 
intracellular water was reduced more than extracellular water, suggesting that in the 
cancer patients there was either fluid retention into the extracellular space or that there 
were fluid shifts from the intracellular to the extracellular compartments. It was of note 
that some of the patients had clinically detectable oedema. Previous work has reported 
that ill patients retain fluid into the extracellular space (Hannan et al., 1995), with a 
consequent expansion of total body water. Overestimation of total body water in 
cachectic cancer patients, using bioelectrical impedance analysis, has also previously
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been reported (Simons et al., 1995). It is possible that, in the present study, as well as 
those patients with oedema, there were also patients with clinically undetectable fluid 
retention, and that together these patients contributed to overestimation of extracellular 
fluid and, consequently, total body water and fat free mass. However, it was clear from 
the 24 hour urinary creatinine excretion and limb circumference measurements that loss 
of muscle mass had occurred.
Higher fatigue scores were recorded in those patients taking benzodiazepine drugs. 
Although benzodiazepines have been suggested as an aetiological factor for weakness 
and fatigue in cancer patients (Regnard and Mannix, 1992), this association does not 
appear to have previously been reported in a prospective study. These are commonly 
prescribed drugs in palliative care patients and it would be important for future studies 
to establish whether or not this is a coincidental finding.
As has been previously reported, there was a relationship demonstrated between 
haemoglobin and fatigue scores and the level of haemoglobin was lower in the cancer 
group. In the present study, there was a trend for FACT-Ftg scores to be lower in those 
with haemoglobin concentrations lower than 12.0 g/dl. This is consistent with previous 
work by Celia (1998), who reported a significant difference in FACT-Ftg scores 
between high and low haemoglobin scores in a larger study of patients with cancer and 
human immunodeficiency virus (HIV) infection.
Raised C-reactive protein concentrations and elevated white cell count, as well as low 
albumin concentrations, were present in the cancer patients. C-reactive protein and 
albumin were correlated, as previously reported (O'Gorman et al., 1999). These
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parameters also seem related to the subjective experience of weakness and fatigue, 
consistent with previous work by Morant (1996). It is of interest that a previous study by 
Morant and colleagues (1993) found no relationship between C-reactive protein and 
weakness and fatigue scores. However, this latter study had a much smaller patient 
group (n = 31) compared with the 1996 study (n = 225) and this may well explain the 
difference between the two studies. The low zinc and raised copper concentrations 
were also related to the magnitude of the inflammatory response, as previously reported 
(Sattar et al., 1997), but not to the weakness and fatigue scores. Vitamin D 
concentrations were inversely related to the inflammatory response, as with other 
vitamins (Galloway, McMillan and Sattar, 2000). The inflammatory response may have 
a role in the production of weakness and fatigue, but low trace element and vitamin 
concentrations appear not to have a primary role in these symptoms. Further work on the 
temporal relationship of the inflammatory response and weakness/fatigue would be of 
considerable interest.
The lack of difference between the weight-stable and the weight-losing group, in terms 
of skinfold thicknesses and bioelectrical impedance measurements, suggests that the 
weight-stable group themselves are also quite ill, and certainly not normal, compared 
with the healthy group. It is also possible that the weight-losing group had retained more 
fluid - this group had lower albumin concentrations - and, thus, the accuracy of the 
bioelectrical impedance results may have been affected, with a consequent 
overestimation of lean body mass. The skinfold thickness measurements in the weight- 
losing patients were similar to those of the weight-stable patients, suggesting that both 
patient groups had lost fat compared with the healthy group. However, the weight-losers 
had clearly lost muscle compared with the weight-stable patients as mid-thigh
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circumference, thigh muscle area and 24 hour urine creatinine were reduced. There are 
more errors inherent to measures of skinfold thickness than in measure of limb 
circumference (Burkinshaw et ah, 1973) and this may, in part, have influenced the 
results.
Weakness and fatigue were more marked in the weight-losing group and weight loss, as 
well as the limb circumferences and triceps skinfold thickness, were associated with the 
severity of weakness/fatigue. It may be, therefore, that cancer cachexia plays a role in 
the production of weakness/fatigue.
The weight-losers needed significantly more help in doing their usual activities (FACT- 
Ftg question 11) and also had a significantly lower performance status, suggesting that 
the weight-losers had poorer functional ability. No difference was noted between the 
weight-stable and weight-losing cancer groups for the author’s activity scale, suggesting 
that it was less sensitive to change than the FACT-Ftg questions or performance status. 
It is of interest that the weight-losers scored significantly worse in the “I have trouble 
starting things because I am tired” question (question 5) of the FACT-Ftg scale than the 
weight-stable patients, but not in the “I have trouble finishing things because I am tired” 
question (question 6). This may give credence to the suggestion that it is possible to 
differentiate between difficulty in initiating activity and difficulty in continuing activity 
(Morant et ah, 1993). The terms “weakness” and “fatigue” may be used synonymously 
by cancer patients, but it may be possible to describe difficulty in activity as weakness 
and the subjective element as fatigue. The FACT-Ftg scale, by including questions on 
activity, may tap into both dimensions and may explain why the prevalence of fatigue 
would be higher on the FACT scale than the EORTC scale. However, it may be
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academic as to whether or not it is possible to differentiate between weakness and 
fatigue in terms of definition. Ultimately, what matters most are the problems reported 
by the patient and how these problems affect their life.
Although there was more weakness and fatigue in the weight-losing group, the 
haemoglobin was not reduced compared to the weight-stable group. This would suggest 
that anaemia in itself may not be the most important factor in the aetiology of these 
symptoms, although weakness, fatigue and anaemia seem often to co-exist. C-reactive 
protein and white cell count were elevated and albumin was reduced in the weight- 
losing patients, consistent with the inflammatory response having a role in weight loss.
In summary, this study has found a relationship between patient-rated weakness and 
more comprehensive fatigue scales, suggesting that weakness, fatigue and tiredness are 
overlapping parts of the same phenomenon. The cancer patients had altered body 
composition and had lost both fat and muscle. Cancer cachexia and the inflammatory 
response appear to be important factors in the production of weakness and fatigue. 
Anaemia and benzodiazepine drugs also appear to be factors in the aetiology of 
weakness/fatigue. There appears to be a spectrum ranging from healthy individuals to 
weight-stable cancer patients, to weight-losing cancer patients, with loss of muscle, 
deranged biochemistry, increasing levels of weakness/fatigue and increasing difficulty in 
initiating and performing daily activities. However, for some aspects of body 
composition, such as body water, there was little difference between the weight-stable 
and weight-losing cancer groups. The relationships between these factors would, 
therefore, appear to be complex and merit further study.
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Table 6.1 Healthy Subject and Cancer Patient Characteristics
Healthy Subjects Cancer Patients p-value
(n=15) (n=68)
Sex (M/F) 7/8 41/27 NS
Age 64 (46-74) 64 (38-83) NS
Healthy Weight (kg) 68.0 (52.0-87.0) 63.5 (44.5-114.3) NS
Current Weight (kg) - 58.0 (35.0-95.0) <0.01
Healthy BMI (kgm'^) 24.6 (20.9-28.9) 24.3 (15.9-40.0) NS
Current BMI (kgm'^) - 21.4(13.8-33.3) <0.01
%age of Healthy BMI 107 (91-126) 93 (60-145) <0.01
Karnofsky 
Performance Status
100 (90-100) 65 (25-100) <0.001
Cancer Tvnes (M/FI Male Female p -value
Lung 23 15 NS
Mesothelioma 4 0 NS '
Gastrointestinal 5 8 NS
Hormone Dependent 1 6 NS
Others* 4 2 NS
* = 2 Non-Hodgkin’s lymphoma, 1 patient with both non-small cell lung cancer & 
colonic carcinoma, 1 patient with both prostate and head & neck malignancies, 1 with 
cerebral astrocytoma and 1 with head & neck cancer
M /F  = M ale/F em ale B M I = B ody M ass Index N S  = N o t S ign ifican t 
Data is presented as median (range)
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Table 6.2 Body Composition of Healthy Subjects and Cancer Patients
p-valueHealthy Subjects 
(n=15)
Cancer Patients 
(n=58)
Total Body Water (1) 31.5(23.8-41.5) 26.7(17.3-41.0) <0.01
Volume ECF (1) 18.0(13.2-23.6) 16.1 (10.6-24.1) <0.10
Volume ICF (1) 14.3(10.6-18.9) 10.4 (6.8-20.9) <0.01
ÏCF/ECF Fluid Ratio 0.78 (0.64-1.00) 0.70 (0.40-1.25) <0.05
Triceps Skinfold 
Thickness (mm)
17.0(6.5-32.0) 10.0 (2.5-34.5) <0.01
Biceps Skinfold 
Thickness (mm)
10.0 (3.5-29.5) 6.3 (2.0-20.5) <0.01
Thigh Skinfold 
Thickness (mm)
18.3 (8.5-56.5) 12.5 (3.0-39.5) <0.05
Mid-Arm
Circumference (cm)
31.2 (25.6-33.5) 25.2 (16.5-37.1) <0.001
Arm Muscle Area (cm^) 49.1 (36.9-65.5) 36.2 (19.3-76.7) <0.001
Mid-Thigh 
Circumference (cm)
51.3 (44.8-59.1) 44.6 (28.0-66.3) <0.001
Thigh Muscle Area (cm^) 163.1 (96.2-209.5) 120.5 (58.3-294.4) <0.01
Twenty Four Hour 
Urinary Creatinine 
(mmol/1)
12.0 (7.0-19.2) 8.2(1.4-20.4)' <0.05
n = 27
E C  F  = E xtracellu lar Fluid; IG F  ~  In tracellu lar F lu id  
Data is presented as median (range)
146
Table 6.3 Activity Levels In Healthy Subjects and in Cancer Patients Before 
Diagnosis and at Study Entry
Activity level 
0 
0-1 
1
1-2
2
2-3
3
Healthy subjects 
(n=15)
Cancer patients 
pre-diagnosis 
(n=65)
5
5
42
7
6
Cancer patients 
at study entry 
(n=68)
3
46
7
4
Key:
0 = Inactive; mainly bed or chair bound
1 = Sedentary lifestyle, some walking
2 = Moderately active, walks a lot, light sporting activity
3 = Very active, training or sports
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Table 6.4 Baseline Data for Linear Analogue Scales of Weakness and Strength, 
FACT-Ftg Scale and EORTC Fatigue Scale in Healthy Subjects 
and Cancer Patients
Healthy Subjects Cancer Patients p-value
(n=15) (n=66)
Linear Analogue Scales
Weakness Scale (cm) 1,0 (0.1-3.3) 4.2 (0.4-8.3) < 0.001
Strength Scale (cm) 9.2(4.8-10.0) 4.4 (0.4-10) <0.001
FACT-Ftg Scale 49 (43-51) 28 (0-47) <0.001
EORTC-Fatigue Subscale 0 (0-33.3) 55.6 (0-100) <0.001
Data is presented as median (range)
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Table 6.5 Baseline Data for Blood Tests in Healthy Subjects and Cancer Patients
Healthy Subjects Cancer Patients p-value 
(n=15) (n=67)
Haemoglobin (g/1) 144 (123-161) 123 (91-177) <0.001
White Cell Count 6.5 (4.08-8.40) 9.3 (4.39-27.17) <0.001
Sodium (mmol/1) 139(137-144) 137 (123-145) <0.01
Potassium (mmol/1) 4.3 (3.6-4.8) 4.4 (3.3-5.6) NS
Urea (mmol/1) 5.5(3.8-17.7) 6.2 (2.0-17.6) NS
Creatinine (pmol/l) 90 (74-323) 83 (56-161) NS
Albumin (g/1) 44 (41-47) 39 (23-46) <0.001
Creatine Kinase (IU/1) 105 (38-199) 35(10-318) <0.001
Calcium (mmol/1) 2.31 (2.23-2.52) 2.37 (2.14-3.29) <0.05
Magnesium (mmol/1) 0.85 (0.69-1.03) 0.87 (0.58-1.02) NS
Zinc (jamol/1) 12.4 (9.1-18.5) 10.0(4.7-15.8) <0.001
Copper (p,mol/l) 18.2 (11.4-27.5) 21.6(10.8-37.5) <0.01
Vitamin D (nmol/1) 35 (21-82) 22 (< 6-128) <0.01
C-Reactive Protein (mg/1) 4(1-30) 40(1-214) <0.001
N S  = N o t S ign ifican t
Data is presented as median (range)
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Table 6.6 Spearman Rank Correlations Between C-Reactive Protein and Other 
Parameters in Cancer Patients
r-value p-value
EORTC Fatigue scale 0.41 < 0.01
FACT-Ftg scale -0.36 <0.01
Weakness scale 0.29 <0.05
Albumin -0.63 < 0.001
Zinc -0.40 <0.01
Copper 0.40 <0.01
White cell count 0.39 < 0.01
Vitamin D -0.25 0.05
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Table 6.7 Characteristics of Weight-Stable and Weight-Losing Cancer Patients
p-valueWeight-Stable
(n=36)
Weight-Losing
(n=32)
Sex (M/F) 22/14 19/13 NS
Age 64 (45-83) 64 (38-81) NS
Healthy Weight (kg) 63.5 (44.5-95.3) 66.8 (45.3-114.3) NS
Current Weight (kg) 64.0 (35.0-92.5) 54.0 (39.0-95.0) <0.10
Weight Loss from pre­
illness weight (kg)
2.1 (-18.8 to 22.3) 12.8 (-3.3 to 36.3) <0.001
Healthy BMI (kgm’^ ) 23.6(15.9-33.9) 25.0 (16.8-40.0) NS
Current BMI (kgm‘^ ) 22.8(13.8-31.5) 19.9(14.8-33.3) <0.05
% age Ideal BMI 99 (60-137) 86 (64-145) <0.05
Kamofsky 
Performance Status
75 (40-100) 60 (25-85) <0.01
Cancer Tvnes tM/FI
Lung 17(11/6) 21 (12/9) NS
Mesothelioma 2 (2/0) 2 (2/0) NS
Gastrointestinal 5 (0/5) 8 (5/3) NS
Hormone Dependent 6 (1/5) 1 (0/1) NS
Others 6 (4/2) - <0.05
M /F  = M ale/Fem ale B M I  = B ody  M ass Index N S  = N o t S ignificant 
Data is presented as median (range)
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Table 6.8 Baseline Anthropometries for Weight-Stable and Weight-Losing 
Cancer Patients
Weight-Stable Weight-Losing p-value
(n=31) (n=27)
Volume ECF (1) 17.2 (12.3-24.1) 14.9(10.6-21.7) NS
Total Body Water (1) 30.0 (20.9-41.0) 25.1 (17.3-37.5) NS
Volume ICF (1) 11.1 (7.0-20.9) 10.0 (6.8-16.2) NS
ICF/ECF Fluid Ratio 0.72 (0.40-1.25) 0.69 (0.56-0.97) NS.
Triceps Skinfold 
Thickness (mm)
10.0 (2.5-34.5) 10.0 (3.0-33.5) NS
Biceps Skinfold 
Thickness (mm)
6.5 (2.0-20.5) 5.8 (2.0-20.5) NS
Thigh Skinfold 
Thickness (mm)
12.5 (3.0-39.5) 12.5 (3.5-36.5) NS
Mid-Arm
Circumference (cm)
26.6(16.5-37.1) 24.2(17.1-37.0) NS
Arm Muscle Area (cm^) 38.9 (19.3-69.8) 34.1 (19.6-76.7) NS
Mid-Thigh 
Circumference (cm)
45.4(28.0-66.3) 41.8 (32.3-57.1) <0.05
Thigh Muscle Area (cm^) 136.2 (58.3-294.4) 111.4 (76.2-212.6) <0.05
Twenty Four Hour 
Urinary Creatinine 
(mmol/1)
9.9 (6.2-20.4)^ 6.1 (1.4-9.5)' <0.01
“ n = 7; *’ n = 20
E C F  = E xtracellu lar Fluid; IC F  = In tracellu lar F lu id  N S  = N o t S ignificant 
Data is presented as median (range)
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Table 6.9 Baseline Data for Linear Analogue Scales of Weakness and Strength, 
FACT-Ftg Scale and EORTC Fatigue Scale in Weight-Stable and 
Weight-Losing Cancer Patients
Weight-Stable Weight-Losing p-value
(n=35) (n=31)
Linear Analogue Scales
Weakness Scale 3.0 (0.4-7.5) 5.1 (1.3-8.3) <0.01
Strength Scale 5.0 (0.2-10.0) 4.1 (0.2-9.6) NS
FACT-Ftg Scale 30 (12-47) 24 (0-43) < 0.05
EORTC-Fatigue Scale 55.6 (0-88.9) 61.1 (11.1-100) <0.10
N S  = N ot S ign ifican t
Data is presented as median (range)
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Table 6.10 Blood Tests in Weight-Stable and Weight-Losing Cancer Patients
Weight-Stable 
(n=35)
Weight-Losing
(n=32)
p-value
Haemoglobin (g/1) 124 (96-177) 122 (91-153) NS
White Cell Count 7.4 (4.4-16.9) 10.7 (5.8-27.2) <0.001
Sodium (mmol/1) 138 (134-145) 136(123-144) <0.05
Potassium (mmol/1) 4.4 (3.5-5.6) 4.4 (3.3-5.1) NS
Urea (mmol/1) 5.8(2.2-13.1) 6.5 (2.0-17.6) NS
Creatinine (pmol/1) 79 (56-161) 91 (62-161) NS
Albumin (g/1) 41 (31-46) 37 (23-44) <0.01
Creatine Kinase (IU/1) 46(16-205) 30 (10-318) <0.05
Calcium (mmol/1) 2.35(2.18-2.61) 2.41 (2.14-3.29) NS
Magnesium (mmol/1) 0.85 (0.58-1.02) 0.88 (0.63-0.99) NS
Zinc (pmol/l) 10.5 (5.3-15.8) 9.5 (4.7-12.4) <0.10
Copper (pmol/1) 21.3(11.6-35.3) 22.1 (10.8-37.5) NS
Vitamin D (nmol/1) 22 (<6-128) 21 (<6-68) NS
C-Reactive Protein (mg/1) 14(1-204) 67 (2-214) <0.01
N S  = N o t S ignificant
Data is presented as median (range)
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CHAPTER 7: A STUDY OF THE RELATIONSHIPS BETWEEN WEAKNESS, 
FATIGUE, OBJECTIVE STRENGTH AND FUNCTION AND THEIR IMPACT 
ON QUALITY OF LIFE IN PATIENTS WITH ADVANCED CANCER
7.1 Introduction
Weakness and fatigue are the commonest symptoms in patients with advanced cancer, 
and as previously discussed in chapter 6, patients probably use these terms 
synonymously to refer to the same problems. Many patients complain of reduced 
strength, but the literature describing the relationship between the subjective experience 
of weakness or fatigue and objective measures of strength in patients with advanced 
cancer is very limited. Stone and colleagues (1999) recently reported that there was no 
relationship between voluntary handgrip strength and fatigue as measured by the Fatigue 
Severity Scale, in patients with advanced cancer and poor performance status. However, 
Glaus and co-workers (1996) suggested that strength might be a key dimension of 
weakness to be isolated and studied. Lichter (1990) suggested that loss of muscle mass 
in cancer patients would lead to loss of muscle strength.
Many cancer patients report difficulty in performing daily activities and symptoms such 
as weakness, fatigue and tiredness often prevent them caring for themselves (Rhodes 
et al., 1988; Dunlop, 1989; Morant et ah, 1993). Many quality of life questionnaires 
recognise that performance of ordinary daily activities are important and some, like the 
EORTC QLQ-C30 questionnaire (Aaronson et al., 1993), contain subscales which 
measure physical functioning. As previously noted in chapter 6, the FACT-Ftg 
questionnaire (Yellen et ah, 1997) also includes some questions related to the
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performance of activity. Cancer patients, and in particular those who have lost weight, 
have difficulty in initiating activity and need increased help in performance of activity. 
Karnofsky Performance Status (Kamofsky et al., 1948) is also commonly used in 
studies of patients with advanced cancer (O'Gorman et ah, 1998; McMillan et al., 
1999) as an ohserver-rated measure of functional ability.
The relationship between strength and functional ahility has not been formally studied in 
cancer patients. Previous studies in the healthy elderly have found relationships between 
muscle strength and power and objective measures of function. One study in 70 year old 
men and women reported positive correlations between isokinetic and isometric 
quadriceps strength, walking speed and maximum step height attainable (Aniansson 
et al., 1980). Another study in octogenarian men and women in a residential care setting 
reported positive correlations between quadriceps power and speed of rising from a 
chair, stair climbing and walking (Bassey et ah, 1992). Cress and co-workers (1995) 
demonstrated a positive relationship between self-perceived physical function - 
measured using a subscale of the Sickness Impact Profile questionnaire (Bergner et ah, 
1981) - and walking speed in a group of men and women over the age of 60, as well as 
an inverse correlation between physical function and time to stand up from a chair.
Research in palliative care has emphasised the importance of patient-rated quality of life 
(Ahmedzai, 1990; Hjermstad et ah, 1995). Quality of life is multi-dimensional and 
includes physical, emotional, cognitive and spiritual elements (Richards and Ramirez,
1997). Although there are no specific quality of life instruments developed for use with 
palliative care patients, the importance of quality of life in this patient group has 
recently been demonstrated using the EORTC QLQ-C30 questiormaire (Aaronson et ah.
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1993) in a group of patients with advanced gastrointestinal cancer (O'Gorman et al.,
1998).
The aim of this study was to examine the relationships between objective tests of 
strength and function and measures of weakness and fatigue and patient-related quality 
of life in patients with advanced cancer.
157
7.2 Material and Methods
7.2.1 Patients
Sixty eight patients and healthy controls, as previously described in chapter 6.2.1, 
participated in this study. Tests and questionnaires used in this study were carried out at 
the same time as those tests previously described (chapter 6). Ethics committee approval 
and informed consent, as previously described in chapter 6.2.1., applied to this study.
7.2.2 Questionnaires
Different aspects of patient-rated quality of life, including self-perceived physical 
function, were measured using the EORTC QLQ-C30 general quality of life 
questionnaire version 2.0, as described in chapter 4.2. The Hospital Anxiety and 
Depression scale was administered as a measure of patient-rated anxiety and depression, 
as described in chapter 4.5.
7.2.3 Strength Measures
Baseline muscle strength was graded in proximal and distal limb muscles using the 
Medical Research Council (MRC) 0-5 scale (see appendix 1). Handgrip strength was 
measured in all patients, as previously described in chapter 3.2.1. Isokinetic and 
isometric quadriceps strength was measured in most of the patients with good 
performance status (performance status > 70), as described in chapter 3.2.2. In the 
quadriceps testing, to try and establish whether patients had performed maximal efforts 
when asked to do so, electrical stimulation of the quadriceps was performed using the 
technique described in chapter 3.2.2.
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7.2.4 Functional Tests
Chair stand time and triple chair rise time were measured, using the method described in 
chapter 3.3.1. Time for ascent and descent of four, 15 centimetre, stairs was measured as 
described in chapter 3.3.2. Walking distance for 2 minutes and 6 minutes was measured 
using the method outlined in chapter 3.3.3.
7.2.5 Statistics
Data is presented as medians, with ranges. Comparisons were carried out, where 
appropriate, using Fisher’s Exact test and the Mann Whitney U test, and correlations 
were calculated using the Spearman Rank Correlation (SPSS Inc., Chicago, Illinois, 
USA). Correlations were only carried out on the cancer patient data. Multiple regression 
analyses were carried out as appropriate and are described in chapter 7.4.
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7.3 Results
The characteristics of the healthy subjects and cancer patients have been previously 
described in Tables 6.1 and 6.2. There was no difference between the median values of 
MRC muscle strength for the healthy subjects and the cancer patients in any of the 
muscle groups (median value 5). However, handgrip strength was significantly lower in 
the cancer patient group. This was true for both dominant (p < 0.01) and non-dominant 
(p < 0.05) handgrip strength (Table 7.1). There was an excellent correlation between 
dominant and non-dominant handgrip strength (r = 0.95, p < 0.001) with the dominant 
handgrip strength significantly greater than that of the non-dominant (p < 0.01). 
Therefore, the dominant handgrip strength was used in subsequent analyses. Isometric 
torque was significantly lower in the cancer group (p < 0.05). There were good 
correlations between handgrip strength and both isokinetic (r = 0.72, p < 0.001) and 
isometric (r = 0.73, p < 0.001) torque measurements. Handgrip strength and age were 
related (r = -0.50, p < 0.001).
The cancer patients were significantly slower than the healthy subjects in both the single 
chair stand test and the triple chair rise (p < 0.001, Table 7.2), with 8 patients using the 
chair arms during the chair tests. The cancer group was also significantly slower in both 
ascending and descending the stairs than the healthy subject group (p < 0.001), with 
21 cancer patients and 5 healthy subjects using the banisters. The cancer patients walked 
a significantly shorter distance in 2 minutes and 6 minutes, compared with the healthy 
subjects (p < 0.001). Seven patients who participated in the walking tests had to stop 
walking before 2 minutes had elapsed. The chair stand and triple chair rise test times 
were strongly correlated (r = 0.81, p < 0.001) and correlations between these two tests
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and the other functional tests were virtually identical. The stair ascent and descent times 
were also strongly correlated (r = 0.92, p < 0.001) and correlations between both and the 
chair and walking tests were also virtually identical. Correlations between all the 
functional tests, except the 6 minute walk, were strong.
The cancer group had significantly poorer scores on all of the functional scales of the 
EORTC QLQ-C30 questionnaire, compared with the healthy group (p < 0.01, 
Table 7.4). They also scored significantly higher on all of the symptom scales (p < 0.05), 
except for the diarrhoea scale.
The cancer group scored significantly higher on both the anxiety and depression 
subscales of the Hospital Anxiety and Depression (HAD) scale compared with the 
healthy group (p < 0.001, Table 7.5). Eleven patients (17.5%) had anxiety scores of 
11 or more, fitting the criteria for an anxiety disorder, with another 19 patients (30.2%) 
being borderline cases (scores 8-10). Fifteen patients (24.2%) scored 11 or more in the 
depression scale, fitting the criteria for clinical depression, with another 16 patients 
(25.8%) in the borderline category. None of the healthy group scored more than 10 in 
either the anxiety or depression subscales. The anxiety and depression scales were 
related (r = 0.43, p < 0.001).
On dividing the cancer patients into weight-stable (median weight loss 2.1 kg from pre­
illness weight) and weight-losing patients (median weight loss of 12.8 kg from pre­
illness weight), handgrip strength was significantly lower in the weight-losing group 
(p < 0.05, Table 7.6). There was no significant difference between the weight-stable and 
weight-losing groups for isokinetic torque (see appendix 3). There were too few subjects
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in the isometric weight-losing group (n=5) and this parameter was not tested 
statistically. Handgrip strength and the degree of weight loss were related (r = -0.28, 
p < 0.05), but there were no relationships between weight loss and the other strength 
measures.
The weight-losing patients were significantly slower in both of the chair tests than the 
weight-stable patients (p < 0.01, Table 7.6). The weight-losing patients were also slower 
than the weight-stahle patients on both stair ascent and stair descent (p < 0.01). There 
was no significant difference between weight-losing and weight-stable patients for the 
2 minute walking test. There were too few patients who completed the 6 minute walk to 
make meaningful statistical comparisons.
Comparing the weight-losing and weight-stahle groups for the scores recorded in the 
EORTC QLQ-C30 questionnaire (Table 7.7), the weight-losers scored significantly 
poorer in the physical functioning scale (p < 0.01), but there were no significant 
differences for any of the other functional scales. In the symptom scales, weight-losing 
patients rated themselves as having significantly more constipation and diarrhoea, 
nausea and vomiting, pain and poorer appetite (p < 0.05). The sleep scores of the 
weight-losers were poorer (p = 0.05). Weight-losing patients scored significantly higher 
on hoth the anxiety and depression subscales of the HAD scale (p < 0.05; Table 7.8).
Taking the cancer patients as a whole, there were no relationships established between 
the subjective weakness linear analogue scale and any of the measures of objective 
strength, nor between the subjective strength scale and the objective strength measures. 
There were, however, correlations between the FACT-Ftg scale and handgrip strength
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(r = 0.30, p < 0.05) and between the EORTC fatigue suhscale and handgrip strength 
(r = “0.27, p < 0.05). There was no relationship found between the fatigue scales and 
either the isokinetic or isometric strength measures.
Vitamin D concentrations were related to maximum isometric torque (r = 0.48, 
p < 0.05), but there was no similar relationship with the other strength measures.
The electrical stimulation tests did not produce clear data and in particular the results 
from the isokinetic studies were unsatisfactory. There were no definite twitches 
produced in any of the isokinetic tests, although in some series of contractions dips in 
the force tracing were noted shortly after the angle of stimulation (Figure 7.1). Many 
patients were unable to produce smooth force tracings and many did not reach the peak 
force at 70°, nor reach the peak force at the same angle on consecutive contractions. In 
later patients, the angle of delivery of the electrical stimulus was altered to take account 
of the most consistent angle of peak force attained during the warm-up. However, even 
then, during the test, the peak force was not consistently reached at the same angle. As 
there were no obvious twitches seen on the force tracings, the maximum force attained 
was recorded as the maximum voluntary force, and torque calculated from this.
The isometric testing was more successful and did produce twitches in many - but not 
all - of the patient and healthy subject tracings (Figure 7.2). The twitches were produced 
most consistently in healthy subjects. As there were no discernible twitches in any of the 
maximum isometric forces achieved, this was recorded as the maximum voluntary force 
and torque calculated from this.
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Isometric torque was correlated with the chair stand, and handgrip strength was related 
to both chair tests (Table 7.9), but otherwise there were no relationships established 
between objective strength and the functional tests. There was a correlation between 
Karnofsky Performance Status and the physical functioning scale of the EORTC QLQ- 
C30 questionnaire. There were correlations between performance status and all of the 
functional tests, and a similar pattern was seen with the physical functioning scale. 
Performance status and the physical functioning scale were both correlated with 
handgrip strength, the FACT-Ftg scale and the weakness scale. Both the FACT-Ftg 
scale and the weakness scale were correlated with the chair stand time and the FACT- 
Ftg scale with the triple chair rise and the 2 minute walk (Table 7.9).
There was a correlation between the EORTC QLQ-C30 global quality of life scale and 
the FACT-Ftg scale as well as inverse correlations with the weakness scale and the chair 
stand time (Table 7.10). There were relationships between many of the symptom scales 
of the EORTC QLQ-C30 questionnaire and the FACT-Ftg scale, the weakness scale and 
the chair tests, but not with any of the other functional tests.
The group of patients with depression scores of 11 or more had significantly higher 
weakness scores (p < 0.01), significantly more fatigue on the FACT-Ftg scale 
(p < 0.001) and significantly lower handgrip strength (p < 0.001) than those with scores 
in the normal range (0-7). There was significantly more fatigue (FACT-Ftg) (p < 0.001) 
in the group with anxiety scores of 11 or more compared to those with normal anxiety 
scores. There were also good inverse correlations between the depression subscale and 
Kamofsky Performance Status, the EORTC QLQ-C30 global quality of life scale and 
many of the symptom scales (Table 7.10). There were correlations between the
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depression score and the FACT-Ftg score (see Figure 7.3), the weakness score, 
handgrip strength, both chair tests and the walking test. The relationships described for 
the FACT-Ftg score in Tables 7.9 and 7.10 were also generally true of the EORTC 
fatigue score.
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7.4 Relationship of Weakness and Fatigue Scales and Handgrip Strength With 
Other Variables
In the present study, many of the variables examined were related to the weakness and 
fatigue scales and to handgrip strength. For example, among other variables, the 
weakness scale score was related to weight loss, pain and depression score, the FACT- 
Ftg score was related to weight loss, handgrip strength, haemoglobin, many of the 
symptom scores and depression score, and handgrip strength was related to age, body 
mass and muscle area (see Tables 7.11-7.14). To determine which were the most 
important of these variables, multiple regression analyses were carried out in a stepwise 
fashion.
As with previous fatigue research (Stone et al., 1999), performance status, the physical 
functioning scale, the role functioning scale and the quality of life scale were excluded 
from the regression analysis for the weakness scale and the two fatigue scales as these 
variables were most likely to be outcomes of weakness/fatigue rather than causes. They 
were also excluded from the handgrip strength regression for the same reason.
Only those predictors which were significantly correlated on univariate analysis were 
entered into the regression model. The 6 significant variables related to the weakness 
score on univariate analysis were entered into the regression model and are listed in 
Table 7.11. Depression was the strongest predictor of weakness, accounting for 25% of 
the variance, with pain accounting for a further 8%. When question 8 of the HAD scale 
(“I feel slowed down”) was omitted, then these two factors remained the most
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important, but were reversed, with pain accounting for 21% of the variance and 
depression a further 9%.
Those variables related to the FACT-Ftg scale on univariate analysis are listed in Table 
7.12. Depression was the strongest predictor of the FACT-Ftg score, accounting for 45% 
of the variance, and social function and anxiety score a further 8% and 6% respectively. 
When question 8 of the HAD scale was removed it did not alter the analysis.
Those variables related to the EORTC fatigue score on univariate analysis are listed in 
Table 7.13. Depression was again the strongest predictor of the fatigue score, accounting 
for 32% of the variance, with dyspnoea and pain accounting for a further 14% and 6% 
respectively. When question 8 of the HAD scale was removed emotional functioning 
was the strongest predictor, accounting for 30% of the variance, with social functioning 
and the depression score accounting for a further 12% and 8% respectively.
Those variables related to handgrip strength on univariate analysis are listed in Table 
7.14. The strongest predictor of strength was arm muscle area, accounting for 43% of 
the variance with patient age accounting for a further 11%.
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7.5 Discussion
In this work, the cancer group had both increased subjective weakness/fatigue and 
reduced objective strength. The inverse relationship between the weakness scale scores 
and the strength scale scores (see chapter 6.3) suggests that they were measuring 
opposites, i.e., that patients regarded weakness as loss of strength. However, in this 
work, there was no direct relationship established between subjective weakness and any 
of the measures of objective physical strength, nor between subjective strength and 
objective strength. Correlations between both fatigue scales and handgrip strength were 
weak.
It has been suggested that reduction in physical strength is an important part of fatigue 
and that this component of fatigue might be considered as weakness (Glaus et ah, 
1996). In the present work, objective strength was reduced and subjective 
weakness/fatigue was increased in the patient group, compared with the healthy control 
group. However, it would appear that the relationship between subjective 
weakness/fatigue and objective strength is not strong. This would indicate that a 
distinction must be drawn between the patient’s own experience and what can be 
objectively measured. As Portenoy (1998) suggests, we must not wait for objective 
evidence of muscle weakness, before we believe the patient’s complaint of weakness. 
Indeed, some patients in the present work had high weakness/fatigue scores and yet had 
normal strength measurements, compared with the healthy group. The implication of 
these findings may be that attempts to improve physical strength p e r  se  may not actually 
improve the patient’s symptoms of weakness.
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The significant relationships between the different strength measures suggest that, in 
this group of patients, when strength is lost compared to baseline, it is lost in different 
muscle groups at the same time. MRC muscle strength, although at times giving a rough 
impression of muscle strength, appears less sensitive in picking up change than handgrip 
strength or quadriceps strength. Dominant handgrip strength was measured in all 
patients, unlike the isokinetic and isometric dynamometry which would not have been 
tolerated by all patients.
During the course of the study it became clear that there were conflicting opinions as to 
whether dominant or non-dominant handgrip strength should be used. It is argued that 
dominant handgrip strength may allow those with manual occupations to have an 
advantage by virtue of a training effect in that hand (Buchner et al., 1993; Burman and 
Chamberlain, 1996). However, this is far from clear and McMurdo and Burnett (1992) 
used dominant handgrip strength in their study of elderly patients. Later assessments in 
the present study included a measure of non-dominant handgrip strength. The strength 
of the correlation between dominant and non-dominant strength and the fact that the 
dominant value was consistently and statistically significantly higher than the non­
dominant value across the patient group, is strong evidence that dominant handgrip 
strength is a perfectly acceptable test in cancer patients. It also allowed comparison with 
dominant isokinetic/isometric quadriceps strength.
The failure of the electrical stimulation component of the study to give information 
about the voluntary and non-voluntary components of quadriceps muscle strength is 
disappointing. The stimulation technique did produce twitches during isometric testing 
in the majority of the healthy group, but not as consistently in the patient group. This
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may be because of lower tolerance of the patients to the stimulus delivered and, 
therefore, the current could not be increased to a level both comfortable to the patient 
and high enough to produce visible twitches on the force tracing. In those patients and 
volunteers for which the technique did produce twitches on sub-maximal muscle 
contractions, the voluntary maximum force tracings produced showed no twitches, 
suggesting that these subjects were fully activating their muscles.
In some patients during isokinetic testing, there were consistent dips in the force tracing 
after the angle of stimulation (Figure 7.1). It is likely that the dips indicate that 
stimulation has occurred, the dip caused by a combination of factors, including the 
surprise of the stimulus and the refractory period of multiple motor units synchronised 
during the stimulus. The refractory period is the period after electrical stimulation, when 
the muscle fibres are insensitive to further stimulation and lasts about 1 to 3 
milliseconds (Ganong, 1981a). Negative feedback from inhibitory neurones which 
synapse on to the original motor neurone and other motor neurones, briefly stopping 
the neuronal electrical discharge, may have been another factor (Ganong, 1981b).
Due to the type of patient, the time constraints of the study and the number of other tests 
carried out at the same time, it was impractical to arrange for a pre-test familiarisation 
session on the machine. However, a recent study in healthy students, using similar 
methods to those adopted in this study, has reported that it is possible to achieve 
consistent angle of peak force and twitches in motivated subjects who are familiar with 
the technique (Coogans and Deighan, 1998). It may be that this technique is worthy of 
further study in this patient group, although some of the difficulties encountered in this
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study will need to be considered. It is clearly important that any future work considers 
patient acceptability.
The cancer group performed significantly less well in all the functional tests than the 
healthy subject group, despite the cancer patients completing the stair and walking tests 
being significantly younger than the healthy group. Given that strength and function are 
both known to decline "with age (Aniansson et ah, 1980; Kallman et al., 1990) and, all 
other things being equal, one might expect the younger group to perform better than the 
older group. The fact that the younger, cancer, group performed less well emphasises 
how poorly the cancer patients did in these tests. The cancer group as a whole performed 
less well in the walking tests and may have been limited in part by their increased 
symptom burden, compared with the healthy group.
The use of timed tests has been questioned (Gillies et al., 1999), as one might argue that 
what is important is safe completion of a task, not how quickly the patient performs it. 
However, the more time that individual tasks take, the greater the proportion of the day 
that will be taken up by doing those tasks. Consequently, more effort ’will be expended 
on activity and the patient will become more tired.
Cancer patients have difficulty in performing daily activities (Rhodes et al., 1988). 
Cress and co-workers (1995), in research carried out in the elderly population, have 
previously reported a relationship between self-perceived physical function and actual 
performance in chair stand and walking tests. In the present study, chair stand time, 
triple chair rise, stair descent and 2 minute walking distance were all found to correlate 
significantly with a patient-assessed functioning score (the EORTC physical functioning
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scale), suggesting that cancer patients are also able to assess their own level of 
functioning accurately. This is an observation that has not previously been reported in a 
cancer population.
Observer rating of patients’ physical function using the Karnofsky Performance Status 
also correlated well with patients’ own assessment of their level of function. Of the 3 
measures of weakness and fatigue used in this work, the FACT-Ftg scale correlated best 
with both subjective assessment of function and with actual performance of activity. 
This may well be because the FACT-Ftg scale is a 13 item scale which not only 
measures subjective feelings of tiredness, weakness and fatigue, but also includes 
questions on performance of activity, whereas the shorter 3 item EORTC fatigue scale 
and the weakness linear analogue scale are primarily measuring subjective symptoms. In 
the present work, the relationship found here between fatigue and patient-rated function 
in cancer patients is consistent with previous work which reported a relationship 
between fatigue and physical function (Irvine et al., 1994).
There were significant relationships between handgrip strength and the chair tests, and 
between isometric torque and chair stand time. However, there were no other significant 
relationships established between the functional tests and any of the strength measures. 
These results are less striking than some of the results reported from research in the 
elderly, which have reported significant relationships between muscle strength and 
power and chair rising, stair climbing and walking speed (Aniansson et al., 1980; 
Bassey et al., 1990; Bassey et al., 1992). However, it has been observed that although 
strength may decline in a linear fashion, function declines quantally, i.e., loss of strength 
may not become apparent until the person crosses the threshold of being just able to
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perform an activity to not being able to do it (Young, 1986; Loy et al., 1994). Skelton 
and colleagues (1995) reported that strength training in the elderly produced only a 
limited improvement in function. A more recent study has suggested that it is possible to 
improve daily functioning in the elderly by simply practising important daily activities 
like getting out of a chair or stair climbing (Gillies et al., 1999). If this can be 
extrapolated to cancer patients, it may be that strength training in cancer patients may be 
less useful than training patients to perform specific important functional activities.
The cancer patient group scored more poorly on almost all of the individual scales of the 
EORTC quality of life questionnaire, indicating a self-assessed poor level of functioning 
and high symptom burden. The weakness and fatigue scales all correlated with the 
global quality of life measure on the EORTC questionnaire, suggesting that these 
symptoms do indeed impact on patients’ overall quality of life. Many of the symptom 
scales were also related to the weakness and fatigue scores, suggesting either that 
weakness and fatigue are symptoms that tend to co-exist with other symptoms in this 
patient group, or that these symptoms are important in the aetiology of weakness and 
fatigue, or that both are correct. In the multiple regression analyses for the weakness and 
EORTC fatigue scales, pain and dyspnoea explained some of the variance in the scores 
and would appear to be important symptoms related to fatigue. This is consistent with 
previous work by Stone and colleagues (1999).
There was a greater level of psychological distress in the cancer group compared to the 
healthy group. Around a quarter of the patients scored within the range for diagnosis of 
clinical depression, which is comparable to other studies in this population (Vachon, 
1998; Lloyd-Williams, Friedman and Rudd, 1999). Other studies have found lower
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levels of depression, although similar levels of anxiety (Maher et al., 1996). It is of 
interest that patients completing the HAD scale often scored the “I feel slowed down” 
question (question 8) with the highest or second highest score. The questionnaire was 
originally designed to be free of somatic symptoms (Zigmond and Snaith, 1983) and this 
question was designed to pick up slowing of the affect. However, in this patient group, 
many patients are physically slowed down because of their illness and may well have 
rated this question accordingly. Thus, depression scale scores may be artificially 
elevated in this study. However, the depression scores were more strongly related to the 
other parameters than the anxiety scores in this study. Those with presumed clinical 
depression (scores greater than 10) scored more highly on the weakness and fatigue 
scales and had lower handgrip strength. Even when question 8 was excluded from the 
depression score, depression was still, by far, the strongest predictor of fatigue on the 
FACT-Ftg scale on multivariate analysis. Depression score was also related to 
performance status, the functional tests, the EORTC global quality of life scale and 
many of the symptom scales. It is difficult to determine from this study as to whether 
depression leads to poorer quality of life, strength and function or whether poorer 
strength and function leads to poorer quality of life and psychological distress. However, 
it is clear that depression is a very important correlate of fatigue. Longitudinal data may 
help to disentangle these relationships.
With reference to the cancer patients, the weight-losing group had lower handgrip 
strength and performed less well in both the chair and stair tests, but not the walking 
test. As previously reported in chapter 6, mid-thigh circumference was reduced in the 
weight-losing group (Table 6.8). Therefore, the poorer performance in the chair and stair 
tests in the weight-losers may, in part, have been due to loss of muscle bulk in the thigh
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muscles, as the quadriceps is important in the activities of rising from a chair and 
climbing stairs (St. Pierre et al., 1992). Although there was no similar reduction in mid­
arm circumference that might explain the reduced handgrip strength in weight-losers, 
arm muscle area was clearly the strongest predictor of handgrip strength on multivariate 
analysis. This would suggest that arm muscle mass is an important factor in determining 
handgrip strength in patients with advanced cancer. This is consistent with previous 
work in the elderly population (Larsson et al., 1979; Frontera et al., 1991). Muscle 
strength is known to decline with age (Kallman et al., 1990) and increasing age was 
also an important factor in reduced handgrip strength in this patient group.
It is also known that in cancer patients type 2 muscle fibres are lost preferentially and 
these are the fibres involved in activities such as standing up from a chair and using the 
stairs (Warmolts et al., 1975; Gomm et al., 1990). As the quadriceps is involved in 
these activities, but plays less of a role in walking (Moore, 1985), this may explain the 
similar walking distances in the two cancer groups in the face of clear differences for the 
other functional tests.
Both weight-stable and weight-losing patients had poor levels of functioning, as rated by 
the EORTC questionnaire. Although the median values in all the functional scales were 
lower in the weight-losing group, only the physical functioning scale was scored 
significantly more poorly. It is possible that the patients regarded ability to perform 
physical tasks as more important than other aspects of function. However, the physical 
functioning scale is the only one of the functional scales rated as a Yes/No alternative 
with the other functional scales graded 1-4, which may have influenced the results. The 
weight-losers had an increased symptom burden, compared to the weight-stable patients.
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with more bowel dysfunction, nausea and vomiting, pain and anorexia and poorer sleep. 
Weight-losers also had significantly more psychological distress than the weight-stable 
patients.
Although the weight-stable and weight-losing cancer groups were both poorer at the 
functional tests, compared with the healthy subjects, and also had scored more poorly on 
the global quality of life scale, the relationship between these variables does not seem 
linear. This, in conjunction with the poor EORTC function scale scores in both cancer 
groups, adds weight to the concept that quality of life is a multi-dimensional 
phenomenon and is not purely related to physical ability.
In summary, this study has shown that cancer patients have reduced physical strength, 
poorer performance in activities of daily living and also poorer self-perceived physical 
function. Loss of weight, and muscle in particular, seems important in the aetiology of 
reduced strength in this patient group. Loss of muscle bulk and loss of type 2 muscle 
fibres may be important factors in determining loss of function. There was no clear 
relationship established between objective physical strength and objective function, 
suggesting that perhaps to focus on training patients in specific functional tasks may be 
a better approach to rehabilitation than generalised strength training. Similarly to the 
findings for weakness and fatigue in chapter 6, there is a spectrum ranging from normal 
muscle strength, good function, good quality of life and low levels of psychological 
distress in the healthy population, through to weight-stable cancer patients with modest 
derangements, and then to poor levels of strength and function, increased symptom 
burden and high levels of psychological distress in the weight-losing cancer patients.
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The FACT-Ftg scale appears good at not only measuring fatigue, but also at describing 
abilities to perform activities of daily living. It was also clear from the study that 
handgrip strength and the chair tests were straightforward tests tolerated by most of the 
cancer patients and with the advantage of being portable. They were also sensitive to 
differences across the study groupings. The relationships between high levels of 
weakness and fatigue, high levels of symptom and psychological distress and poor 
performance in functional tests remain unclear, and although they tend to co-exist, the 
relationships may not be causal. However, depression seems to be the most important 
single factor related to fatigue. Longitudinal assessments may shed more light on these 
issues. In order to develop interventional strategies to improve function, further study of 
the relationships between strength and function is merited.
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Table 7.1 Baseline Data for Handgrip Strength, Isokinetic Quadriceps Torque and
Isometric Quadriceps Torque in Healthy Subjects and Cancer Patients
Healthy Subjects Cancer Patients p-value 
(n=15) (n=23)
Dominant Handgrip Strength 28.5 (20.0-49.0) 21.0(6.5-51.0)^ <0.01
(kgW)
Non-Dominant Handgrip Strength 28.0 (18.0-50.5) 20.5 (2.0-46.0) <0.05
(kgW)
Maximum Isokinetic Torque 181.4 (71.9-302.4) 125.1 (62.1-223.5) <0.10
(Nm)
Maximum Isometric Torque 185.4 (73.8-268.2) 118.9 (60.1-270.3) < 0.05
(Nm)
n = 68
Data presented as median and range
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Table 7.2 Chair, Stair and Walking Tests in Healthy Subjects and Cancer
Patients
Healthy Subjects Cancer Patients p-value 
(n=15) (n=21)
Chair Rise (s) 0.97 (0.81-1.60) 1.43 (0.70-6.06)' <0.001
Triple Chair Rise (s) 5.00 (3.02-10.71) 7.76 (4.38-33.30)' < 0.001
Stair Ascent (s) 2.09(1.44-2.59) 3.06(1.75-9.28)*’ <0.001
Stair Descent (s) 1.66(1.20-2.40) 2.80(1.46-9.89)*’ <0.001
Two Minute Walk (m) 185 (122-214) 130(30-194)" <0.001
Six Minute Walk (m) 566 (361-614) 395 (279-604) <0.001
n =39; n =44; '  n =57
Data presented as median and range
179
Table 7.3 Spearman Rank Correlations Between the Functional Tests in Cancer
Patients
Chair
Stand
Stair
Ascent
2 minute 
walk
6 minute 
walk
Chair Stand
- 0.68** -0.37* 0.12
Stair
Ascent 0.68** - -0.72** -0.35
2 minute 
walk -0.37* -0.72** - 0.94**
6 minute 
walk 0.12 -0.35 0.94** -
Values listed are r-values
* p < 0.05
** p < 0.001
All other correlations were not significant
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Table 7.4 EORTC QLQ-C30 Quality of Life Scores in Healthy Subjects and
Cancer Patients
Healthy Subjects 
(n=15)
Cancer Patients 
(n=65)
p-value
Functional Scales:
Physical 100 (60-100) 40 (0-100) <0.001
Role 100 (66.67-100) 50 (0-100) <0.001
Emotional 100 (66.67-100) 70.8 (0-100) < 0.001
Cognitive 83.3 (66.7-100) 75 (16.7-100) <0.01
Social 100 (66.7-100) 66.7 (0-100) <0.001
Quality of Life 83.3 (66.7-100) 50(0-100) <0.001
Symptom Scales
Fatigue 0(0-33.3) 55.6 (0-100) <0.001
Nausea & Vomiting 0(0-16.7) 16.7 (0-100) <0.01
Pain 0 (0-50) 33.3 (0-100) <0.01
Dyspnoea 0 (0-33.3) 33.3 (0-100) <0.001
Sleep 0 (0-33.3) 33.3 (0-100) <0.05
Appetite 0 33.3 (0-100) <0.001
Constipation 0(0-33.3) 33.3 (0-100) <0.01
Diarrhoea 0(0-33.3) 0(0-100) NS
Financial 0 0 (0-100) <0.001
N S  = N ot S ign ifican t
Data presented as median and range
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Table 7.5 Hospital and Anxiety and Depression Scale in Healthy Subjects and
Cancer Patients
Healthy Subjects Cancer Patients p-value 
(n=15) (n=63)
Anxiety Subscale 2(0-10) 7(0-17) <0.001
Depression Subscale 1 (0-5) 8(1-18) <0.001
Data presented as median and range
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Table 7.6 Baseline Handgrip Strength, Chair, Stair and Walking Tests in
Weight-Stable and Weight-Losing Cancer Patients
Weight-Stable Weight-Losing p-value
(n=24) (n=14)
Handgrip strength (kgW) 23.3(10.0-44.0)'' 19.3(6.5-51.0)' <0.05
Chair Rise (s) 1.33(0.7-4.9)' 1.61 (0.8-6.06)" <0.01
Triple Chair Rise (s) 7.19(4.38-33.30)' 9.07(4.76-23.85)*’ <0.01
Stair Ascent (s) 2.76(1.75-8.75) 3.56(2.06-9.28)" <0.01
Stair Descent (s) 2.31 (1.46-7.94) 3.03 (1.70-9.89)" <0.01
Two Minute Walk (m) 130 (30-160) 127 (70-194) NS
*n = 20;'’ n = 2 5 ; 'n  = 3 2 ;“ n = 3 6
N S  = N o t S ign ifican t
Data presented as median and range
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Table 7.7 EORTC QLQ-C30 Quality of Life Scores in Weight-Stable and
Weight-Losing Cancer Patients
Functional Scales
Weight-Stable Weight-Losing p-value
(n=35) (n=30)
Physical 60 (0-100) 40 (0-80) <0.01
Role 50 (0-100) 33.3 (0-100) NS
Emotional 75 (25-100) 66.7 (0-100) NS
Cognitive 83.3 (16.7-100) 66.7 (16.7-100) NS
Social 66.7(16.7-100) 50 (0-100) NS
Quality of Life 58.3 (0-100) 50 (0-100) NS
om Scales
Fatigue 55.6 (0-88.9) 61.1 (11.1-100) <0.10
Nausea & Vomiting 0 (0-66.7) 16.7 (0-100) <0.05
Pain 16.7 (0-100) 33.3 (0-100) <0.05
Dyspnoea 33.3 (0-100) 33.3 (0-100) NS
Sleep 0(0-100) 33.3 (0-100) 0.05
Appetite 0 (0-100) 33.3 (0-100) <0.05
Constipation 0 (0-100) 33.3 (0-100) <0.01
Diarrhoea 0 (0-66.7) 0 (0-100) <0.01
Financial 0(0-100) 0(0-33.3) NS
N S  = N o t S ignificant
Data presented as median and range
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Table 7.8 Baseline Data for Hospital Anxiety and Depression Scale in Weight-
Stable and Weight-Losing Cancer Patients
Weight-Stable Weight-Losing p-value
(n=33) (n=30)
Anxiety Subscale 6(0-13) 8(0-17) <0.05
Depression Subscale 6(1-13) 9(2-18) <0.05
Data presented as median and range
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Table 7.9 Spearman Rank Correlations between Weakness and FACT-Ftg Scales, 
Strength Tests, Performance Status and Function in Cancer Patients
Physical
Functioning
Scale
KPS Chair
Stand
Triple 
Chair Rise
Stair
Ascent
Stair
Descent
2
Minute
Walk
Physical
Functioning
Scale
- 0.69*** -0.51*** -0.46*** -0.29 -0.37* 0.38*
KPS 0.69*** - -0.63*** -0.47*** -0.50** -0.53** 0.44**
Weakness
Scale -0.34** -0.35** 0.41*** 0.20 0.10 0.21 -0.12
FACT-Ftg
Scale 0.65*** 0.61*** -0.48*** -0.33* -0.12 -0.17 0.39*
Handgrip
Strength 0.25* 0.51*** -0.29* -0.32* -0.25 -0.29 0.14
Isometric
Torque 0 -0.15 -0.49* -0.42 0.30 0.30 0
Values listed are r-values
KPS = Karnofsky Performance Status
* p < 0.05
** p < 0.01 
***p< 0.001
All other correlations were not significant
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Table 7.10 Spearman Rank Correlations Between Weakness and FACT-Ftg 
Scales, Handgrip Strength, Function, EORTC QLQ-C30 and the 
HAD Scale in Cancer Patients
Weakness
Scale
FACT- 
Ftg Scale
Handgrip
Strength
Chair
Stand
Triple
Chair
Rise
2
minute
walk
Depression
KPS -0.35** 0.61*** 0.51*** -0.63*** -0.47*** 0.44** -0.67***
Global 
Quality of 
Life
-0.39** 0.51*** 0.11 -0.30* -0.22 0 -0.51***
Pain 0.39** -0.40** 0 0.32* 0.35** -0.23 0.33**
Dyspnoea 0.19 -0.41** -0.11 0.21 0.20 -0.38* 0.34**
Sleep 0.29* -0.34** -0.34 0.15 0 -0.31 0.48***
Appetite 0.15 -0.36** -0.20 0.35** 0.31* -0.17 0.35**
Anxiety 0.22 -0.52*** -0.14 0.20 0.18 -0.15 0.43***
Depression 0.44*** -0.69*** -0.49*** 0.48*** 0.33* -0.51*** -
KPS = Karnofsky Performance Status
Values listed are r-values
* p < 0.05
** p < 0.01 
*** p < 0.001
All other correlations were not significant
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Table 7.11 Relationships With Weakness Scale on Univariate and Multivariate
Analysis in Cancer Patients
Univariate
(p-value)
Multivariate
(p-value)
Weight Loss <0.05 0.11
Mid-Thigh Circumference <0.05 0.25
Emotional Functioning <0.05 0.58
Nausea & Vomiting <0.05 0.71
Pain < 0.01 0.18
Depression < 0.001 <0.05
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Table 7.12 Relationships With FACT-Ftg Scale on Univariate and Multivariate
Analysis in Cancer Patients
Univariate
(p-value)
Multivariate
(p-value)
Weight Loss <0.01 0.13
Triceps Skinfold Thickness 0.05 0.38
Mid-Arm Circumference <0.05 0.76
Handgrip Strength <0.05 0.38
Haemoglobin <0.05 0.96
White Cell Count <0.05 0.56
Albumin <0.01 0.65
Emotional Functioning <0.001 0.80
Cognitive Functioning <0.01 0.83
Social Functioning <0.01 0.18
Pain <0.01 0.36
Dyspnoea <0.01 0.81
Appetite <0.01 0.92
Constipation <0.01 0.35
Anxiety <0.001 0.26
Depression <0.001 <0.001
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Table 7.13 Relationships With EORTC Fatigue Scale on Univariate and
Multivariate Analysis in Cancer Patients
Univariate
(p-value)
Multivariate
(p-value)
Handgrip Strength <0.05 0.72
White Cell Count <0.01 0.31
Albumin <0.01 0.83
Calcium <0.05 0.35
C-Reactive Protein <0.01 0.63
Emotional Functioning <0.001 0.14
Cognitive Functioning <0.01 0.41
Social Functioning <0.001 0.29
Pain <0.01 0.27
Dyspnoea <0.001 0.14
Constipation <0.05 0.69
Anxiety <0.01 0.52
Depression <0.001 0.12
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Table 7.14 Relationships With Handgrip Strength on Univariate and
Multivariate Analysis in Cancer Patients
Univariate Multivariate
Age
Current Body Mass Index
Mid-Arm Circumference
Arm Muscle Area
Mid-Thigh Circumference
Thigh Muscle Area
FACT-Ftg
EORTC Fatigue
Constipation
Depression
Albumin
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
<0.05 
<0.05 
< 0.01 
< 0.001 
< 0.01
< 0.01
0.51
0.50
<0.05
0.12
0.20
0.44
0.61
0.17
0.20
0.36
191
: oe
I
&D
11
o
i n
o
o
om oo o o
I
§
1I
I
I
I 
1
( n ) a o j o j .1*pE^
<D
•S
.§
G
919
899
89>
90 8 "  
88% H
LZ
Z9Z
Z9'l
60
zro
o
8 I ooCM OO Oo
I
(N)
I
I
iPh
0
1
CM
Figure 7.3 Plot of FACT-Ftg Scores Against Depression Scores
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CHAPTER 8: LONGITUDINAL STUDY OF WEIGHT LOSS, STRENGTH. 
FUNCTION, WEAKNESS AND FATIGUE. THE INFLAMMATORY 
RESPONSE AND OUALITY OF LIFE IN PATIENTS WITH ADVANCED 
CANCER
8.1 Introduction
As has previously been described in chapters 6 and 7, weakness and fatigue are common 
symptoms in patients with advanced cancer arid they are commoner in patients who 
have lost weight. Weight-losing patients also have reduced muscle strength, compared 
with weight-stable patients, as well as increased difficulty in performing the activities of 
daily living. Weight-losing patients have increased psychological distress and poorer 
quality of life, and these factors seem related to the experience of weakness and fatigue. 
The presence of weight loss is associated with an inflammatory response, including a 
raised white cell count and elevated C-reactive protein concentrations.
The studies described in chapters 6 and 7 provide snapshot data regarding the 
continuum which appears to exist from healthy subjects to weight-stable and weight- 
losing cancer patients. However, such studies have limitations as it is difficult to 
establish the temporal nature of the relationships between these variables. There are few 
longitudinal studies in patients with advanced cancer, due to the inevitable attrition rate 
encountered.
O’Gorman, McMillan and McArdle (1999) reported that as patients with advanced 
gastrointestinal cancer continue to lose weight, so Karnofsky Performance Status
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declines, triceps skinfold thickness falls and C-reactive protein concentrations rise. In 
addition, they reported that those patients who gained weight over the follow-up period 
had significantly lower initial C-reactive protein and significantly higher initial albumin 
concentrations than those who subsequently lost weight.
In the following study, the longitudinal relationships between weight loss, strength, 
function, performance status, weakness and fatigue, the inflammatory response and 
quality of life was studied in a group of patients with advanced cancer and in a group of 
healthy age and sex matched controls.
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8.2 Material and Methods
The patients and healthy controls studied were those previously described in chapter 7. 
Questionnaires, strength tests, functional tests, blood tests and tests of body composition 
were performed - as previously described in sections 6.2 and 7.2 - at baseline, 6 weeks, 
12 weeks and 6 months in the patient group and at baseline and 12 weeks in the 
controls.
Data is presented as medians, with ranges. Comparisons were carried out where 
appropriate using Fisher’s Exact test and the Mann Whitney U test and analysis of data 
between different time points was performed using the Wilcoxon signed rank test (SPSS 
Inc., Chicago, Illinois, USA).
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8.3 Results
Fifteen healthy controls completed baseline measurements, as previously described in 
chapters 6 and 7. Of these subjects, one was unavailable for follow-up assessment at 12 
weeks. There was no significant change over the 12 weeks in weight, anthropometries, 
handgrip strength, functional tests, Karnofsky Performance Status, weakness and fatigue 
scores, anxiety and depression scores, blood parameters and EGRTC quality of life 
scale scores (see appendices 3.18-22). However, there was a significant increase in both 
mid-arm circumference (p < 0.01) and mid-thigh circumference (p < 0.05), as well as a 
significant improvement in chair rise time (p < 0.05) and in isometric torque (p = 0.05). 
There was also a fall in white cell count (p < 0.05).
Sixty eight cancer patients completed baseline measurements, and these have previously 
been described in chapters 6 and 7. Of these patients, only 32 had follow-up 
measurements at six weeks. Of the 36 patients with no follow-up, 12 patients were 
either unavailable (5), refused follow-up (4), or were lost to follow-up for other reasons 
(3). Of the remaining 24 patients, 19 died and 5 (due to disease progression) were too 
unwell to undergo follow-up assessment. Of the thirty two patients with follow-up, 12 
were weight-losing at baseline and 20 were weight-stable.
The baseline characteristics of the 32 patients with follow-up were compared with the 
baseline characteristics of the 24 patients with no follow-up due to death or disease 
progression (Tables 8.1, 8.2). The two groups were similar in terms of age, sex, cancer 
type, weight and anthropometry. The no follow-up group had lost significantly more of 
their healthy weight (p < 0.05) and had significantly lower handgrip strength (p < 0.01,
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Table 8.3) and Karnofsky Performance Status (p < 0.001, Table 8.1) than the follow-up 
group. There were too few completed measures in the group with no follow-up to allow 
meaningful statistical comparison of the isokinetic and isometric dynamometry 
measurements.
Nine of the patients in the no follow-up group were unable to participate in any of the 
functional testing, while all of the patients in the follow-up group at least completed the 
chair stand test (p < 0.001). The follow-up group performed significantly better in the 
chair stand test (p < 0.05, Table 8.3) and stair descent (p < 0.05). Walking distances 
were similar between the two groups in those who had completed the 2 minute tests (see 
appendix 3). There were insufficient numbers in the no follow-up group for statistical 
comparison of the 6 minute walk distances.
The group with no follow-up had significantly more fatigue, as measured by both the 
FACT-Ftg scale and the EORTC QLQ-C30 questionnaire (p < 0.001, Table 8.4), 
although linear analogue scale measurements of weakness were similar. This group also 
had significantly higher anxiety and depression scores than the follow up group 
(p < 0.05).
The no follow-up group had significantly lower albumin (p < 0.001, Table 8.5), 
haemoglobin (p < 0.01), zinc (p < 0.01), vitamin D (p < 0.01), sodium (p < 0.05) and 
creatine kinase (p < 0.05) concentrations, as well as significantly higher C-reactive 
protein concentrations (p < 0.001) and white cell count (p < 0.01).
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The no follow-up group scored more poorly on the physical (p < 0.001) and role 
functioning (p < 0.01) scales of the EORTC QLQ-C30 quality of life questionnaire. This 
group also had more dyspnoea (p < 0.001) and constipation (p < 0.05) and poorer 
appetite (p < 0.05).
Those 32 patients with follow-up were then grouped according to whether or not they 
went on to lose weight over the six weeks of study (Tables 8.7-8.9). Twenty four 
patients had remained weight-stable (median gain 1.0 kg over baseline weight, p < 0.01) 
and 8 patients lost weight as defined by a loss of at least 2.0 kg of their baseline weight, 
(median -3.3 kg, p < 0.05).
At baseline these two groups were not significantly different with regard to age, sex, 
cancer type, weight, degree of weight loss from healthy weight at study entry, 
anthropometry, handgrip strength, weakness and fatigue scores, anxiety and depression 
scores, the majority of the blood parameters and EORTC quality of life scale scores. In 
contrast, at baseline, the weight-losing group had a significantly lower Karnofsky 
Performance Status compared with the weight-stable group (p < 0.05). The weight- 
losing group, at baseline, were also slower at the chair stand (p < 0.05), stair ascent and 
stair descent (p < 0.01). Baseline C-reactive protein concentrations were higher 
(p < 0.05) in the weight-losing group.
In the group which remained weight-stable there was a significant improvement over the 
follow up period in mid-arm circumference (p < 0.05), arm muscle area (p < 0.05), chair 
stand (median -0.08 (-1.38 to 0.40), p < 0.05; see appendix 3), stair ascent (median 
-0.07 (-1.06 to 0.64), p < 0.05; see appendix 3) and FACT-Ftg score (p < 0.05).
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In the group which lost weight there was a significant reduction in mid-arm 
circumference (p < 0.05). Too few patients completed the chair tests (n=5) or the stair 
tests (n=3) at the six week assessment for meaningful statistical comparison to baseline 
(see appendix 3.16).
Twenty three patients were followed up to 12 weeks (See Appendices 3.23-27). Of the 
thirty two patients who had follow-up measurements performed at 6 weeks, 2 were 
unavailable, 2 declined any further follow-up, one had died and 4 (due to disease 
progression) were too unwell to undergo further assessment. Of the twenty three 
patients, 9 were in the weight-losing group at baseline and 14 were in the weight-stable 
group. When these patients were grouped according to whether or not they had lost 
weight over the 12 weeks of study, 18 patients had remained weight-stable and only 5 
had lost weight. Due to the small number of patients in the weight-losing group, no 
further statistical analysis was carried out.
Seventeen patients were followed up to 6 months (see Appendices 3.28-3.32). Of the 
twenty three patients who had follow-up measurements performed at 12 weeks, one 
declined any further follow-up, 3 had died and 2 (due to disease progression) were too 
unwell to undergo further assessment. Of the seventeen patients, 5 were in the weight- 
losing group at baseline and 12 were in the weight-stable group. When the patients were 
grouped according to whether or not they subsequently lost weight, there were only 3 
patients who had lost weight and therefore no further statistical analysis was 
appropriate.
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8.4 Discussion
In this study, a group of patients with advanced cancer was followed up over a period of 
6 months. Only 47% of the original patient group could be followed up to 6 weeks, with 
this proportion falling to 34% at 12 weeks and only 25% at 6 months. This attrition rate 
is typical of other longitudinal studies in this patient group (McMillan et ah, 1999; 
Stone et ah, 1999) and explains why such studies are uncommon. In contrast, only one 
healthy subject had dropped out of the study at 12 weeks due to unavailability.
The healthy subjects appeared to remain well over the 12 week study period, with no 
significant alterations in physical, psychological, biochemical and quality of life 
parameters. There were improvements in limb circumferences, perhaps reflecting the 
fact that the 12 week assessments for the healthy subjects were mainly carried out in the 
summer, when they were likely to be more active and have a greater muscle bulk. This 
may also explain the improvements in isometric torque and in the chair rise test, 
although this may also reflect increased familiarity with the tests, an observation 
previously reported by Gillies and colleagues (1999).
In the published literature, there do not appear to be studies which have compared the 
baseline characteristics of cancer patients followed up longitudinally, with those who 
were not followed up due to death or disease progression. Nevertheless, it is clear that 
the no follow-up group in this study are different to the follow-up group in a number of 
ways.
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The no follow-up group appear to have been at a more advanced stage in their disease 
process. They had lost a greater proportion of their healthy weight prior to the study, 
compared to the follow-up group. They had poor subjective physical functioning and 
observer-rated performance status, as well as being poorer at carrying out the activities 
of daily living. They also had reduced handgrip strength. Fatigue and psychological 
distress were greater in this group, compared with the follow-up group. The no follow- 
up group had a greater symptom burden and were more anaemic. This group also had 
more deranged biochemistry, with poorer nutritional parameters and a more marked 
inflammatory response.
In the present study, patients who subsequently lost weight over 6 weeks of follow-up 
had poorer Karnofsky Performance Status and performed more poorly in the chair and 
stair tests at baseline. At baseline, degree of weight loss from healthy weight and 
muscle bulk were not significantly different between the weight-stable and weight- 
losing groups and there was no correlation between degree of weight loss from healthy 
weight and performance status, or with performance in any of the functional tests. 
Therefore, neither weight nor muscle bulk are likely to be the only determinants of 
functional ability. Weight loss and deterioration in functional ability are both likely to be 
related to disease progression. Only 62% of the group which lost weight over 6 weeks 
were able to complete the chair tests at follow-up and only 50% were able to complete 
the stair tests. Although there was a reduction in mid-arm circumference in the weight- 
losing group after 6 weeks, there was no reduction in arm muscle area, nor in mid-thigh 
circumference. Therefore, loss of muscle bulk appears unlikely to be the main reason for 
this inability to participate in the functional tests. As has previously been discussed in 
chapter 7, patient performance in functional tests may decline to the point where there is
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a transition from being just able to perform an activity to being just unable to perform 
that activity (Young, 1986). Poor function may, therefore, relate to advancing disease 
where the threshold is crossed from disability to inability. It is possible that the sequence 
of events may be reduced muscle strength, leading to reduced activity and muscle 
disuse, followed by a loss of function.
The group which remained weight-stable improved in the chair rise and stair ascent 
tests. Although there was a significant gain in weight and in mid-arm circumference and 
area, there was no gain in thigh circumference, suggesting that the improvement was 
unlikely to relate merely to increased muscle bulk. The improvement may have been 
related partly to improved muscle function and, as with the healthy group, part of the 
improvement may have been due to increased familiarity with the test.
This study found no change in performance status over time. Previous work has 
reported a fall in Karnofsky Performance Status with continued weight loss (O’Gorman 
et al., 1999). However, the degree of weight loss between the weight-stable and weight- 
losing groups at 6 weeks in the present study was less than that reported by O’Gorman 
and colleagues. Nevertheless, the results of the present study suggest that simple 
functional tests are more sensitive indicators of decline than observer-rated performance 
status. They also suggest that it may be possible to maintain function if weight loss can 
be prevented. Although weight and function are not directly related, the weight-losing 
group are more unwell and also functionally impaired. Therefore, prevention or slowing 
of weight loss may contribute to the prolongation of normal function. It could be that 
slowing of weight loss and of general physical deterioration may lead to increased 
activity levels, followed by an improvement in level of functioning.
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The weight-stable group were also less fatigued at 6 weeks than at baseline, suggesting 
that future strategies aimed at maintaining weight may have some impact on fatigue. 
Fatigue is unlikely to be purely related to weight loss, as the weight-losing group was 
not more fatigued after 6 weeks, although numbers were small. As reported in chapter 6 
weight loss and fatigue tend to co-exist and probably relate to disease progression. It 
was of note that there was no change in depression scores. Given that fatigue and 
depression are strongly related (see chapter 7), it would seem more likely that 
depression comes after fatigue and relates to increasing illness and disability of which 
fatigue is an important feature. If depression had been the most important cause of 
fatigue, one would have expected a change in both fatigue and depression at follow-up. 
Larger studies may help to clarify this issue. There was no change in the weakness score 
in either group, suggesting that a simple linear analogue scale measure is less sensitive 
to change than a multi-item questionnaire, such as the FACT-Ftg scale.
The group which lost weight had higher C-reactive protein concentrations than the 
weight-stable group at baseline. Similar results have been recently reported (O'Gorman 
et al., 1999). Although O’Gorman and colleagues reported further changes in C-reactive 
protein over time, the results of the present study are consistent with the concept that the 
presence of an inflammatory response is associated with weight loss and impaired 
nutritional status. The inflammatory response is also likely to relate to poor prognosis.
In summary, the control group validated the use of the various measures carried out in 
this study, in that there was little or no change over time. Those patients who were not 
followed up, due to death or disease progression, had performed or scored less well in a 
large number of the tests compared to the follow-up group, suggesting that these
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measures may be predictive of future outcome. The group which remained weight-stable 
at follow-up behaved in a similar way to the control group, in that there was little 
change, or a tendency to improvement with time. In contrast, although there were few 
statistically significant changes over time in the group which lost weight, this group was 
clearly becoming less able to perform activities of daily living and had a poorer 
nutritional status. In addition, these changes were preceded by detectable differences in 
Karnofsky Performance Status, the functional tests and the inflammatory response. This 
study highlights the importance of monitoring change in patients ’with advanced cancer 
and gives some indication of likely therapeutic targets, e.g., weight, patient functional 
ability and the inflammatory response. Moreover, monitoring of fatigue levels in 
patients who either lose or maintain weight may give a better picture of the pattern of 
fatigue development and whether any therapeutic interventions may reduce patient 
experience of fatigue.
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Table 8.1 Baseline Characteristics in Cancer Patients With and Without Follow-
Up at 6 Weeks
No Follow-up Follow-up p-value
(n=24) (n=32)
Sex (M/F) 17/7 18/14 NS
Age 69 (38-81) 62 (43-79) <0.10
Healthy Weight (kg) 66.8 (45.3-114.3) 63.5 (44.5-101.5) NS
Current Weight (kg) 58.5 (39.8-85.0) 55.9 (39.0-95.0) NS
Amount of Weight Loss 12.3 (-4.5-36.3) 6.0 (-18.8-18.0) <0.05
Healthy BMI (kgm‘^ ) 25.0(16.8-40.0) 23.8 (15.9-36.0) NS
Current BMI (kgm'^) 20.1 (15.2-29.9) 21.7(14.8-33.3) NS
Karnofsky 
Performance Status
58 (25-80) 78 (50-100) <0.001
Cancer Tvnes
Lung 13 20 NS
Mesothelioma 3 1 NS
Gastrointestinal 7 4 NS
Hormone Dependent 0 5 NS
Others* 1 2 NS
* = One patient each with Non-Hodgkin’s lymphoma, cerebral astrocytoma and head & 
neck cancer
M /F  -  M ale/F em ale N S  — N o t S ign ifican t 
Data presented as median and range
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Table 8.2 Baseline Body Composition in Cancer Patients With and Without
Follow-Up at 6 Weeks
No Follow-up Follow-up p-value
(n=22) (n-30)
Total Body Water (1) 26.7 (21.9-37.7) 27.8 (17.3-41.0) NS
Triceps Skinfold 10.0(3.5-24.5) 9.5 (3.0-33.5) NS
Thickness (mm)
Biceps Skinfold 6.0 (2.5-20.5) 6.0 (2.0-14.5) NS
thickness(mm)
Thigh Skinfold 13.8 (4.0-36.5) 11.5 (3.5-29.5) NS
Thickness(mm)
Mid-Arm 24.1 (17.6-36.4) 25.2(17.1-37.0) NS
Circumference(cm)
Arm Muscle Area (cm^) 34.7 (20.7-65.6) 36.6 (19.6-76.7) NS
Mid-Thigh 42.0 (32.3-52.5) 45.1 (32.5-66.3) < 0.10
circumference (cm)
Thigh Muscle Area 133.3 (76.7-184.4) 130.4 (73.1-294.4) < 0.10
(cm^)
N S  = N o t S ignificant
Data presented as median and range
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Table 8.3 Baseline Handgrip Strength and Functional Tests in Cancer Patients
With and Without Follow-Up at 6 Weeks
No Follow-up Follow-up p-value
(n= ll) (n=25)
Handgrip Strength (kgW) 17.8 (6.5-43.0)’^ 23.5 (10.0-51.0)' < 0.01
Chair Stand (s) 1.80 (0.80-6.06)" 1.37 (0.70-3.18)' < 0.05
Triple Chair Rise (s) 9.01 (5.05-33.30)" 7.12 (4.38-19.46)' < 0.10
Stair Ascent (s) 3.78 (2.06-9.28) 2.83 (1.75-8.69) <0.10
Stair Descent (s) 3.36(1.70-8.22) 2.31 (1.46-9.89) <0.05
" n = 14; n = 24; '  n = 32
N S  = N o t S ign ifican t
Data presented as median and range
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Table 8.4 Baseline Linear Analogue Scales of Weakness and Strength, FACT-Ftg
Scale and HAD Scale in Cancer Patients With and Without Follow-Up
at 6 Weeks
No Follow-up Follow-up p-value
(n=23) (n=31)
Linear Analogue Scales
Weakness Scale (cm) 5.0 (1.0-8.3) 4.1 (0.4-8.0) NS
Strength Scale (cm) 4.0 (0.2-9.6) 5.1 (1.9-8.9) NS
FACT-Ftg Scale 18 (0-39) 29 (17-47) < 0.001
EORTC Fatigue Scale 66.7 (22.2-100) 44.4 (0-88.9) < 0.001
HAD Scale
Anxiety 8(3-17) 6(0-11) <0.05
Depression 11(2-12) 6(1-13) <0.01
N S  = N o t S ign ifican t
Data presented as median and range
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Table 8.5 Baseline Blood Tests in Cancer Patients With and Without Follow-Up at 
6 Weeks
No Follow-up Follow-up p-value
(n=24) (n=31)
Haemoglobin (g/1) 117(91-152) 127 (101-177) <0.01
White Cell Count 12.5 (4.9-27.2) 8.1 (4.4-16.1) <0.01
Sodium (mmol/1) 136(123-140) 137(131-145) <0.05
Potassium (mmol/1) 4.4 (3.3-5.1) 4.4 (3.5-5.6) NS
Urea (mmol/1) 6.3 (2.0-17.6) 6.4 (3.5-13.1) NS
Creatinine (pmol/l) 82 (62-120) 78 (56-161) NS
Albumin (g/1) 35 (23-41) 41 (32-46) <0.001
Creatine Kinase (IU/1) 26(10-318) 40(10-151) <0.05
Calcium (mmol/1) 2.43 (2.24-2.58) 2.37(2.14-3.29) NS
Magnesium (mmol/1) 0.88 (0.73-1.02) 0.87 (0.65-0.98) NS
Zinc (pmol/l) 9.4 (5.6-11.8) 10.5(4.7-15.8) <0.01
Copper (pmol/l) 22.1 (10.8-35.3) 21.8(11.3-37.5) NS
Vitamin D (nmol/1) 18 (<6-48) 26 (<6-128) <0.01
C-Reactive Protein (mg/1) 99 (12-214) 19 (2-201) <0.001
N S  = N o t S ign ifican t
Data presented as median and range
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Table 8.6 Baseline EORTC QLQ-C30 Quality of Life Questionnaire Scores in
Cancer Patients With and Without Follow-Up at 6 Weeks
No Follow-up Follow-up p-value
(n=22) (n=32)
Functional Scales:
Physical 20 (0-60) 60 (20-100) <0.001
Role 33.3 (0-83.3) 50 (0-100) <0.01
Quality of Life 50(0-100) 66.7 (25-100) <0.10
om Scales
Fatigue 66.7(22.2-100) 44.4 (0-88.9) <0.001
Nausea & Vomiting 16.7 (0-100) 0(0-83.3) <0.10
Pain 33.3 (0-100) 25 (0-66.7) <0.10
Dyspnoea 66.7 (0-100) 33.3 (0-100) <0.001
Sleep 33.3 (0-100) 33.3 (0-66.7) NS
Appetite 33.3 (0-100) 16.7 (0-100) <0.05
Constipation 33.3 (0-100) 33.3 (0-66.7) <0.05
N S  = N o t S ignificant
Data presented as median and range
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CHAPTER 9: CONCLUSIONS
Weakness and fatigue are the commonest symptoms in patients with advanced cancer. 
They are symptoms which have largely eluded precise definition, but have been reported 
to seriously affect quality of life and ability to perform basic daily activities. Reduced 
muscle bulk due to cancer cachexia and alteration in intrinsic muscle function have been 
postulated as causes of both reduced muscle strength and subjective weakness and 
fatigue. It has also been reported that anxiety/depression, reduced haemoglobin 
concentrations, altered biochemistry and the inflammatory response may contribute to 
weakness and fatigue. However, the relationship between subjective weakness and 
fatigue and objective strength in cancer patients is not clear. To date, such relationships 
have not been studied in cancer patients.
The first aim of the present work was to investigate the importance of weight loss, 
altered body composition, the inflammatory response, haematological and biochemical 
parameters in the experience of weakness and fatigue in patients with advanced cancer. 
Although the healthy control group and the cancer group as a whole were similar in 
terms of age, sex and pre-illness body weight, at study entry the cancer group were 
clearly more unwell. The cancer group had lost weight, compared with the healthy 
group, and this included both fat and lean tissue. Reduced limb muscle area, creatinine 
excretion and creatine kinase confirmed that muscle was being lost by the cancer 
patients. The cancer patients had a lower performance status and had significantly more 
weakness and fatigue, compared with the healthy control group.
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Correlations between the weakness scale and the two fatigue scales suggest that 
weakness and fatigue tend to co-exist. Indeed, the correlations between the weakness 
scale and almost all the individual questions of the fatigue scales suggests that it is 
likely that patients use the terms weakness and fatigue synonymously.
It was of interest that patients taking benzodiazepine drugs had higher fatigue scores 
than those not receiving such drugs. There was no similar relationship with any of the 
other major drug groups implicated in the aetiology of weakness and fatigue, such as 
opioid drugs, corticosteroids and antidepressants.
The cancer patients were more anaemic and had lower serum sodium and vitamin D 
concentrations. They also had evidence of an inflammatory response, with elevated 
C-reactive protein concentrations and white cell count as well as raised copper 
concentrations and reduced albumin and zinc concentrations. It is of interest that 
vitamin D concentration, like other vitamins, was inversely related to the inflammatory 
response and, therefore, may not be a useful nutritional marker in cancer patients.
The weakness scale score, fatigue scores and reduced albumin concentrations were 
associated with C-reactive protein concentrations. Low albumin, anaemia and a raised 
white cell count were associated with fatigue severity. Follow-up data confirmed the 
importance of haemoglobin, white cell count, albumin and C-reactive protein 
concentrations, suggesting that anaemia and the inflammatory response are poor 
prognostic factors and may be aetiological factors in the pathogenesis of weakness and 
fatigue.
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The weight-losing cancer group were clearly less well than the weight-stable group. The 
weight-losing group had lost significantly more of their pre-illness weight and had lost 
muscle, particularly from the thigh, compared with the weight-stable group. The 
weight-losing cancer patients had more weakness and fatigue and from studying the 
individual questions of the FACT-Ftg scale, it was clear that weight-losing patients had 
more difficulty in initiating activity, needed more help in activity and needed to rest 
more than the weight-stable patients. In longitudinal study, weight-stable patients had 
reduced fatigue. It may, therefore, be possible that by maintaining weight in cancer 
patients fatigue severity could be alleviated.
Sodium and albumin concentrations were decreased in the weight-losers and white cell 
count and C-reactive protein were both increased, compared with the weight-stable 
patients. It would appear, therefore, that the inflammatory response is associated with 
ongoing weight loss. Although the inflammatory response was associated with both 
weight loss and subjective weakness and fatigue, there was no linear relationship 
between degree of weight loss and the severity of weakness or fatigue.
The second aim of this work was to examine the relationships between objective tests of 
strength and function and measures of weakness and fatigue and patient-related quality 
of life in patients with advanced cancer. It was evident that the cancer patients were 
weaker and more fatigued and had lost physical strength compared with the healthy 
controls. The cancer group also had considerably more difficulty in rising from a chair, 
stair climbing and walking than the healthy group and had poorer levels of self-rated 
functioning, an increased symptom burden and poorer quality of life.
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The lack of correlation between the weakness scale and the strength measures implies 
that when a patient complains of weakness, the presence of an objective decrement in 
strength cannot be assumed. Indeed, some patients rated their level of weakness as high, 
but had a normal grip strength. However, follow-up data suggests that both fatigue 
severity and reduction in handgrip strength are important factors indicating a poor 
prognosis in cancer patients. The cancer patients as a whole had higher levels of 
weakness and fatigue and lower strength than the healthy group and there were weak 
relationships between grip strength and both fatigue scales. However, it would appear 
unlikely that loss of voluntary muscle strength is the only determinant of perceived 
weakness and fatigue.
Handgrip strength would appear a very useful measure of strength in cancer patients 
and, unlike the isokinetic/isometric dynamometry, was tolerated by all the cancer 
patients. Handgrip strength was lower in the weight-losing patients compared with the 
weight-stable group. The handgrip and quadriceps strength measures were related to 
each other, suggesting that when strength is lost it is lost in a number of different muscle 
groups at the same time. These results indicate that reduction in muscle strength in 
cancer patients is the result of a systemic process and, presumably, is related to disease 
progression. However, there was no linear relationship between degree of weight loss 
and strength. Similarly, functional decline seemed to relate to disease progression and 
affected different activities at the same time.
The use of electrical stimulation to explore whether there were voluntary or central 
components to muscle strength in cancer patients proved difficult and produced
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unreliable results. However, multivariate analysis suggested that muscle bulk, as well as 
age, was important in determining muscle strength.
Fatigue, as measured by the FACT-Ftg scale correlated well with patient assessed 
function - as measured by the physical functioning scale of the EORTC quality of life 
questionnaire - and with the chair tests and 2 minute walk. The weakness scale 
correlated with patient perceived function and the chair stand only. Grip strength and 
isometric quadriceps torque were both associated with performance in the chair test. 
Therefore, those patients who have the most difficulty in activity, and the lowest 
strength, have more weakness and fatigue than more able patients. There was no 
relationship between any of the weakness/fatigue scales and performance in the stair 
tests. Cancer patients were able to rate their own level of functioning accurately, and this 
implies that the physical functioning scale of the EORTC quality of life questionnaire 
may be a useful screening tool for functional ability in the palliative care setting and, 
unlike measures of performance status, has the advantage of being rated by the patient. 
The FACT-Ftg scale also contains questions on functional activity and may also provide 
information on cancer patient function.
The weight-losers’ poorer scores in the FACT-Ftg questions on activity were confirmed 
by their poorer self-assessed physical function on the EORTC physical functioning scale 
and their poorer performance in the chair and stair tests. There was no linear relationship 
between objective function and the degree of weight loss.
In longitudinal study, although mid-arm circumference and muscle area increased in the 
group which remained weight-stable and decreased in the group which lost weight, there
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was no corresponding change in handgrip strength. Although at baseline muscle bulk 
was determined to be important factor for handgrip strength, these results suggest that 
muscle bulk may not be the only determinant of muscle strength in cancer patients. 
However, it is possible that the change in muscle bulk was insufficient to cause a change 
in strength. Similarly, although the weight-stable patients improved in the functional 
tests, there was no corresponding increase in thigh muscle bulk. Nevertheless, it seems 
clear that the weight-losing group consisted of patients with poorer nutritional status and 
that lower handgrip strength and poorer function are symptoms of progressing disease, 
perhaps leading to inactivity and loss of ability.
Karnofsky Performance Status has previously been used as an indicator of functional 
ability in cross-sectional and longitudinal studies. However, in this work, performance 
status did not change over time, but performance in the various functional tests did, 
suggesting that the latter may be more sensitive indicators of a patient’s ability to 
function than performance status.
Patient-rated global quality of life was correlated with fatigue, weakness, the chair stand 
time and depression. Therefore, it is likely that poor quality of life, in part, is the result 
of weakness and fatigue and poorer functioning. Depression was strongly correlated 
with the FACT-Ftg fatigue scale and was the strongest single predictor for fatigue on 
multi-variate analysis. In longitudinal study, the weight-stable cancer patients became 
less fatigued and yet there was no alteration in depression scores. Therefore, it is 
possible that, chronologically, fatigue comes first and contributes to a lowering of mood 
in cancer patients. Further study is necessary to further explore the relationship between 
fatigue and depression in this patient group.
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Weight-losing patients had more severe symptoms than the weight-stable patients, with 
more nausea and vomiting, pain and bowel dysfunction, as well as poorer appetite and 
poorer sleep. Those who had lost weight also had more anxiety and depression. Many of 
the symptom scores of the EORTC questionnaire were correlated with the weakness and 
fatigue scores. The reason for this may be that cancer patients often have multiple 
symptoms and become increasingly symptomatic as the illness progresses, but it is also 
possible that other symptoms may contribute to the pathogenesis of weakness/fatigue. 
Pain and dyspnoea also explained some of the variance in weakness/fatigue scores on 
multivariate analysis, although these factors were not as strongly related as depression.
Patients who could not be followed up due to a deterioration in condition had poorer 
Kamofsky Performance Status, slower chair stand and stair descent, increased anxiety 
and depression, poorer scores on the physical functioning scale, more dyspnoea and 
constipation and reduced appetite compared to the group followed up to 6 weeks. These 
are, thus, likely to be poor prognostic factors and require further study.
In previous research in the elderly, a more striking relationship was demonstrated 
between strength and functional ability. However, it is clear that, from this work, cancer 
patients were a more rapidly changing group than the healthy elderly and this may 
explain the differences between the two groups. Moreover, small decrements in strength 
could lead to a large deterioration in function as the patient crosses the threshold of 
ability to inability.
222
Research in the elderly has suggested that functional training, i.e., practising the tasks 
the individual needs to perform, may be more beneficial than strength training and it 
may be that this approach would also be useful in the cancer population.
In conclusion, this work has confirmed that weakness and fatigue are common problems 
in patients with advanced cancer who are not receiving active treatment. Patients tend to 
use the terms weakness and fatigue synonymously. Weakness/fatigue become more 
severe with increasing weight loss and illness progression. Weight-losing cancer 
patients are more unwell than weight-stable patients and have lost muscle mass and 
muscle strength and are more functionally disabled. Weight-losers have poorer quality 
of life and are more depressed. It is evident that these parameters change together, but 
the longitudinal relationships between strength, function, weakness/fatigue, weight loss 
and quality of life require further study. The relationship between depression and fatigue 
is strong and the basis of this relationship warrants further investigation.
Future research is required in several areas. The relationship between objective 
measures of strength and ability and the subjective experience of weakness/fatigue 
requires to be teased out further, to establish whether there are sub-groups with either 
predominantly subjective symptoms or predominantly physical impairment. There is 
likely to be a spectrum in between these two extremes. The longitudinal relationships 
between strength, function, weakness/fatigue, weight loss and depression appear to be 
important and require further investigation. Possible areas for future intervention 
include the cachexia process and the inflammatory response, as it seems clear that 
weight-losing patients with inflammation are a group with a poor prognosis. The role of
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exercise in cancer remains to be established. However, functional training in the cancer 
population may be an alternative, or additional, strategy to exercise.
It is clear that future research, and in particular longitudinal studies, will need to 
consider the issue of patient attrition, as this will remain a major challenge for any 
studies in the palliative care population. It will also he important that research in this 
area is truly multi-disciplinary and involves not only medical and nursing staff, but also 
physiotherapists and occupational therapists, as they will hring their own perspectives to 
what are complex, and important, problems for patients with advanced cancer.
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APPENDIX 1: QUESTIONNAIRES AND SCALES USED IN STUDY
Kamofskv Performance Status
Definition % Criteria
Able to carry on normal activity and 
to work. No special care is needed.
100 Normal; no complaints; no evidence 
of disease.
90 Able to carry on normal activity;
minor signs or symptoms of disease.
80 Normal activity with effort; some 
signs or symptoms of disease.
Unable to work; able to live at home, 70 Cares for self. Unable to carry on
care for most personal needs. A 
varying amount of assistance is needed.
normal activity or do active work.
60 Requires occasional assistance, but is 
able to care for most of his needs.
50 Requires considerable assistance and 
frequent medical care.
Unable to care for self. Requires the 
equivalent of institutional or hospital 
care. Disease may be progressing 
rapidly.
40 Disabled, requires special care and 
assistance.
30 Severely disabled, hospitalisation is 
indicated although death not 
imminent.
20 Hospitalisation necessary, very sick,
active supportive treatment 
necessary.
10 Moribund, fatal processes
progressing rapidly.
0 Dead.
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EORTC QLQ-C30 (Version 2.0)
W e are interested in some things about you and your health. P lease answer all o f  the 
questions yourself by circling the num ber that best applies to you. There are no “right” or 
"wrong" answers. The information that you provide will remain strictly confidential.
P lease fill in your initials;
Y our birthdate (Day, M onth, Year): 
Today’s date (Day, M onth, Year):
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
3. Do you have any trouble taking a short walk outside o f  the house?
4. Do you have to stay in a bed or a chair for most o f the day?
5. Do you need help w ith eating, dressing, washing yourself or 
using the toilet?
During the past week;
Not at 
all
6. W ere you limited in doing either your w ork or other 
daily activities?
7. W ere you limited in pursuing your hobbies or other
leisure tim e activities?
8. W ere you short o f  breath?
9. Have you had pain?
10. Did you need to rest?
11. Have you had trouble sleeping?
12. Have you felt weak?
13. Have you lacked appetite?
14. Have you felt nauseated?
15. Have you vom ited?
16. Have you been constipated?
Sample
copy
A
little
No Yes
2 
2 
2 
2 
2
Quite 
a bit
Very
much
4
4
4
4
4
4
4
4
4
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During the past week:
17. Have you had diarrhoea?
18. W ere you tired?
19. Did pain interfere with your daily activities?
20. Have you had difficulty in concentrating on things, 
like reading a new spaper or w atching television?
21. Did you feel tense?
22. Did you worry?
23. Did you feel irritable?
24. Did you feel depressed?
25. Have you had difficulty remem bering things?
26. Has your physical condition or medical treatm ent 
interfered with your family life?
27. Has your physical condition or m edical treatm ent 
interfered with your social activities?
28. Has your physical condition or medical treatm ent 
caused you financial difficulties?
N ot a t 
a
Sample
A Q uite  
little  a  b it
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
V ery
m uch
4
4
4
4
4
4
4
4
4
4
For the following questions please circle the number between 1 and 7 that 
best applies to you
29. How would you rate your overall h ea lth  during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30. How would you rate your overall q u a lity  o f life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
EORTC QLQ-C30 (Version 2.0) ©
Reproduced by kind permission of EORTC Quality of Life Group, Brussels, Belgium
258
Scoring Information for EORTC OLQ-C30 Version 2.0 Questionnaire 
Functional Scales
Physical Functioning (Questions 1-5T
Add scores of Q1-Q5 and divide by number of items:
PF = (Q1+ Q2 + Q3 + Q4 + Q5)/5 
Convert to 0-100 score using the equation:
100-((P F -l)x  100)
Role Functioning (Questions 6 & 7)
Add scores of questions 6 & 7 and divide by number of items:
RF = (Q6+Q7)/2 
Convert to 0-100 score:
100- ((RF-1) X 100/3)
Emotional Functioning (Questions 21-24)
Add scores of questions 21-24 and divide by number of items:
EF = (Q21+Q22+Q23+Q24)/4 
Convert to 0-100 score:
100-((E F -l)x  100/3)
Cognitive Functioning (Questions 20 & 25); Social Functioning (Questions 26 & 271
Scored as Role Functioning scale
Global Health Status/Qualitv of Life (Questions 29 & 30)
Add scores of questions 29 & 30 and divide by number of items:
QL = (Q29+Q30)/2 
Convert to 0-100 score:
(QL-l)x 100/6
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Symptom Scales/Items
Fatigue Scale (Questions 10,12. 18)
FA = (Q10+Q12+Q18)/3 
Convert to 0-100 scale:
(FA-1) X  100/3
Nausea & Vomiting Scale (Questions 14 & 15)
NV = (Q14+Q15)/2 
Convert to 0-100 scale:
(N V -l)x 100/3
Pain Scale /Questions 9 & 19)
Scored as nausea & vomiting scale 
Single Items:
Dvsnnoea (Question 81:
Convert to 0-100 scale:
(DY-1) X  100/3
Sleep (Question 11): Appetite (Question 131: Constipation (Question 16k 
Diarrhoea (Question 17): Financial (Question 28k
All scored as dyspnoea question
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FACT-Ftg (Version 3)
Below is a list of statements that other people with your illness have said are important. 
By circling one number per line, please indicate how true each statement has 
been for you during the past 7 days.
not a little som e- quite very
at all bit what a bit much
1. I feel fatigued 0
2. I feel weak all over 0
3. I feel listless (“w ashed out”) 0
4. I feel tired 0
5. I have trouble starting things because I am tired 0
6. I have trouble finishing things because I am tired 0
7. I have energy 0
8. I am able to do my usual activities 0
9. I need to sleep during the day 0
10. I am too tired to eat 0
11. I need help doing my usual activities 0
12. I am frustrated by being too tired to do the things I want to do 0
13.1 have to limit my social activity because I am tired 0
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
Reproduced by kind permission of Kimberley Webster, M.A., Evanston Northwestern 
Healthcare, Evanston, Illinois, USA.
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I d  W A A L.t.
Name; Trial No;
Hospital No: Date:
Doctors are aware that emotions play an important part in most illnesses. If  your doctor knows about 
these feelings he will be able to help you more.
This questionnaire is designed to help your doctor to know how you feel. Read each item and place a 
firm tick in the box opposite the reply which comes closest to how you have been feeling in the past week.
Don’t take too long over your replies: your immediate reaction to each item will probably be more 
accurate than a long thought-out response.
Tick only one box in each section
I feel tense or ‘wound up’:
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all
I still enjoy the things I used to enjoy: 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all
I get a sort of frightened feeling as if 
something awful is about to happen:
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all
□
H
H
□□□□
I feel as if I am slowed down:
Nearly all the time 
Very often 
Sometimes 
Not at all
I get a sort of frightened feeling like . 
‘butterflies’ in the stomach:
Not at all 
Occasionally 
Quite often 
Very often
I have lost interest in my appearance:
Definitely
I don’t take so much care as I should 
I may not take quite as much care 
I take just as much care as ever
H□
□□□□
□
□
□
□
I can laugh and see the funny side of things:
As much as I always could 
Not quite so much now | |
Definitely not so much now [ [
□Not at all
W orrying thoughts go through my mind:
A great deal of the time [ |
A lot of the time [ [
From time to time but not too often | j
Only occasionally |— j
I feel cheerful:
Not at all 
Not often 
Sometimes 
Most of the time
I can sit at ease and feel relaxed:
Definitely 
Usually 
Not often 
Not at all
□
□
□
□
B
□
□
I feel restless as if I have to be on the move:
Very much indeed 
Quite a lot
Not veiy much ]
□Not at all
I look forward with enjoyment to things:
As much as I ever did 
Rather less than I used to 
Definitely less than 1 used to 
Hardly at all
I get sudden feelings of panic:
Very often indeed 
Quite often 
Not very often 
Not at all
□
□
□□
□
□
□
□
I can enjoy a good book or radio or TV programme:
Often 
Sometimes 
Not often 
Very seldom
□
□□
□
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Scoring Information For Hospital Anxiety and Depression Scale
Questions numbered 1 to 14, reading down left hand colunm first, then down right hand 
column. Alternate questions are questions relating to anxiety or depression, i.e., 
questions 1,3,5,7,9,11,13 make up the anxiety subscale and questions 2,4,6,8,10,12,14 
make up the depression subscale. Each component of each question is assigned a score 
of 0-3 in the order shown below. Each scale is summed to give a total out of 21.
Q1 3 Q2 0 Q3 3 Q4 0
2 1 2  1 
1 2  1 2  
0 3 0 3
Q5 3 Q6 3 Q7 0 Q8 3
2 2 1 2
1 1 2  1
0 0 3 0
Q9 0 QIO 3 Q ll 3 Q12 0
1 2  2 1 
2 1 1 2  
3 0 0 3
Q13 3 Q14 0
2 1
1 2
0 3
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Medical Research Council (MRC) Grades of Muscle Weakness
Grade 0 - No contraction
Grade 1 - Flicker of contraction
Grade 2 - Active movement with gravity eliminated
Grade 3 - Active movement against gravity
Grade 4 - Active movement against gravity and resistance
Grade 5 - Normal power
(Ref: Griggs and Bradley, 1994)
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APPENDIX 2: DATA FROM STRATHCARRON HOSPICE PATIENTS WITH 
CANCER WHO DIED BETWEEN 1®^  JUNE AND 30™ NOVEMBER 1996
There follows the raw data taken from the casenotes of the 229 Strathcarron Hospice 
patients with cancer who died between 1®^ June and 30^ "^  November 1996 and which is 
discussed in Chapter 5, Below is a list of abbreviations used in the tables:
F = Female 
M “  Male 
N = No
NK = Not known 
No. = Patient Number
NSAIDs = Nonsteroidal anti-inflammatory drugs 
Y = Yes
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APPENDIX 3; DATA FROM HEALTHY SUBJECTS AND CANCER PATIENTS 
FROM  STUDIES DESCRIBED IN CHAPTERS 6-8
There follows the raw data from the 15 healthy subjects (VI-VI5) and 68 cancer 
patients who participated in the studies described in chapters 6-8. Below is a list of the 
abbreviations used in the tables:
AMA = Arm Muscle Area
BMI = Body Mass Index
BST = Biceps Skinfold Thickness
cm = centimetres
cmsq. = Square centimetres
DED -  Dexamethasone Equivalent Dose (24 hours)
EORTC = European Organisation for the Research and Treatment of Cancer 
F = Female
FACT-Ftg = Functional Assessment of Cancer Therapy Fatigue Subscale 
g/1 = grams per litre
HAD -  Hospital Anxiety and Depression Scale
icf/ecf ratio = intracellular fluid/ extracellular fluid ratio
IU/1 = International Units per litre
kg = kilograms
kgW = kilogram Watts
KPS = Karnofsky Performance Status
LASA = Linear Analogue Self-Assessment Scale
LN -  Lymph Nodes
m = metres
M = Male
MAC = Mid-Arm Circumference 
max. = maximum
MED = Morphine Equivalent Dose (24 hours) 
mg/1 = milligrams per litre
282
min. = minutes
mm = millimetres
mmol/1 = millimoles per litre
MTC = Mid-Thigh Circumference
N & V = Nausea and Vomiting
ND = Non-Dominant
NK = Not Known
Nm = Newton metres
nmol/1 = nanomoles per litre
NSAIDs = Nonsteroidal Anti-Inflammatory Drugs
Pred. Vecf/VtbwWicf (1) = Predicted volume of extracellular fluid/total body water/
intracellular fluid (litres)
QOL = Quality of life 
Qu. = Question 
s = seconds
Study No. = Study Number 
ThST = Thigh Skinfold Thickness 
TMA "  Thigh Muscle Area 
TST = Triceps Skinfold Thickness
V = Volunteer (Healthy Control Subject)
WL = Weight-Losing at Study Entry 
WS = Weight-Stable at Study Entry
Y = Yes
24hr creat. = 24 hour urinary creatinine excretion
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